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ABSTRACT 
Transmembrane signal transduction is achieved by activation of G protein-coupled 
receptors (GPCRs) like the human cannabinoid type 1 (CB1) receptor, the human 
cannabinoid type 2 (CB2) receptor, and the human mu-opioid receptor.  These receptors 
exist in the membrane in an ensemble of conformations each of which might bind to 
different signaling molecules and cause different physiological effects.  Understanding the 
structural basis of their activation will eventually help us in designing drugs that target 
these receptors with potentially minimal undesirable side effects.  CB1 is of particular 
interest because it is located in the central nervous system and modulates hunger, making 
it an attractive anti-obesity drug target.  In this receptor, mutating a single residue, 
threonine 210, to isoleucine in the third transmembrane (TM3) domain makes it far more 
active than the wild-type (WT) receptor, whereas mutating it to alanine makes it fully 
inactive.  CB1 is difficult to model because it has a small sequence identity with the 
receptors that have been crystallized.  We used the first principles-based GEnSeMBLE 
method to predict 3D structures of these receptors representing the fully inactive to highly 
constitutively active states.  With this software, we quickly found a set of low energy 
receptor conformations by sampling trillions of helix orientations.  Differences in the 
intracellular surface explain experimental differences in activation for the CB1 receptor and 
its mutants.  These predictions were validated by designing double mutants that were 
expected to switch the inactive T210A to WT levels of activation and expected to switch 
the very active L207A to T210A levels of activation.  These predictions were first verified 
computationally then experimentally with GTPγS assays.  The accuracy of our predictions 
indicate that the GEnSeMBLE method is a useful procedure for predicting GPCR 
structures at various activation states.  Known inverse agonists were docked to these 
predicted CB1 receptor structures, and the resulting complexes were inserted into a 
solvated lipid bilayer for 50 ns of NPT molecular dynamics with NAMD software.  The 
inverse agonist preferentially binds to a pre-activated CB1 state, but during MD, traits of 
the inactive structure start to form suggesting that the ligand induces conformational 
changes. 
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Chapter I 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted with permission from: 
Scott CE, Abrol R, Ahn KH, Kendall DA, Goddard WA, III (2013) Molecular basis for 
dramatic changes in cannabinoid CB1 G protein-coupled receptor activation upon single 
and double point mutations. Protein Sci 22:101-113. 
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BACKGROUND 
 
Transmembrane proteins, existing on the cellular surface, are important drug targets due to their 
ability to relay information from the environment to the cell interior.  We are interested in two 
types of drugs—the ones that interact with transmembrane proteins to cause downfield signaling 
and a physiological response and the ones that block the transmembrane proteins from interacting 
and thus preventing the intended physiological impact.  In this study, we will examine the 
structures of the members of the class A G protein-coupled receptors (GPCRs) and the human 
glycoprotein Ecgp96 with the intention of designing drugs to interact with their respective 
binding sites. 
 
Human cannabinoid CB1 receptor mediates hunger sensations 
One example of a GPCR that has multiple active states is the human cannabinoid type 1 (CB1) 
receptor.  CB1 is located primarily in the central nervous system and is so named because it is 
activated by the psychoactive component of cannabis, tetrahydrocannabinol, a chemical that 
causes feelings of hunger, euphoria, and relaxation.  After ingestion of cannabis, people often 
report feeling excessively hungry.  Therefore, marijuana is sometimes prescribed to AIDS or 
cancer patients who have lost their appetite and are having trouble maintaining a healthy weight.  
Marijuana has also makes the user feel content and relaxed.  All of these psychoactive side 
effects—hunger, relaxation, and euphoria—are results induced through CB1.  The human body 
produces its own endogenous cannabinoids, or endocannabinoids, which have the same 
psychoactive impact as cannabis, but are less efficacious (1).  One type of endocannabinoid, 
anandamide—whose name is derived from the Sanskrit word for ‘bliss’—is naturally found in 
chocolate (2).  Cannabis, however, contains much larger doses of a more powerful chemical than 
that which the body normally produces (or what is found in chocolate), which is why it is 
impossible to get ‘high’ off of chocolate as one would from cannabis. 
 
CB1 receptors are located throughout the brain including a region called the hypothalamus, which 
is responsible for appetite regulation amongst other things.  In a normally functioning brain, this 
region receives neurotransmitters with messages telling us that we are full and don’t need to eat.  
By blocking the release of these chemicals, CB1 ensures that the brain does not get those 
messages, resulting in hunger (3; 4). 
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Besides anecdotal evidence, many studies demonstrate the link between the endocannabinoid 
system and appetite.  In an early experiment from 1971, thirteen people were separated into two 
groups.  One group smoked two marijuana cigarettes and the other acted as the control by not 
smoking anything.  After the marijuana ingestion, each person ate on average 46 marshmallows, 
whereas the people who didn’t smoke anything ate on average only four marshmallows (5).  In 
more recent studies, after given agonist drugs like cannabis that activate CB1, rats have been 
shown to work harder to obtain food, but when they are given drugs that block it, they do not try 
as rigorously (6).  Mice genetically engineered to lack this receptor continue to receive hunger 
signals.  They feel full sooner, so they do not work as hard to get food, and they do not respond to 
incentives (7).  They also naturally eat fewer calories, which means that they weigh less and have 
less fat tissue (8).  Research also shows that the addition of cannabinoid activators increases the 
nerve responses to sweeteners, which may explain how these molecules cause the improved 
palatability and increased motivation for food (6; 9). 
 
Recently, scientists started trying to attack obesity by designing drugs to manipulate the role of 
CB1, in order to decrease food cravings and eliminate unwanted appetite.  Studies show that 
obese rats have elevated levels of agonist endocannabinoids and CB1 receptors compared to lean 
ones (10).  Agonists are molecules that cause a certain physiological effect—in this case for the 
user to think that they are hungry and need food.  Blocker drugs fill the CB1’s reaction site to 
prevent it from interacting with endocannabinoids and functioning normally.  The cannabinoid 
receptor works by preventing the release of neurotransmitters that tell the brain we are full.  
Antagonists prevent this receptor from operating, so the neurotransmitters are released and the 
brain gets the “full” message sooner and more often.  People receiving such drugs have a reduced 
appetite and, as a result, eat less and are more likely to lose weight. 
 
In 1994, researchers at the pharmaceutical company Sanofi-Aventis understood that hunger and 
psychology are intricately connected and designed the antagonist/inverse agonist rimonabant to 
help people who practice healthy habits, but still need to lose weight (11).  Rimonabant was 
supposed to be the next blockbuster drug.  In a European study, patients with an average weight 
of 222 lbs taking the 20 mg dose lost 14.5 lbs over a year (12).  This is an impressive number 
compared to the average 7.7 lbs lost over 2-3 years due to lifestyle changes alone (13).  The drug, 
however, had serious side effects such as depression and increased risk of suicide.  One study 
concluded that people participating in clinical trials were 2.4 times more likely to drop out due to 
mood disorders than those taking the placebo (14).  It is unknown if these mood disorders are the 
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result of off-target interactions.  If the structure of CB1 was known, a drug could be designed 
specifically for the CB1 binding site, thus limiting the possibility of it interacting with other 
proteins.  However, CB1, like many other GPCRs, has never been crystallized, so its structure 
remains unknown. 
 
G protein-coupled receptor (GPCR) activation procedure 
GPCRs are some of the most popular drug targets with approximately 40% of prescription drugs 
designed to interact with GPCRs (15).  This class of proteins is characterized by the seven alpha-
helices that span the hydrophobic lipid bilayer.  In its resting state, the GPCR resembles a funnel 
extending through the membrane, that is, the extracellular end of the helix bundle is wider than 
the intracellular end.  When an activating ligand, or agonist, binds to a GPCR, it causes the 
receptor to change shape in a process called activation (Figure 1.1), in which the intracellular end 
of the receptor widens so that the global conformation resembles a hollow cylinder rather than a 
funnel.  These conformational changes impact the receptor’s interactions with other intracellular 
proteins, including the guanyl nucleotide-binding protein (G protein), initiating a signaling 
cascade and a physiological response (Figure 1.2).  Agonists can be external substances like 
drugs, or they can be endogenous like neurotransmitters or hormones.  They stabilize the active 
state, whereas inverse agonists, ligands that have the opposite physiological effect of agonists, 
stabilize the inactive state.  Antagonists, ligands that prevent the agonists and inverse agonists 
from accessing the binding site, have no physiological impact.  Like the inverse agonists, they 
will stabilize to the inactive state. 
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Figure 1.1 Schematic illustrations of the cannabinoid 1 (CB1) receptor undergoing activation after 
interaction with an agonist.  CB1 (blue trapezoid) binds to agonists (light blue crescent), such as 
endocannabinoids or cannabis.  This event causes the protein to undergo activation by changing its shape.  
The intracellular end of the receptor expands, so the whole complex resembles a cylinder.  The receptor can 
now interact with proteins inside the cell. 
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Figure 1.2 Schematic illustration explaining GPCR activation.  Activation of GPCRs affects the body’s 
behavior and by understanding the receptor’s conformational changes, scientists can understand how to 
manipulate the subsequent physiological responses. 
 
In the activated state, the GPCR’s widened intracellular end has enough space for the 
heterotrimeric G protein to insert itself.  When the G protein itself undergoes activation, 
guanosine diphosophate (GDP) is replaced with guanosine triphosophate (GTP), which causes the 
G protein to dissociate into α and βγ subunits that interact with other proteins leading to a 
physiological response.  Multiple types of GPCRs, including the ones examined herein—the 
cannabinoid and opioid receptors—primarily interact with the inhibitory Gi protein (16-18).  This 
protein prevents the production of the second messenger cyclic adenosine monophosphate 
(cAMP) as opposed to the Gs protein that stimulates its production (19). 
 
Originally, it was believed that GPCRs switched between two conformations—an ‘off’ or 
inactive conformation and ‘on’ or active one.  There is, however, experimental evidence that 
proves that GPCRs are dynamic and can exist in an ensemble of active or inactive states (20-23).  
At room temperature, only the lowest energy, most favorable, states are accessible.  So when 
crystallized, the apo-receptor lacking a ligand will be captured in its inactive state.  By adding an 
agonist to the receptor, the inactive state is destabilized and the activated G protein-coupled state 
becomes more energetically favorable.  Sometimes a mutation can destabilize the inactive state 
and stabilize the active state without the assistance of an agonist or the G protein (24).  These 
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mutants are referred to as ‘constitutively active mutants,’ or CAMs, and there are multiple 
examples of CAMs of GPCRs including the CB1 (25-28) and human mu-opioid (hMOR) 
receptors (29). 
 
It is unknown how or what initiates the GPCR activation process.  There are two main theories: 
conformational selection and induced fit (Figure 1.3).  In conformational selection, the GPCR 
samples many different structures, some of them corresponding to the active ones, and an agonist 
binds to the receptor capturing the activated state.  In induced fit, the agonist binds to the receptor 
in its inactive state, and the binding action induces activation and the conformational changes 
(30). 
 
Figure 1.3 Illustration of the proposed receptor-ligand binding mechanisms, conformational selection and 
induced fit. 
 
The transmembrane proteins’ structures, however, are mostly unknown due to their instability 
outside the membrane leading to difficulty in isolation and crystallization.  Thus, it is challenging 
to design drugs that interact with these receptors due to the lack of knowledge about their 
conformations and the drug’s binding site.  Even so, crystallographically characterized receptors 
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are just a single snapshot of a dynamic macromolecule.  The GPCRs’ activation mechanism 
remains a mystery, and the process of conformational changes going from an inactive 
conformation to an activated one is not well understood. 
 
Due to the putative stability of the inactive state, most GPCR crystal structures correspond to this 
form including, but not limited to class-A GPCRs bovine rhodopsin (bRho) (31-41), squid 
(Todarodes pacificus) rhodopsin (sRho) (42; 43), human β2 adrenergic receptor (inactHβ2AR) 
(44-46), turkey (Meleagris gallopavo) β1 adrenergic receptor (inactTβ1AR) (47; 48), human A2A 
adenosine receptor (inactHA2AAR) (49; 50), human D3 dopamine receptor (hDD3R) (51), human 
CXCR4 receptor (hCXCR4) (52), human chemokine CCR5 receptor (hCCR5) (53), human 
sphingosine 1-phosphate 1 receptor (hS1P1) (54), mouse (Mus musculus) µ-opioid receptor 
(mMOR) (55), mouse δ-opioid receptor (mDOR) (56), human κ-opioid receptor (hKOR) (57), 
human NOP opioid receptor (hXOR) (58), human muscarinic M2 receptor (inactHMM2R) (59), 
and human muscarinic M3 receptor (hMM3R) (60).  However, several crystal structures have 
captured one or more of the “active” forms of GPCRs: bovine opsin (bOps) (61; 62), bovine 
metarhodopsin II (meta II) (63), human β2 adrenergic receptor (actHβ2AR) (64; 65), human A2A 
adenosine receptor (actHA2AAR) (66-68), human muscarinic M2 receptor (actHMM2R) (69), 
human neurotensin NTS1 receptor (70), and human P2Y12 receptor (71).  These latter structures 
provide molecular level hints concerning the mechanisms of GPCR activation, but little is known 
about the structural transformations underlying the conversion of a GPCR from an inactive form 
through a constitutively active form to an even more constitutively active form.  Only one GPCR 
has been crystallized in conjunction with the Gs protein (65), and the Gi protein has never been 
crystallized with a GPCR. 
 
STATEMENT OF PROBLEM 
 
While recent technological advances have caused the explosion in the number of crystallized 
GPCRs, there are still many receptors such as CB1 and CB2 that have not been crystallized and 
even more that have never been crystallized in the activated state.  Even then, the crystallized 
conformation is just one of an ensemble of possible structures.  GPCRs bind to a variety of 
intracellular proteins and ligands, and it is unknown how the GPCR structure changes to 
accommodate these new interactions.   
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Almost half the medication on the market is created to target a GPCR, but most of these drugs are 
designed without prior structural knowledge of the receptor, thus, increasing the likelihood of off-
target side effects.  A prime example of this problem is the CB1 blocker rimonabant.  However, 
with predicted binding sites, drugs can be designed to interact specifically with these receptors. 
 
 
PURPOSE OF STUDY 
 
Here, we use computational techniques to predict an ensemble of structures for the GPCRs and 
their respective mutants representing various functional states.  The Monte Carlo GEnSeMBLE 
(GPCR Ensemble of Structures in Membrane BiLayer Environment) method quickly and 
efficiently does a complete sampling of approximately a trillion GPCR structures to identify a 
small number of possible conformations.  To validate the predicted structures, we dock known 
ligands to them in order to explain experimental site-directed mutagenesis and structure-activity 
relationship data.  Based on the predicted binding sites, we design novel ligands to interact with 
the receptors.  Collaborators will experimentally test these predictions.  Ideally, we would 
calculate energies using quantum mechanical methods, but such computations are too expensive 
given the size of the receptors.  Lastly, we use density functional theory to determine the 
reactivity of a high valent metal-oxo catalyst that could activate hydrocarbons. 
 
OUTLINE OF THE THESIS  
 
Chapter II:  Methodology overview focusing on GPCR structural prediction methods and 
hierarchical ligand docking programs developed within the Goddard lab. 
 
Chapter III:  Structure prediction of the human cannabinoid type 1 (CB1) receptor and various 
mutants representing the inactive and constitutively active states. 
 
Chapter IV:  Docking of known inverse agonist/antagonist rimonabant to the ensemble of predict 
CB1 structures and design of new CB1-selective inverse agonist based on proposed binding site. 
 
Chapter V:  Molecular dynamics simulations of the predicted apo-CB1 receptor and the CB1 
receptor-rimonabant complex to validate the stability of the structures and to see how they change 
over time. 
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Chapter VI:  Structure prediction of the human cannabinoid type 2 (CB2) receptor and proposal 
of mutants that could capture the fully inactive state. 
 
Chapter VII:  Structure prediction of the human mu-opioid receptor (hMOR) and multiple 
mutants with various binding affinities for an opioid agonist as well as comparison to published 
crystal structure. 
 
Chapter VIII:  Docking of ligands to the human glycoprotein Ecgp96 with and without 
glycosylated units.  Proposal of new ligands with greater predicted binding affinities and 
exploration of novel docking regions.  
 
Chapter IX:  Quantum mechanical calculations of the reactivity of the trans-dioxovanadium (V) 
porphyrin complex and free energy states involved in hydrocarbon activation. 
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Chapter II 
 
METHODOLOGY:  STRUCTURE AND BINDING SITE PREDICTION BASED ON 
COMPLETE SAMPLING MONTE CARLO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted with permission from: 
Scott CE, Abrol R, Ahn KH, Kendall DA, Goddard WA, III (2013) Molecular basis for 
dramatic changes in cannabinoid CB1 G protein-coupled receptor activation upon single 
and double point mutations. Protein Sci 22:101-113. 
 
Ahn KH, Scott CE, Abrol R, Goddard WA, III, Kendall DA (2013) Computationally-
predicted CB1 cannabinoid receptor mutants show distinct patterns of salt-bridges that 
correlate with their level of constitutive activity reflected in G protein coupling levels, 
thermal stability, and ligand binding. Proteins: Struct, Funct, Bioinf 81:1304-1317. 
 
Bray JK, Abrol R, Goddard WA, III, Trzaskowski B, Scott CE (2014) SuperBiHelix 
method for predicting the pleiotropic ensemble of G-protein-coupled receptor 
conformations. Proc Natl Acad Sci U S A 111:E72-E78. 
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The following chapter describes the background and technical details regarding the general 
methodology.  Exceptions and further details for each computation will be noted in the respective 
chapters. 
 
I.  GEnSeMBLE procedure for generating an ensemble of receptor structures: 
Most receptor structural prediction programs rely on homology modeling where the GPCR crystal 
structure’s sequence is modified to match that of the target sequence.  There are three problems 
with this procedure.  First, while this method is particularly effective for predicting the structures 
of GPCRs closely related (over 40% sequence identity) to the crystal template, it is not useful for 
proteins that are not related to any crystallized GPCRs.  For example, when we started predicting 
the structure for the CB1 receptor, it had a sequence identity to the crystallized GPCRs ranged 
from 9.96 to 16.10%, which means that none of the templates would be reliable since the 
sequences have so little in common (for more details see Chapter III).  Second, many 
experimental and computational studies shown that single point mutations can cause significant 
changes in the binding site and hence receptor function.  This can result from very modest 
changes in the interhelical interactions, which can cause rotations of the helix that completely 
modify the binding site.  Homology methods do not address this issue.  Homology modeling 
assumes that the changes in the sequence do not have a major impact on the structure, so they are 
not sensitive enough to capture the structural effect of a single change in the sequence.  Third, 
homology modeling offers a limited number of predictions for the receptor structure.  For 
example, to date, there are only six GPCRs crystallized in the active state (1-11)—only one 
crystallized in complex with the Gs protein (1).  However, GPCRs bind to multiple agonists and 
intracellular proteins, so they have multiple activated (and possibly inactive) states (12-14) that 
homology modeling cannot capture. 
 
Our lab has been developing methods (15-19) for predicting receptors’ structures that address the 
three issues discussed above.  The GEnSeMBLE (GPCR Ensemble of Structures in Membrane 
Bilayer Environment) procedure is based on first-principles, that is, we seek to predict the three-
dimensional (3D) structure of the receptor based on its amino acid sequence with limited reliance 
on structural information from previously crystallized proteins.  Briefly, we construct the seven 
individual helices from canonical helices using a combination of molecular dynamics (MD) 
simulations and minimization followed by aligning the helices to a GPCR template and 
determining the energies of trillions of receptor conformations by rotating and tilting the helices.  
This method allows us to thoroughly sample and calculate the energies of many receptor 
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conformations in a fast and efficient manner.  Rather than obtaining a single solution for each 
GPCR, there is an ensemble of low energy conformations, and by constructing the helices from 
scratch, we build different conformations based on different receptor sequences, even if the only 
change is a single mutation.  While these methods have been tested and validated with class A 
GPCRs, the procedures were designed to be general enough to apply to cases with little structural 
knowledge and no related crystallized templates.  Currently, our co-workers are using these 
techniques to predict the structures of the distantly related class B GPCRs (20). 
 
The procedure involves four steps outlined in Figure 2.1: 1) predicting the transmembrane (TM) 
helix regions of the receptor, 2) generating the template of the receptor bundle, 3) sampling a 
complete set of seven helix bundle conformations, and 4) identifying the lowest energy receptor 
conformations.  We have verified our procedure using the few crystallized GPCR structures, and 
we find that our predicted structures are accurate (15; 17).  Previously, Abrol et al. predicted the 
inactive human adenosine A2A receptor (inactHAA2AR) conformation starting from the inactive 
human β2 adrenergic receptor (inactHβ2AR) template using the GEnSeMBLE method.  After 
sampling, the inactHAA2AR predicted structure has a small 1.4 Å backbone root-mean-squared 
deviation (RMSD) with respect to the actual inactHAA2AR crystal (17).   
 
Figure 2.1 Outline of GEnSeMBLE method (15; 16; 18). 
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Part A: Predicting the wild-type (WT) receptor structures 
Step 1: Predict transmembrane (TM) helix regions of the receptor 
Based on the hydrophobic character of the target receptor amino acid sequence, we predict the 
TM regions using the PredicTM method.  In the first step of PredicTM, a BLAST (21) search 
with an E-value of 0.1 is performed, or the program searches the BLAST database to find all 
related sequences based on our target receptor.  The E-value represents the probability that a 
particular sequence pulled from the database is related to the target sequence.  For example, a 
larger E-value means that a larger number of less related sequences will be found in the BLAST 
search.  A smaller E-value means that a smaller number of sequences a higher conserved 
sequence identity will be found.  With an E-value of 0.1, we find related seven helix GPCR 
sequences with sequence identities ranging in from 100% to single digits.   
 
Our second step in PredicTM uses MAFFT software (22) based on the ‘E-INS-i’ method, which 
performs a multiple sequence alignment of the sequences identified by the BLAST search.  
MAFFT aligns the sequences according to their conserved portions and ignores the parts of the 
receptor with few conserved residues.  This method is especially useful for GPCRs since the TMs 
are highly conserved, and the loop regions are not.  This step is followed by using the Wimley-
White octanol hydrophobicity scale (23) to assign a numeric hydrophobicity value to each amino 
acid position in the aligned sequence.  The values are averaged over the whole set of aligned 
amino acids from each sequence and then these raw averages are averaged over traveling 
windows ranging in size from local sampling (7, 9, or 11 residues) to larger sampling (21 
residues) to capture the hydrophobic character of the helix.  The seven residue window 
corresponds to roughly two helix turns, while 21 residues is about the length of the full TM helix.  
Next, all eight traveling windows are averaged, so that each amino acid is assigned a single 
hydrophobicity value.  These values for the target sequence are plotted to identify the seven 
obvious hydrophobic regions lying above the 0 baseline which correspond to the seven TM 
helical domains spanning the hydrophobic lipid bilayer providing the length and the hydrophobic 
center for each TM domain.  The midpoint of the raw hydrophobic region or the residue bisecting 
the hydrophobic area for each helix provide the buoyant centers of the TM domains, with all 
seven residues lying in the same plane at the center of the membrane. 
 
This hydrophobic analysis provides the raw hydrophobic regions of the helices, but GPCR crystal 
structures of bovine rhodopsin (PDB ID: 1U19) (24) and human chemokine receptor CXCR4 
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(hCXCR4) (PDB ID: 3ODU) (25) show that the hydrophobic helices can extend one or two turns 
out of the lipid bilayer into the solvent.  To extend the hydrophobic regions of the helices, we 
developed a consensus helix capping method using three secondary structure prediction servers: 
Porter Protein Secondary Structure Prediction Server (26; 27), APSSP2: Advanced Protein 
Secondary Structure Prediction Server (28; 29), and PSIPRED: Protein Prediction Server (30-32). 
 
Step 2: Optimize helix shapes for the seven TM segments  
Step 2.1: Optimizing helices using molecular dynamics and minimization with OptHelix 
Then, the OptHelix method was used to build and optimize the 3D structures of the TM domains.  
OptHelix performs a series of MD and energy minimizations to find the most stable structure of 
each individual helix.  First, a canonical polyalanine helix is built matching the length of the 
predicted capped TM domains.  Here, the glycine and proline residues from the original sequence 
are mutated into the helices using SCREAM (Side Chain Rotamer Excitation Analysis Method), a 
side chain optimization program (33).  Proline and glycine residues are known helix-breakers that 
affect the backbone structure (34-36).  The backbones of these TM domains are minimized to a 
root-mean squared (RMS) force of 0.5 kcal/mol/Å or to a maximum of 1000 steps in order to 
describe the modification on the backbone structure caused by mutating alanines to prolines or 
glycines.  Previous studies have shown that the serine and threonine residues can either enhance 
or decrease the kink by interacting with the proline or amide groups within one helical turn (37).  
Thus, the appropriate alanine residues are changed to serine or threonine residues using 
SCREAM before doing a “warm-up” MD for each of the seven helices separately to prevent 
distortions that may be caused by the original assignment of velocities.  The “warm-up” MD 
consists of heating in 50 K increments from 50 K to 250 K for 10 ps each with a 2 fs timestep for 
a total of 40 ps.  Finally, the system is equilibrated with MD at 300 K for 2 ns with a 2 fs 
timestep.  Ignoring the first 0.5 ns, snapshots are saved every 10 ps for a total of 150 snapshots.  
The snapshots with the lowest potential energy or with the RMSD closest to the average structure 
of the simulation are selected, and all residues are changed to their proper amino acid using 
SCREAM.  The final structure is minimized to an RMS of 0.5 kcal/mol/Å or for a maximum 
number of 100 steps. 
 
Step 2.2: Optimizing helices using homologized helices, or helix templates from crystallized 
GPCRs. 
In addition to the above procedure with OptHelix, we also built helices using templates from 
crystal homology models.  These templates bias the calculations to match the helix shape of the 
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crystallized GPCRs such as the inactive turkey β1 adrenergic receptor, the inactive human β2 
adrenergic receptor, the inactive human adenosine A2A receptor, and hCXCR4 to name a few.  In 
each case we start with the crystal structure, remove the loops, mutate the residues to the target 
sequence, extend or shrink the length of the helices to match those of the OptHelix helices, and 
use the new helices to sample all 35.8 million combinations of the eta (rotation, η) angles using 
the same methodology described below.  The helices are minimized 100 steps or to an RMS 
0.0005 kcal/mol/Å.  The homology helices are the same length as the OptHelix helices, so we can 
compare the total energy of the receptors since they all have the same number of atoms.  
Homology modeling is not expected to be effective for receptors distantly related to the target.  
Moreover, our results show dramatic changes in TM orientations with just a single point 
mutation, invalidating the fundamental assumption of homology modeling. 
 
Step 3: Generate template for receptor bundle 
The seven optimized helices are then aligned to experimental crystal templates.  The initial GPCR 
crystal template provides initial values for the x, y positions and the theta (θ, tilt), phi (ϕ, sweep), 
and eta (η, rotation) angles for each helix.  The z-position corresponds to the hydrophobic center 
determined from PredicTM in Step 1 or the aligned homologized helix residue, with all seven 
hydrophobic centers on the same midpoint plane.  Then, we exhaustively sample what we 
consider to be a complete set of θ, ϕ, and η angles to find the low energy receptor conformations. 
 
Figure 2.2 Six degrees of freedom for a helix.  We can sample four of them (θ, ϕ, and η angles and z-axis) 
with the SuperBiHelix and SuperComBiHelix programs. 
 
Step 4: Create ensemble of orientations of seven helices 
We have found that it is essential to rotate all seven helices simultaneously to find the optimum 
combinations.  Thus, considering 30° increments in η (which was found to be the minimum 
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sampling size), there are 127 = 35.8 million combinations, all of which must be examined in order 
to select the optimum packings of the bundles.  The BiHelix and ComBiHelix programs were 
developed (15) to enable a complete sampling of all these 35.8 million conformations to identify 
the ensemble of low energy poses that might play a role in binding ligands and activation,. 
 
The first step, BiHelix, independently considers just the 12 pairs of helices that are close enough 
to interact [1-2, 1-3, 1-7, 2-3, 2-4, 2-7, 3-4, 3-5, 3-6, 3-7, 4-5, 5-6, and 6-7].  For each of the 
122=144 combinations of each pair, the side chains are optimized using SCREAM, and the energy 
is minimized for 10 steps.  Summing the total intra- and interhelical values from these 
12*144=1728 pairwise interaction energies leads to an energy estimate for all 35.8 million 
receptor bundles.  Then, CombiHelix selects the combinations for the seven helix bundles 
predicted to have the lowest energy (38) and constructs the entire seven helix bundle to evaluate 
the total energy after using SCREAM to optimize the side chains and minimizing the energy for 
10 steps.  Ranking these bundles by their minimized total energy, we select the lowest energy 
bundle.  This ComBiHelix bundle is chosen as the starting point for simultaneous optimization 
refinement of the tilt angles (θ and ϕ) while re-optimizing the η angles. 
 
The lowest total energy ComBiHelix structure is used as the starting structure for SuperBiHelix, 
or further refinement in which the tilt angles (θ, ϕ) are optimized simultaneously with η.  First, 
using SCREAM, the two terminal residues on each TM are replaced with alanine residues if they 
are one of the five charged residues (arginine, lysine, aspartic acid, glutamic acid, or histidine).  
This alanization of the terminal residues eliminates the strong electrostatic interactions at the ends 
of the helices, which may bias the calculations of the side chain interaction energies.  This 
alanization step must be done when allowing variations in the θ and ϕ angles along with 
variations in the η angle.  In SuperBiHelix (18), the η and ϕ angles are sampled over ±30° in 15° 
increments, while the θ is sampled over ±10° in 10°.  With these ranges we consider 
(5*5*3)7=13.3x1012 or ~13 trillion packings from which we select the top 2000 based on lowest 
total Super BiHelix combinations of pair-wise energies.  These packings are built into full seven-
helix bundles in SuperComBiHelix.  Then, the full energy of each of these 2000 structures is 
evaluated after optimizing side chains and minimizing the energy. 
 
Step 5:  Choose the lowest energy structures 
From the 2000 best receptor bundles from SuperComBiHelix, an ensemble of 10 low energy 
poses are chosen based on average energy rank.  Here, we use four ways to calculate the energy.  
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Two ways use the normal charged form of aspartic acid, glutamic acid, lysine, arginine, and 
histidine, while the other two consider neutral forms for each of those residues.  Two ways to 
combine the energies are considered.  In addition to the total energy, we also consider only 
interhelical interactions with either charged or neutralized residues.  From studies over many 
systems for which we can compare to x-ray crystal structures, we find that ranking the structures 
using all four methods and averaging this ranking leads to the most reliable predictions.  The all 
atom Dreiding force field (39) is used for all energy calculations. 
 
Part B:  Predicting the mutant receptor structures 
Sometimes it is necessary to build mutants of the WT receptors.  Site-directed mutagenesis is 
useful for testing lingand binding affinity or functionality.  We are especially interested in 
constitutively active mutations (CAMs) because they can significantly change the functionality of 
the receptor by changing a single residue.  GEnSeMBLE is a useful method for structure 
prediction because we construct the mutants starting from the helices and observe the global 
impact a single residue can have on the entire receptor conformation. 
 
 
Mutate the specified residue using SCREAM 
To predict the ensemble of low energy mutant structures, we use the same methodology as 
described for the WT receptor.  Here, the WT helices built in Part A Step 1 are used to generate 
the receptor bundle, but one, two, or even three residues are mutated using SCREAM.  The 
subsequent steps (Steps 2 - 5) are the same for the mutants as they are for the WT receptor (see 
Part A), where full helix bundle conformational sampling is performed for each mutant. 
 
II.  DarwinDock and GenDock procedure for completely sampling ligand poses in the binding 
site 
These predicted conformations from Part I can be further validated by docking known ligands to 
them and explaining experimental site-directed mutagenesis and structure-activity relationship 
(SAR) data.  Site-directed mutagenesis data is useful because it indicates which residues are 
potentially important for anchoring the ligand in the binding site.  If the ligand’s binding affinity 
is significantly decreased when a residue is mutated, either that residue has strong interactions 
with the ligand or the mutation caused the receptor to undergo a conformational change.  Usually, 
the assumption is that the loss in binding affinity is due to the former, but in this work, we check 
the possibility of the latter.  SAR data indicates which portion of the ligand is important for 
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interactions with the receptor.  A particular portion of the ligand is modified multiple times to 
generate many different ligands.  The binding affinity is measured for these ligands and large 
changes in affinity indicate which parts of the ligand are important for interacting with the 
binding site.  The objective is to explain these experimental data on the molecular level with our 
computational studies.  For example, it is expected that the ligand will have strong energetic 
interactions with residues that have a large impact on experimental binding affinity.  Based on our 
predicted binding site, we also expect to be able to explain why modifications in the ligand 
structure impacts the interactions with the receptor and thus the binding affinity and to show 
trends between our calculated binding and cavity energies and the experimental binding affinities. 
 
Many docking programs rely on training sets, that is, they are based on information of previously 
crystallized protein-ligand complexes.  Since there is a dearth of information about GPCR 
structures, these training sets are not relevant to our systems.  Our hierarchical docking methods, 
DarwinDock and GenDock (40-44), generate thousands of ligand conformations to thoroughly 
and completely sample the receptor’s binding site before refining and enriching a small number 
of poses and determining the best one energetically.  Like GEnSeMBLE, this procedure relies on 
completely sampling all potentially important conformations in an efficient manner.  The 
receptor-ligand complexes are chosen using an approach that is not biased by other experimental 
data.  First, we need to construct ligands to dock to various conformations of the receptors and 
determine which receptor conformation the ligand prefers to bind to. 
 
Part A:  Ligand preparation 
The DarwinDock program docks rigid ligands to rigid receptors, so it is necessary to dock 
multiple diverse ligand conformations.  For each ligand, we construct each structure with Maestro 
software (45) and preform a conformational search with MacroModel software (46). We use 
sytematic and extended torsional sampling where the selected rotatable bonds are rotated 360° in 
30° increments.  We save ligand conformations that fall within an energy window of  
10 kJ/mol and an RMSD window of 0.5 Å.  The conformational search is conducted with the 
OPLS 2005 force field (47) and in a dielectric of 80.37 to match water.  We preform two rounds 
of clustering for each ligand—the first round we clustered ligands with a 2.0 Å diversity followed 
by another round with a 1.0 Å.  We calculate the Mulliken populations of each atom with Jaguar 
software (48) using Density Functional Theory (DFT) with the B3LYP functional and the 6-
31G** basis set.  Sometimes one of the conformations for the ligand is constructed from existing 
coordinates from a crystallized small molecule deposited in the Cambridge Structural Database 
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(49).  Then each ligand is minimized with SGB solvation (50) for 100 steps or to a convergence 
threshold RMS of 0.2 kcal/mol/Å with MPSim software (38). 
 
Part B:  Docking procedures 
Using the programs DarwinDock and GenDock (40-44) developed within our lab, we dock 
multiple ligand conformations to two or three selected regions that encompass the binding site of 
the low energy structures of each of the receptors. The docking procedure consists of two steps, 
DarwinDock (Figure 2.3), which generates enough ligand poses to completely sample the 
binding site, and GenDock (Figure 2.4), which enriches the lowest energy complexes from the 
DarwinDock step.  Figures 2.3 and 2.4 show a general overview of the methods, and technical 
details are summarized below. 
 
Step 1: Generate ligand-receptor complexes with DarwinDock 
DarwinDock (Figure 2.3) combines the completeness of generating poses to thoroughly sample 
the space of the binding pocket, indicated by the sphere regions, and the clustering of similar 
poses together to reduce the computational cost of energy scoring by only scoring diverse 
candidates.  In preparation for this step, the receptors are ‘alanized’ by replacing the bulky, 
hydrophobic residues (phenylalanine, isoleucine, leucine, methionine, tyrosine, valine, 
tryptophan) with alanine residues.  This residue substitution increases the amount of sampling 
space in the binding site because the larger residues will not clash with the ligand.  We believe 
that the stronger interactions occur with the polar ones, so the ligands will be anchored in the 
binding site by hydrogen bonds and salt bridges, while the phobic residues can fill in around these 
previously formed contacts. 
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Figure 2.3 DarwinDock procedure diagram.  The above schematic explains the process DarwinDock uses 
to generate approximately 150 complex poses that will enter GenDock, the enrichment phase. 
 
The first step is to use Dock6 (51) to generate thousands of ligand poses in the alanized receptor.  
Each iteration of DarwinDock consisted of a series of steps: first, Dock6 produced 5000 ligand-
receptor complex poses and then the ligand poses were grouped into ‘families’ using Vornoi 
clustering where every member of the family was within a 2.00 Å RMSD of another.  A ligand 
pose is discarded if it clashes or bumps the receptor residues more than a specified number of 
times depending on the size of the ligand.  These steps are repeated until ‘completeness’ is 
reached.  The definition of ‘completeness’ is when the number of new families created is less 
than 2% of the number of existing families indicating that the binding site has been thoroughly 
and completely sampled.  A representative pose termed the ‘family head’ is chosen for each 
family.  Each family head’s energy is calculated, and 10% of the family heads with the lowest 
energies are chosen.  The program then scores the energies of all the poses in the respective 
families of the identified low energy family heads.  One hundred and fifty receptor-ligand poses 
are selected for the next step, GenDock, based on their energies.  Fifty poses are chosen 
according to the lowest phobic energy, another 50 poses according to the lowest polar energy, and 
50 poses according to the lowest total energy. 
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Step 2:  Refine ligand-receptor complexes with GenDock 
The GenDock program used three modules to refine and enrich the 150 docked ligand-receptor 
poses generated by DarwinDock.  Figure 2.4 outlines this procedure using the WT CB1 receptor 
and the cannabinoid agonist WIN55212-2 as examples.  The first module uses the SCREAM 
program (33) to replace alanines with the original hydrophobic residues (refer to the DarwinDock 
section) and to sample the side chain rotamers of any residue within 4.00 Å of any ligand pose.  
Then the entire complex including the receptor backbone is minimized for 10 steps.  The second 
module neutralizes the receptor by adding protons to the acidic residues (aspartic acid, glutamic 
acid) and removing a proton from the basic residues (lysine, arginine, and histidine).  Depending 
upon the pKa of the ligand, it will either gain or lose protons until its total charge is zero.  The 10 
steps of minimization are repeated for the entire complex.  These neutralized energies are more 
realistic for comparisons between different complexes (52).  The last module consists of a full 
relaxation of the entire complex with 50 steps of minimization with the Dreiding III FF (39).  We 
believe that this FF is more reliable than the energy scoring function used by Dock6. 
  
 
Figure 2.4 GenDock procedure diagram.  Lowest energy poses from DarwinDock procedure undergo 
enrichment phase illustrated above. 
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Step 3:  Select the best complex energetically 
We modified the Dreiding III FF by replacing the exponential-6 term with the Lennard-Jones (LJ) 
one to better account for repulsive actions between atoms.  Using MPSim software (38), we 
minimized the selected complexes from the previous step with the modified Dreiding III-LJ force 
field in vacuum for 50 steps or to an RMS threshold of 0.5 kcal/mol/Å.  
 
There are multiple types of energies that can accurately identify the correct ligand pose in the 
receptor’s binding site.  The binding energy (SnapBE) is defined as the energy difference 
between the complex and the sum of the receptor and ligand energies.  Most of the docking 
complexes herein are ordered according to the binding energy with the ligand strain and ligand 
solvation added (SnapBE-strain-ligsolv).  The cavity energy (UCav) is the energy between the 
ligand and the residues in the unified binding site, or the list of residues interacting with each 
ligand pose is combined to create a unified list.  The energy between the ligand and all the 
residues in this list is calculated. 
 
III.  Applications to GPCRs and other membrane proteins 
The focus of this thesis is how we applied these structural prediction methods to GPCRs and 
another membrane protein, the human glycoprotein Ecgp96, in order to obtain accurate 
predictions and understand how these proteins interact with small molecules and drugs.  The 
human CB1 receptor is a stellar example of the application of these methods to predict the 
structure of a TM receptor that has not been crystallized.  At the start of this project, none of the 
crystallized GPCRs were closely related to CB1.  Thus, we used the GEnSeMBLE method to 
perform a thorough sampling of trillions of CB1 conformations to obtain an ensemble of low 
energy structures.  We repeated this procedure for two single-point mutants that had significantly 
different levels of activity compared to the WT.  The resulting structures for the three receptors 
are dramatically different on a global scale and had different patterns of charged interactions on 
the intracellular end where the G protein binds.  Most importantly, the structural differences 
explain the experimentally confirmed functional differences.  To test our structural 
understanding, we designed double and triple mutants with specific levels of activity in mind.  
Subsequent experiments later confirmed our predictions proving that certain charged interactions 
are important for stabilizing the active or inactive conformations of the CB1 receptor.  Hence, the 
above methodology is sensitive enough to detect the impact that a single residue has on the global 
conformation of the GPCR, which cannot be done with the homology methods. 
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To further support our predicted structures, we docked the known CB1 inverse agonist/antagonist 
rimonabant to our ensemble of CB1 predicted structures and were able to explain experimental 
site-directed mutagenesis and SAR data.  Our proposed rimonabant binding site is different from 
that which has been published previously (53-57).  Based on the newly predicted binding site, we 
identified ligands in the PubChem database (58) that are commercially available and have not 
been tested with the CB1 receptor.  We predict that these ligands are strong CB1-selective inverse 
agonists, which could be effective anti-obesity drugs.  Thus, these methods have been very 
successful in providing insight into the structure and function of CB1 as well as other GPCRs 
discussed herein. 
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Chapter III 
 
STRUCTURAL BASIS OF HUMAN CANNABINOID CB1 G PROTEIN-COUPLED 
RECEPTOR ACTIVATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The GTPγS assay results shown herein were preformed by Dr. Kwang Hyun Ahn and 
Professor Debra Kendall. 
 
Adapted with permission from: 
Scott CE, Abrol R, Ahn KH, Kendall DA, Goddard WA, III (2013) Molecular basis for 
dramatic changes in cannabinoid CB1 G protein-coupled receptor activation upon single 
and double point mutations. Protein Sci 22:101-113. 
 
Ahn KH, Scott CE, Abrol R, Goddard WA, III, Kendall DA (2013) Computationally-
predicted CB1 cannabinoid receptor mutants show distinct patterns of salt-bridges that 
correlate with their level of constitutive activity reflected in G protein coupling levels, 
thermal stability, and ligand binding. Proteins: Struct, Funct, Bioinf 81:1304-1317. 
 
Bray JK, Abrol R, Goddard WA, III, Trzaskowski B, Scott CE (2014) SuperBiHelix 
method for predicting the pleiotropic ensemble of G-protein-coupled receptor 
conformations. Proc Natl Acad Sci U S A 111:E72-E78. 
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ABSTRACT 
 
There is considerable interest in determining the activation mechanism of G protein-coupled 
receptors (GPCRs), one of the most important types of proteins for intercellular signaling.  
Recently it was demonstrated, for the cannabinoid CB1 GPCR, that a single mutation T210A 
could make CB1 completely inactive whereas T210I makes it essentially constitutively active.  
To obtain an understanding of this dramatic dependence of activity on mutation, we used first 
principles-based methods to predict the ensemble of low energy seven helix conformations for the 
wild-type (WT) and mutants (T210A, T210I, and L207A).  We find that the transmembrane (TM) 
helix packings depend markedly on these mutations, leading for T210A to both TM3+TM6 and 
TM2+TM6 salt bridge couplings in the cytoplasmic face that explain the inactivity of this mutant.  
In contrast, T210I and L207A have no such couplings across the receptor explaining the ease in 
activating these mutants.  The WT receptor only has the TM3+TM6 coupling, known to be 
broken upon GPCR activation.  To test the hypothesis that the TM2+TM6 salt bridge ensures 
inactivity, we predicted double mutants and a triple mutant that would convert the inactive mutant 
to normal activity, and then our collaborators confirmed this experimentally.  We also proposed a 
adding a second mutation to the constitutively active L207A receptor to make it fully inactive, 
which was also confirmed experimentally.  This CB1 activation mechanism, or one similar to it, 
may be applicable to other constitutively active class A GPCRs as well. 
 
INTRODUCTION 
 
Activation of G protein-coupled receptors (GPCRs) by extracellular sensory and non-sensory 
signals affects multiple intracellular signaling cascades by modulating G protein and/or β 
arrestin-coupled pathways (1).  This pleiotropic consequence on GPCR activation is facilitated by 
their remarkable conformational flexibility, enabling the formation of multiple distinct 
conformations that can influence function.  The human cannabinoid type 1 (CB1) receptor, which 
is located mainly in the central nervous system, displays partial constitutive activity.  We have 
shown previously (2) and confirmed using GTPγS assays (Figure 3.1), that mutating the 
threonine residue T210 near the cytoplasmic end of the third transmembrane region (TM3) to 
alanine makes CB1 inactive, whereas mutating it to isoleucine makes it highly constitutively 
active (2).  The residue T210 will be referred to as T3.46 throughout the remainder of this thesis 
[using the Ballesteros-Weinstein numbering scheme (3)], indicating that it is located one helix 
turn above the conserved R3.50 residue on the intracellular end of TM3.  Changes in binding 
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profiles for the inverse agonist rimonabant in the presence and absence of G protein-coupling 
indicated that the T3.46I receptor adopts the active state, while the T3.46A receptor is in an 
inactive state (2).  We found experimentally that a high concentration of GTPγS precludes G 
protein-coupling, promoting the inactive form.  Under these conditions, T3.46I, which otherwise 
has a weak binding affinity for inverse agonists, displayed a 30-fold enhancement in its affinity 
for rimonabant.  In comparison, the wild-type (WT) receptor displayed a 5-fold increase in 
rimonabant affinity, while the T3.46A receptor showed a negligible increase in affinity for this 
ligand.  This hierarchy of rimonabant affinity changes parallels the ease with which each receptor 
adopts an inactive conformation (2).  These major activity changes upon single point mutations 
provide an excellent system for probing the molecular mechanisms of GPCR activation, allowing 
us to follow the structural changes from the fully inactive form, through the weakly constitutively 
active form typically seen in WT receptors, to the highly constitutively active form. 
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Figure 3.1 Comparison of basal GTPγS binding to HEK293 cell membranes expressing the CB1 receptors.  
The level of [35S]GTPγS binding was measured in the absence of ligand for the WT, T3.46I, and T3.46A 
receptors.  The [35S]GTPγS binding for the mock-transfected, and for the membrane expressing the WT 
receptor with inverse agonist rimonabant treatment, are shown for comparison. Data are presented as 
specific binding of GTPγS to the membrane preparation.  Nonspecific binding was determined in the 
presence of 10 µM unlabeled GTPγS.  Each data point represents the mean ± S.E.M. of at least three 
independent experiments performed in duplicate.  Statistical significance of the differences between the 
level of each receptor and that of a mock-transfected sample was assessed using one-way analysis of 
variance and Bonferroni’s post-hoc test; *, p < 0.05; **, p < 0.01; ***, p < 0.001.  The dashed line indicates 
the level of non CB1-mediated GTPγS binding obtained from [35S]GTPγS binding to the mock-transfected 
membrane sample. 
 
To evaluate the basal G protein-coupling activity of the WT, T3.46A, and T3.46I receptors, we 
measured the level of [35S]GTPγS binding to HEK293 cell membranes expressing the receptors in 
the absence of ligand (Figure 3.1).  Specific GTPγS binding for the T3.46A receptor is 52.6 
fmol/mg in the absence of the ligand, which is comparable to the level observed in a mock-
transfected sample and with the level of the WT sampled after treatment with the rimonabant 
inverse agonist.  Thus, we refer to T3.46A as ‘fully inactive.’  For the WT receptor in the absence 
of ligand the level of GTPγS binding is 91.3 fmol/mg, an increase of 37.8 fmol/mg above the 
level of the mock-transfected sample whereas for the T3.46I mutant it is 112.4 fmol/mg, an 
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increase of 58.9 fmol/mg.  These data are consistent with the previous ligand binding profile (2), 
confirming that the T3.46A receptor is inactive and unable to bind to G protein, the WT receptor 
has constitutive activity, and the T3.46I receptor is much more constitutively active, with the 
latter two able to couple to the G protein. 
 
To provide the structural information needed to understand activation of GPCRs, we used first 
principles-based computational methods (4-7) to predict the ensemble of energetically favorable 
conformations available to play a role in multiple GPCR-mediated pathways.  Our objective is to 
accurately predict multiple conformations of a GPCR that may or may not be closely related to 
the crystallographically characterized receptors.  Homology modeling approaches are not yet 
capable of predicting such multiple conformations, as shown below in the discussion.  We report 
here the results of applying these methods to CB1, providing a structural basis for understanding 
the dramatic effects on activation observed experimentally for single mutations at the T3.46 
position in this receptor (2).  We then use this structural understanding to predict two double 
mutants expected to convert the fully inactive T3.46A to WT-level constitutive activity, which we 
subsequently confirm experimentally by GTPγS binding assays.  Conversely, we design another 
double mutant to convert the highly constitutively active L3.43A mutant to T3.43A-level full 
inactivity.  To prove that a coupling involving the R2.37 residue maintains the inactive structure, 
we designed a triple mutant predicted to be constitutively active.  Subsequent GTPγS assays agree 
with the functional levels and strongly support the predicted structures, thus reaffirming the 
proposed structural basis for the activation mechanism for the CB1 receptor. 
 
METHODS 
 
(For more details about structure prediction methodology, see Chapter II.) 
 
To identify a structural basis for the experimental findings, we used the GEnSeMBLE method (4-
8) to predict the ensemble of energetically favorable conformations, in other words the packing 
within the seven helix bundle, for all CB1 receptors discussed herein.  
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Part A: Predicting the WT receptor structures 
Step 1: Predict transmembrane (TM) helix regions of the receptor 
Using a BLAST (9) search, we found 1387 sequences of seven-helix proteins with sequence 
identities ranging in from 100% to 8.47%.  Table 3.1A compares the sequence identities of the 
crystallized GPCR sequences to the human CB1 receptor sequence.  The overall sequence 
identities of the seven crystal structures fall in the ~10-16% range with TM sequence identities 
ranging between ~16-28%.  The other member of the human cannabinoid family, CB2, has a 
32.42% overall sequence identity with human CB1 and a 52.59% sequence identity within the 
CB1 TM regions.  The human CB1 receptor lacks certain motifs common to other class A GPCRs 
such as the conserved proline in TM5 and a disulfide bond between TM3 and the second 
extracellular loop (EC2).  Thus, homology modeling is not expected to be effective as 
demonstrated by the total energy comparison discussed below in Part A Step 4.  Moreover, our 
results show dramatic changes in TM orientations with just a single point mutation, invalidating 
the fundamental assumption in homology modeling.   
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Table 3.1 Constructing the WT, T3.46A, T3.46I receptors using first principles-based methods.   
(A) Comparison to the human CB1 receptor sequence of the overall sequence identity and TM sequence 
identity of human CB2 and crystallized GPCR sequences including the human adenosine A2A receptor 
(HA2AAR) (10), the turkey β1 adrenergic receptor (Tβ1AR) (11), the human β2 adrenergic receptor 
(Hβ2AR) (12), the squid rhodopsin receptor (sRho) (13; 14), the human dopamine D3 receptor (hDD3R) 
(15), the bovine rhodopsin receptor (bRho) (16), and the human chemokine CXCR4 receptor (hCXCR4) 
(17).  (B) Sampling rotation angles for CB1 receptors.  Optimized eta (η, rotation), angles from the 
ComBiHelix program for the three receptors: T3.46A, WT, and T3.46I.  The crystal inactTβ1AR (PDB ID: 
2VT4) (11) is the reference case.  (C) Energy comparison for CB1 receptors with OptHelix helices and 
homologized helices.  Optimized eta (η, rotation), angles from the ComBiHelix analysis for the WT 
receptors with various helices: OptHelix helices aligned to crystal inactTβ1AR (PDB ID: 2VT4) template, 
homology inactTβ1AR (PDB ID: 2VT4) helices, homology inactHβ2AR (PDB ID: 2RH1) (18) helices, and 
homology inactHA2AAR (PDB ID: 3EML) (10) helices.  * = Different selection of eta residue. 
A. 
GPCR Name Overall Sequence 
Identity (%) 
TM Sequence 
Identity (%) 
Human CB1 Receptor 100 100 
Human CB2 Receptor 32.42 52.59 
Turkey Beta 1 Adrenergic Receptor 15.89 28.45 
Human A2A Adenosine Receptor 16.10 26.31 
Human Beta 2 Adrenergic Receptor 14.19 24.65 
Human D3 Dopamine Receptor 10.81 24.09 
Bovine Rhodopsin Receptor 10.59 21.94 
Human CXCR4 Receptor 9.96 18.57 
Squid Rhodopsin Receptor 13.14 16.27 
 
B. 
 η  (°) 
Receptor H1 H2 H3 H4 H5 H6 H7 
T3.46A -120 -150 0 0 -120 30 -90 
WT 90 -60 0 0 -120 30 -120 
T3.46I 150 -90 0 30 -120 0 -30 
 
C. 
 η  (°) PostMinE 
Method H1 H2 H3 H4 H5 H6 H7 (kcal/mol) 
Gensemble—
inactTβ1AR template 
90 -60 0 0 -120 30 -120 -110.4 
Homologized 
inactTβ1AR Helices 
-30 0 0 -30 -210* 0 90 108.1 
Homologized 
inactHβ2AR Helices 
0 0 0 0 -90* 0 90 15.9 
Homologized 
inactHA2AAR Helices 
0 0 0 -30 90* 90 -120 109.6 
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In the second step, we aligned the 1387 amino acid sequences and found an average 
hydrophobicity value for each residue.  The CB1 hydrophobicity values are plotted in Figure 3.2, 
and we can clearly identify the seven hydrophobic regions above the 0 baseline corresponding to 
the seven TM helical domains.  The midpoint of the hydrophobic region for each helix represents 
the point where the helix crosses the hydrophobic plane passing through the center of the helical 
bundle. 
 
Figure 3.2 CB1 hydrophobicity plot.  This graph indicates the hydrophobic portions of the amino acid 
sequence, which include the hydrophobicity values above the baseline.  The seven hydrophobic regions 
correspond to the seven TM regions of the amino acid sequence. 
 
Step 2: Optmize helix shapes for the seven TM segments using OptHelix 
Figure 3.3 shows the OptHelix products for TMs 6 and 7. These helices contain proline residues, 
which impact the backbone shape by altering the bend, wobble, and face shift angles, as defined 
in Ref. (19) and indicated in the figure. The P6.50 residue (Figure 3.3A) causes the helix to bend 
11.2°.  The wobble angle, defined to be orientation of the post-proline portion of the helix with 
respect to the axis containing the proline’s alpha-carbon, is a significant -128.7°. The face shift is 
the angle between proline’s alpha-carbon and the vector between the alpha-carbons of the (i-3) 
and (i-4) residues away from proline indicating if the helix is over- or under-wound.  The positive 
48.1° face shift angle for P6.50 shows that the helix is under-wound.  P7.50 (Figure 3.3B) causes 
a less significant bend of only 6.7°.  TM7’s wobble angle is at 167.5°, which is in the opposite 
direction of the one in TM6.  The face shift angle is less significant in TM7 at 22.1°, but like 
TM6, this helix is under-wound. 
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Figure 3.3 Effect of the proline residue on the shapes of (A) TM6 and (B) TM7. The helical backbone is 
shown in cyan, while the proline alpha-carbon atoms are brown spheres, and the (i-3) and (i-4) residue 
alpha-carbon’s are lavender spheres. The axes and bend, wobble, and face shift angles are labeled in the 
same way as in Ref. (19). 
 
Step 3: Generate template for receptor bundle 
The seven optimized helices are then aligned to the experimental crystal templates inactTβ1AR 
(PDB ID: 2VT4), (PDB ID: 2RH1), and inactHA2AAR (PDB ID: 3EML).  The inactTβ1AR 
template was chosen over the other two templates because our calculations gave lower energies 
for the inactTβ1AR bundles after the ComBiHelix stage.  
 
Step 4: Create ensemble of orientations of seven helices 
Out of 1000 bundles generated by ComBiHelix (6), we select the lowest energy bundle, as shown 
in the Table 3.1B, which will be used by SuperBiHelix (8) as the starting point for sampling the 
tilt angles (θ and ϕ) simultaneously with the η angles. After which, we select the top 2000 based 
on lowest total SuperBiHelix combinations of pair-wise energies.  These are built into full seven 
helix bundles in SuperComBiHelix.  Then we evaluate the full energy of each of these 2000 
conformations after optimizing side chains and minimizing the energy. 
In addition to the above predictions, we repeated this procedure using helices from crystal 
homology models including inactTβ1AR (PDB ID: 2VT4) (11), inactHβ2AR (PDB ID: 2RH1) 
(18), and inactHA2AAR (PDB ID: 3EML) (10).  Table 3.1C shows the final energy comparison 
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of the WT receptor built from various helices.  The OptHelix helices produced the lowest energy 
helix bundle with a post-minimization energy value of -110.4 kcal/mol.  The three cases with 
homologized helices range in energies of 15.9 to 109.6 kcal/mol, which are ~100-200 kcal/mol 
worse than that of the one with OptHelix helices.  Furthermore, we find the homologized helices 
to be physically unreasonable because in the homologized helix structures, rimonabant-binding 
residues W5.43 and/or K3.28 (11; 20) are in positions that are not accessible to the binding site. 
 
Step 5:  Choose the lowest energy structures 
We chose an ensemble of 10 low average energy rank poses that represent the most favorable and 
energetically accessible conformations.   
 
Part B:  Predicting the T3.46A, T3.46I, T3.46A/R2.37A, T3.46A/R2.37Q, L3.43A, 
L3.43A/D2.63A, L3.43A/D2.63A/R2.37A, and L3.43A/K3.28A receptor structures 
Mutate: 
• T3.46 residue into alanine or isoleucine and/or R2.37 into alanine or glutamine 
• L3.43 residue into alanine and/or D2.63 into alanine  
• L3.43 residue into alanine, D2.63 into alanine, and R2.37 into alanine 
• L3.43 residue into alanine and K3.28 into alanine 
using the Side Chain Rotamer Excitation Analysis Method (SCREAM) (21) in the OptHelix 
helices then repeat the subsequent steps outlined above for the WT receptor.  Sometimes multiple 
low energy structures from the ComBiHelix stage were sources of input into SuperBiHelix, and 
all the resulting SuperComBiHelix structures were combined and ranked by average energy rank. 
 
RESULTS 
 
Position of the mutated residue T3.46 
The T3.46 residue (T210) is one helical turn above R3.50 (see Figure 3.4A), which is highly 
conserved among class A GPCRs.  In the WT CB1 receptor, R3.50 makes a critical salt bridge to 
D6.30 (D338).  The crystal structures of bRho (16; 22-31), sRho (13; 14), and hDD3R (15) and 
other experimental studies (32; 33) have concluded that in the inactive form R3.50 forms a salt 
bridge with D/E6.30 on the cytoplasmic end of TM6, leading to the proposal that this salt bridge 
stabilizes the inactive form of the receptors and hinders their activation. 
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Our computational predictions indicate that WT CB1 contains a unique hydrogen bond involving 
T3.46 and S2.45 (Figure 3.4B).  The S2.45 residue usually participates in the highly conserved 
TM2-TM3-TM4 hydrogen bond network as observed in other crystallized GPCRs, but these 
receptors have alanine or leucine at this position, so for all other receptors, this hydrogen bond 
connecting TM2 and TM3 cannot exist.  By mutating this particular residue to alanine or 
isoleucine the hydrogen bond is broken, affecting the interactions between the TM regions.  The 
changes in the receptor conformation are reflected in the changes in experimental GTPγS binding 
shown in Figure 3.1 and will be discussed further below.  
 
 
Figure 3.4 Relative position of T3.46 in the WT receptor.  (A) Predicted structure of TM3 of human CB1 
receptor’s helix 3.  Residues R3.50 and T3.46 (indicated) are on the same face of the helix, pointing into 
the center of the receptor bundle.  (B) Atomic view of the interaction between T3.46 and S2.45 in WT CB1.  
Interaction between T3.46 and S2.45 in WT-1 (lowest average energy rank) conformation.  The two 
residues interact via a hydrogen bond.  The heteroatom distance is indicated by the dotted line. The S2.45-
T3.46 hydrogen bond was found in five of our ten lowest energy protein structures after molecular 
dynamics (MD) annealing (34) on just the side chains of the two residues.  This hydrogen bond is 
especially important because it involves the residue, T3.46, selected for mutation. 
 
Predictions of the stable structural ensembles for CB1 WT and mutant receptors 
We find that the mutations of T3.46 lead to substantial changes in helix packing within the seven-
helix bundle, which in turn lead to major differences in the salt bridge interactions between the 
cytoplasmic end of TM6 that are expected to play a role in activation.  The predicted ensemble of 
low energy structures of WT CB1 and its two mutants, T3.46A and T3.46I, are shown in Table 
3.2A.  The orientations of some helices change dramatically upon mutation.  Here, we denote the 
angle about the helix axis as eta (η, rotation) and the two angles defining the tilt as theta (θ, tilt) 
and phi (ϕ, sweep) as defined in Ref. (35).  The average energy ranges are: 
• T3.46A: -334.3 kcal/mol to -311.2 kcal/mol, 
• WT: -350.8 kcal/mol to -332.0 kcal/mol, 
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• T3.46I: -317.1 kcal/mol to -289.9 kcal/mol. 
And the backbone root-mean-square deviation (RMSD), with respect to the lowest energy 
structure, ranges are: 
• T3.46A: 0.2 Å - 3.5 Å, 
• WT: 0.4 Å - 2.1 Å, 
• T3.46I: 0.9 Å - 2.4 Å. 
The lowest energy conformations for each receptor are structurally similar to one another as 
indicated by their RMSDs.  For the crystallized GPCRs, their crystal resolution ranges from  
1.80 Å (36) to 4.15 Å (28).  All of the calculated RMSD values are either lower than or fall 
within the crystal resolution range indicating that x-ray crystallography could not distinguish the 
various low energy conformations for a particular receptor.  These predicted structures do, 
however, differ greatly from the x-ray crystal structure of inactTβ1AR (PDB ID: 2VT4) (11).  
Thus homology modeling would be ineffective for predicting CB1 receptor conformations, 
especially for the active states. 
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Table 3.2 Comparison of the conformations of the low-lying energy structures for the three receptors 
T3.46A, WT, and T3.46I.  Theta (θ, tilt), phi (ϕ, sweep), eta (η, rotation) angles and the backbone RMSD 
(Å) with respect to the lowest energy conformation of the ten lowest energy T3.46A, WT, and T3.46I 
receptors are shown below.  The inactTβ1AR crystal (PDB ID: 2VT4) (11) is the reference case for the 
angles.  The poses were chosen according to their average energy rank: the average of the charged total 
energy rank, neutralized total energy rank, charged interhelical energy rank, and neutralized interhelical 
energy rank. 
  
 
 
Intermolecular interactions in the inactive T3.46A receptor 
The consensus salt bridge patterns in the predicted ensemble of low energy conformations for the 
T3.46A, WT, and T3.46I receptors are shown in Table 3.3 and Figure 3.5.  The consensus set is 
defined by the presence of the particular interhelical interaction in more than half of the 10 lowest 
energy conformations.  The differences in the consensus set of interactions for each receptor 
clearly show that there are major differences in their respective helical packings.  The 
conformations of the inactive mutant T3.46A receptor lead to a consensus salt bridge pattern 
(Table 3.3 and Figure 3.5A) that includes the following salt bridges, indicated by a plus (+) 
throughout the chapter, and hydrogen bonds, indicated by a dash (-) throughout the chapter:  
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R2.37+D6.30, R3.50+D6.30, D3.49+K4.41, D6.58+K7.32, H1.59-R4.39, H2.41-R6.32, and 
H2.65-K3.28. 
 
Table 3.3 Comparison of consensus salt bridge patterns for each of the previously discussed receptors 
(T3.46A, WT, and T3.46I) plus our proposed double mutants (T3.46A/R2.37Q and T3.46A/R2.37A). 
Receptor Level of 
activity 
R2.37(Q/
A) + 
D6.30 
hydrogen 
bond 
R3.50 
+ 
D6.30 
ionic 
lock 
R2.37(Q/
A) + 
D3.49 
hydrogen 
bond 
R5.71 
+ 
D6.30 
salt 
bridge 
D2.63 
+ 
K3.28 
salt 
bridge 
D3.49 
+ 
K4.41 
salt 
bridge 
T3.46A Fully inactive Yes Yes No No No Yes 
T3.46A/ 
R2.37A 
Partially 
constitutively 
active 
No No No 
 
No Yes Yes 
T3.46A/ 
R2.37Q 
Partially 
constitutively 
active 
No Yes Yes No Yes 
 
Yes/ 
No 
WT Partially 
constitutively 
active 
No Yes Yes No Yes Yes 
T3.46I Highly 
constitutively 
active 
No No Yes Yes Yes No 
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Figure 3.5A-C.  Predicted structures of the T3.46A, WT, and T3.46I receptors, showing the salt bridges 
and hydrogen bonds formed on the cytoplasmic side.  (A-C)  Receptors are selected based on lowest 
average energy in Table 3.2 and best agreement with the consensus pattern of salt bridges and hydrogen 
bonds.  (A) T3.46A is represented by T3.46A-1, (B) WT is WT-3, and (C) T3.46I is T3.46I-4.  These 
models for each receptor are referred to throughout this chapter. Salt bridges and hydrogen bonds in the 
consensus pattern are indicated by arrows and shaded boxes.  Dotted lines show the hydrogen bonds 
between the residues. 
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We propose that the critical interactions opposing activation in this inactive T3.46A receptor are 
two ionic locks, defined as salt bridge interactions that putatively keep a receptor inactive: 
• R3.50+D6.30 between the conserved residue arginine of the DRY motif at the cytoplasmic 
end of TM3 and the aspartic acid on TM6, and  
• R2.37+D6.30 between arginine at the cytoplasmic end of TM2 and aspartic acid on TM6.  
The hydrogen bond between TMs 2 and 6 (H2.41-R6.32, located approximately one turn above 
the R2.37+D6.30 interaction), further strengthens the coupling between TM2 and TM6. 
 
The TM3+TM6 coupling is observed in crystal structures of such inactive GPCRs as bRho (16; 
22-31), sRho (13; 14), hDD3R (15), and thermally stabilized inactTβ1AR (37) and inactHA2AAR 
(38) mutants.  Furthermore, experimental studies showed that protonation of E6.30 of the 
inactHβ2AR causes activation (39), and that breaking of this ionic lock is necessary for full 
activation (40).  The D3.49+K4.41 interaction is similar to the salt bridge between D3.49 and 
R4.37 in the hCXCR4 crystal (17) and the one possibly between D3.49 and R4.41 in hDD3R (15) 
(the side chain of R4.41 was not resolved in chain B of the crystal structure PDB ID: 3PBL).  
Likewise, the extracellular D6.58+K7.32 interaction is similar to the salt bridge between D6.58 
and H7.32 in the hCXCR4 crystal (17).  
 
On the other hand, the TM2+TM6 coupling is unique to this CB1 mutant.  We believe this ionic 
lock is critical for maintaining the receptor in its fully inactive form. 
 
Intermolecular interactions in the constitutively active WT receptor 
The consensus interaction network for the WT conformational ensemble (Table 3.3 and Figure 
3.5B) includes six salt bridges. Three of these salt bridges (D3.49+K4.41, R3.50+D6.30, and 
D6.58+K7.32) were also present in the T3.46A consensus and in the crystallographically 
characterized inactive class A GPCRs discussed above, and are therefore consistent with known 
systems. 
 
The three additional salt bridges found in the WT protein conformational ensemble are 
R2.37+D3.49, H2.41+D3.49, and D2.63+K3.28.  In the T3.46A mutant receptor, we found that 
R2.37 interacts with D6.30, but in the WT receptor, it forms a salt bridge with D3.49 as shown in 
Figure 3.5B.  The most remarkable difference between the WT and T3.46A receptors is that the 
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T3.46A receptor has two polar interactions between TMs 2 and 6, R2.37+D6.30 and H2.41–
R6.32, which are not observed in the WT receptor.  Thus, instead of the direct TM2+TM6 
coupling in the T3.46A mutant, the WT receptor displays the TM2+TM3 coupling between 
nearest-neighbor TMs. 
 
The WT conformational ensemble consensus interaction also has four hydrogen bonds including 
S2.45-T3.46 (Figure 3.4B). This hydrogen bond is especially important because it involves the 
T3.46 residue, whose mutation causes the large changes in the structure being investigated here. 
 
Intermolecular interactions in the more constitutively active (than WT) T3.46I receptor 
The consensus of the highly constitutively active mutant T3.46I conformational ensemble (Table 
3.3 and Figure 3.5C) includes four salt bridges and two hydrogen bonds: R2.37+D3.49, 
H2.41+D3.49, D2.63+K3.28, R5.71+D6.30, Y2.40-R4.39, and C6.47-N7.45.  The three salt 
bridges linking TMs 2 and 3 are present in the WT receptor, but none of them are in the T3.46A 
mutant. The R3.50+D6.30 interaction from the WT is broken in T3.46I as seen in Table 3.3 and 
Figure 3.5C.  Thus, the T3.46I receptor has no salt bridges spanning the cytoplasmic side of the 
TM helix bundle. This end of the T3.46I receptor has a larger diameter (11.6 Å between residues 
D6.30 and R3.50) than that of T3.46A (8.5 Å) or WT (8.9 Å) enabling it to potentially 
accommodate the C-terminal α-helix of the Gα protein during activation, which in actHβ2AR-Gs 
complex is 19.0 Å (PDB ID: 3SN6) (41).  This makes the extracellular ligand binding pocket 
more accessible in the T3.46I mutant. 
 
The R5.71+D6.30 interaction is unique to the T3.46I mutant conformation and is similar to the 
TM5+TM6 salt bridges observed in the constitutively active bRho mutant (PDB ID: 2X72) (31), 
the putatively active bOps (PDB ID: 3CAP, 3DQB) (42; 43), meta II (PDB ID: 3PQR, 3PXO) 
(44), and perhaps in a water-mediated interaction in the nanobody-bound activated actHβ2AR 
(PDB ID: 3POG) (45) crystal structures.  In active bRho, bOps, and meta II, the salt bridge is 
formed between K5.66 and E6.30.  Thus, the T3.46I mutant has similar structural signatures 
observed in other activated GPCRs. 
 
Effect of single amino acid mutations on CB1 receptor TM helix packing 
Tables 3.4A-B highlight the differences in the helix orientation angles (defined in (6) and 
Chapter II) among the three receptors, also shown in Figure 3.6. The helical axis for these angles 
is uniquely defined for a straight or kinked helix by taking the least moment of inertia vector from 
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the eigensolution of the moment of inertia matrix for the helix obtained using only heavy 
backbone atoms (6).  Figure 3.6A and Table 3.4A show that TM2 of WT rotates (η, helix 
rotation angle) toward TM3 by 90º while TM6 sweeps away (ϕ, helix sweep angle) from the 
center of the TM helix bundle clockwise by 30º.  The combination of these two motions breaks 
the TM2+TM6 coupling of T3.46A.  TM2 also tilts (θ, helix tilt angle) towards TM3 by 10º with 
respect to its counterpart in T3.46A.  This movement plus its rotation allows the R2.37+D3.49 
interaction to form.  The TM3+TM6 coupling is maintained for both T3.46A and WT because 
TM3 sweeps towards TM6 by 45º.  As for the D3.49+K4.41 interaction, TM4 of the WT rotates 
clockwise by 30º and sweeps 30º towards the center of the TM helix bundle compared to T3.46A.  
This forward-tilting motion of the cytoplasmic end of TM4 and the rotations of both the TM3 and 
TM4 helices help maintain the TM3+TM4 coupling in WT.   
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Figure 3.6A-C.  Conformational changes in CB1 receptors during activation and the effect on salt bridges.  
(A-B)  Comparisons of TM helix bundle rearrangement caused by the mutation of (A) T3.46A (blue) to 
WT (red), or (B) WT to T3.46I (grey). The structures chosen to illustrate the activation mechanism are 
based upon the lowest average energy rank and the salt bridge patterns shown in Figures 3.5A-C.  The 
T3.46A model corresponds to T3.46A-1, the WT model matches WT-3, and the T3.46I’s counterpart is 
T3.46I-4. Arrows indicate the direction of movement and the change is specified as shifts in the tilt (θ) 
[yellow], sweep (ϕ) [yellow], or rotation (η) [orange] angles.  (C) The ionic locks and salt bridges critical 
for activation are illustrated in the predicted structures of human CB1.  Circles represent the TM regions 
(numbered accordingly).  Lines connecting the TMs indicate the intracellular salt bridges stabilizing the 
alpha-helices.  Extracellular salt bridges have been omitted.  Lines represent the salt bridges present in the 
following receptors: T3.46A (blue), T3.46A/R2.37A (green), T3.46A/R2.37Q (yellow), WT (red), and 
T3.46I (grey).   
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Table 3.4A-B.  The predicted structures for the T3.46A and T3.46I mutants have different helix packing 
angles.  (A-B)  Differences in θ, ϕ, and η angles for the (A) T3.46A and WT structures and (B) WT and 
T3.46I structures, which represent the two steps of activation.  
A. 
  θ  (°) ϕ  (°) η  (°) 
TM# 2 3 4 6 2 3 4 6 2 3 4 6 
T3.46A-1 0 -10 10 0 0 -30 0 30 -150 -15 30 15 
WT-3 -10 -10 10 0 0 15 -30 0 -60 0 0 15 
Change (T3.46A-WT) 10 0 0 0 0 -45 30 30 -90 -15 30 0 
 
B. 
  θ  (°) ϕ  (°) η  (°) 
TM# 2 3 4 5 6 2 3 4 5 6 2 3 4 5 6 
WT-3 -10 -10 10 0 0 0 15 -30 -15 0 -60 0 0 -150 15 
T3.46I-4 -10 -10 10 0 -10 0 0 -15 0 -15 -60 0 30 -90 0 
Change 
(WT-
T3.46I) 0 0 0 0 10 0 15 -15 -15 15 0 0 -30 -60 30 
 
Comparing T3.46I with WT (Table 3.4B and Figure 3.6B), we see that TM6 tilts 10° away from 
the center of the bundle, breaking the TM3+TM6 coupling.  In order to form the TM5+TM6 
coupling of T3.46I, the extracellular ends of TMs 5 and 6 sweep away from each other by 15° 
causing their cytoplasmic ends to come closer together.  These helices also rotate towards each 
other by 60° and 30°, respectively.  The TM3+TM4 coupling is broken by the two helices leaning 
away from each other by 15°, while TM4 rotates by 30° away from TM3.  The TM2+TM3 
coupling is maintained due to the stationary TM2.  This TM does not move despite the mutation 
of the adjacent TM’s T3.46 to I3.46 whose bulkier side chain would clash with the residues on 
TM2.  TM3 sweeps slightly away from TM2 by 15° to provide more space for the larger side 
chain of isoleucine and to avoid repulsive interactions. 
 
Validation of structural basis of T3.46A inactivity by predicting a second mutation (at position 
R2.37) aimed at restoring constitutive activity to the T3.46A mutant 
To evaluate the importance of the TM2+TM6 coupling in maintaining the inactive conformation 
of the receptor (as in T3.46A), we proposed two double mutants: T3.46A/R2.37A and 
T3.46A/R2.37Q (Figures 3.7A and B) that we predicted would restore constitutive activity by 
breaking the TM2+TM6 coupling.  We expected that changing the arginine to a nonpolar alanine 
or to a charge-neutralizing glutamine on the cytoplasmic end of TM2 would break the 
R2.37+D6.30 interaction present in the inactive T3.46A receptor by weakening the interaction 
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with D6.30.  This loss of TM2+TM6 coupling should cause the receptor conformation to change 
and resemble the constitutively active WT receptor, which should be observable in a functional 
assay. 
 
 
Figures 3.7A-B.  Conformational predictions of the constitutively active double mutants, T3.46A/R2.37Q 
and T3.46A/R2.37A.  (A-B)  Receptors are selected based on lowest average energy and best agreement 
with the consensus pattern of salt bridges and hydrogen bonds in Table 3.3.  T3.46A/R2.37A (A) is 
represented by T3.46A/R2.37A-1, and T3.46A/R2.37Q (B) is T3.46A/R2.37Q-3.  Salt bridges and 
hydrogen bonds in the consensus pattern are indicated by arrows and shaded boxes.  Dotted lines show the 
hydrogen bonds between the residues.  (C) Comparison of basal GTPγS binding to HEK293 cell 
membranes expressing the CB1 receptors including the double mutants (T3.46A/R2.37Q and 
T3.46A/R2.37A).  The level of [35S]GTPγS binding was measured in the absence of ligand for the WT, 
T3.46I, T3.46A, T3.46/R2.37A, and T3.46/R2.37Q receptors.  The level of [35S]GTPγS binding for the 
mock-transfected membrane sample is shown for comparison.  The data description is same as for Figure 
3.1. 
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We proceeded to predict the optimum ensemble of structures for these double mutants using the 
same computational procedure as for WT and the two single mutants.  For T3.46A/R2.37A 
double mutant, the consensus interactions of the ten best-predicted conformations agree with our 
expectations, resembling a constitutively active receptor.  All couplings between TM2 and TM6 
and even the R3.50+D6.30 interaction are absent in the lowest energy conformations of this 
double mutant (Figure 3.7A and Table 3.3).  It also lacks the R5.71+D6.30 interaction observed 
in the highly constitutively active T3.46I receptor.  However, it does contain the D3.49+K4.41 
interaction found in the T3.46A and WT receptors.  This receptor also contains the D2.63+K3.28 
interaction on the extracellular side of the receptor bundle.  This salt bridge is observed in both 
the constitutively active WT and T3.46I receptors, but not in the inactive T3.46A receptor.  The 
lack of the TM2+TM6 and TM3+TM6 couplings implies that this receptor would be 
constitutively active.  The presence of the TM3+TM4 coupling as seen in WT and inactive 
T3.46A receptor suggests that this double mutant might be less constitutively active than the 
T3.46I receptor. 
 
For T3.46A/R2.37Q double mutant receptor, the consensus of the ten best conformations agrees 
with our expectations, leading to a hydrogen bond and salt bridge pattern similar to that of the 
WT receptor (Figure 3.7B and Table 3.3).  The glutamine residue at position 2.37 interacts with 
D3.49 as in the WT and T3.46I receptors, whereas in the inactive T3.46A receptor, the 
corresponding arginine interacts with D6.30.  None of the low energy T3.46A/R2.37Q double 
mutant conformations show this interaction as expected.  The R3.50+D6.30 interaction remains 
intact in this double mutant, appearing in eight of the ten lowest energy conformations.  Like the 
T3.46A/R2.37A receptor, it too has the extracellular D2.63+K3.28 interaction, which as 
mentioned above, is seen only in the constitutively active receptors.  Half of the structures have 
the intracellular D3.49+K4.41 interaction found in the T3.49A and WT receptors.  Since the polar 
interaction patterns closely resemble those of the WT, we predict that the T3.46A/R2.37Q double 
mutant would make the inactive T3.46A mutant constitutively active.  These predicted structures 
formed the basis of the subsequent GTPγS assays to test the activity of the double mutants as 
described below. 
 
Experimental confirmation that the double mutants, T3.46A/R2.37Q and T3.46A/R2.37A, are 
constitutively active 
Figure 3.7C shows a comparison of the level of basal GTPγS binding for the double mutants 
along with the other receptors and the mock-transfected sample shown in Figure 3.1.  As 
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predicted, the T3.46A/R2.37A and T3.46A/R2.37Q receptors are more constitutively active 
relative to T3.46A.  The GTPγS binding in the absence of ligand is larger for the T3.46A/R2.37A 
and T3.46A/R2.37Q receptors, with levels of 72.2 fmol/mg and 77.4 fmol/mg, respectively, than 
that of the fully inactive T3.46A receptor (52.6 fmol/mg).  Although these two double mutants 
display less constitutive activity than the WT (91.3 fmol/mg), the mutations of the R2.37 residue 
produce substantial levels of constitutive activity.  This confirms that our models are predictive 
and accurately show the importance of the critical TM2+TM6 ionic lock in keeping the T3.46A 
receptor in the inactive conformation.  Intriguingly, these double mutant receptors show 
somewhat different non-covalent interaction patterns.  The T3.46A/R2.37Q receptor has a 
R3.50+D6.30 interaction, whereas the T3.46A/R2.37A receptor does not (Table 3.3).  However, 
our functional assay data indicate that the difference between the constitutive activities of these 
receptors is not statistically significant (Figure 3.7C). 
 
CB1 has an ensemble of active states:  L3.43A and T3.46I are both active, but have different 
receptor structures 
Previous research suggests that the L3.43A mutant is highly constitutively active like the T3.46I 
mutant (46).  In theory, the smaller alanine residue replaces the bulky leucine residue, which 
should allow enough space for the extracellular end of TM6 to tilt toward TM3.  The L3.43A 
receptor has a slightly enhanced binding affinity for agonists and a significantly decreased 
binding affinity for the inverse agonists and antagonists when compared to the WT.  L3.43A has a 
substantially enhanced GTPγS binding affinity of 114.5 fmol/mg, and T3.46I has a corresponding 
value of 112.3 fmol/mg, which correlates with increased activity.  
 
We anticipated that the L3.43A and T3.46I would have similar conformations based on their 
similar levels of constitutive activity.  However, Figure 3.8 shows that there are major 
differences between the two receptors’ structures.  They have similar TM2 and TM3 contacts—
both receptors have the extracellular D2.63+K3.28 and the intracellular R2.37+D3.49 salt 
bridges.  Both of them lack the stabilizing TM2+TM6 and TM3+TM6 ionic locks as well as the 
TM3+TM4 salt bridge observed in the fully inactive or constitutively active mutants.  However, 
the L3.43A mutant is missing the R5.71+D6.30 salt bridge that is characteristic in the highly 
constitutively active T3.46I mutant.  TMs 5 and 6 in L3.43A are rotated so that it is impossible 
for the salt bridge contact to form. Our predicted structures indicate that the TM5+TM6 coupling 
is not necessary for activation to occur.  
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Figure 3.8 Predicted structure of the L3.43A receptor.  Extracellular and intracellular salt bridges are 
indicated.  L3.43A is missing the R5.71+D6.30 salt bridge found in the similarly highly constitutively 
active T3.46I mutant. 
 
Validation of structural basis of L3.43A activity by predicting a second mutation (at position 
D2.63) aimed at eliminating constitutive activity to the L3.43A mutant 
Previously, we showed that adding a second mutation to the fully inactive T3.46A causes the 
receptor to appear activated and experience a corresponding gain in function.  In this section, we 
show that adding a second mutation causes a highly active mutant receptor to lose function.  The 
L3.43A mutant has an extracellular salt bridge between D2.63 and K3.28, which is present in all 
of our receptors except the fully inactive T3.46A mutant, suggesting that this particular salt 
bridge is necessary for activation.  In the L3.43A mutant, D2.63 was mutated into an alanine, and 
we predicted the structures of the resulting double mutant receptors. 
 
The ensemble of ten low energy conformations of L3.43A/D2.63A shows a strong preference for 
the R2.37+D6.30 ionic lock formation that was observed in the fully inactive T3.46A mutant 
(Figure 3.9).  Previously, we showed that this R2.37 residue is important for preventing 
activation, and the predicted structures suggest that it does so by forming a salt bridge with the 
D6.30 across the helix bundle.  Surprisingly, only two out of the top ten L3.43A/D2.63A mutants 
had both TM2+TM6 and TM3+TM6 ionic locks, which differs from the salt bridge pattern 
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observed in the T3.46A receptor.  The overall conformation of two fully inactive receptors is 
significantly different as their backbone RMSD is 2.32 Å, which is comparable to the difference 
between the two highly constitutively active T3.46I and L3.43A mutants.  Furthermore, it calls 
into question the importance of the TM3+TM6 ionic lock for the fully inactive form of this 
receptor.  These predicted structures for the two mutants suggest that there are multiple possible 
inactive conformations. 
 
 
Figure 3.9 Predicted structure of the L3.43A/D2.63A receptor.  The R2.37+D3.49 salt bridge observed in 
the L3.43A mutant was broken to form the new intracellular R2.37+D6.30 salt bridge (indicated). 
 
Experimental confirmation that the double mutant, L3.43A/D2.63A, is fully inactive 
Again, to confirm our structure and activity level predictions, the level of GTPγS binding was 
subsequently measured with assays to understand the relative levels of G protein binding and 
thus, the constitutive activity level (Figure 3.10).  The L3.43A mutant had very high levels of 
GTPγS binding with a value of 114.5 fmol/mg, and the L3.43A/D2.63A mutant had significantly 
smaller levels of GTPγS binding with a value of 53.3 fmol/mg, which is approximately equal to 
the values for T3.46A (53.2 fmol/mg) and even the mock-transfected membrane (53.3 fmol/mg).  
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Thus, the L3.43A/D2.63A double mutant, much like the T3.46A one, is fully inactive possibly 
due to the presence of the TM2+TM6 coupling. 
 
Figure 3.10 Comparison of basal GTPγS binding to HEK293 cell membranes expressing the CB1 receptors 
including the double mutant L3.43A/D2.63A and the triple mutant L3.43A/D2.63A/R2.37A).  The level of 
[35S]GTPγS binding was measured in the absence of ligand. The level of [35S]GTPγS binding for the mock-
transfected membrane sample is shown for comparison. The data description is same as for Figure 3.1. 
 
Validation of structural basis of L3.43A/D2.63A inactivity by predicting a third mutation (at 
position R2.37) aimed at restoring constitutive activity to the L3.43A/D2.63A double mutant 
Our predicted structure of the fully inactive double inactive mutant, L3.43A/D2.63A, has the 
characteristic TM2+TM6 coupling observed in the fully inactive T3.46A mutant.  We have 
shown above that the R2.37 residue is necessary to stabilize the inactive conformation.  We 
predict that this residue plays the same role in stabilizing the L3.43A/D2.63A double mutant.  To 
confirm this hypothesis, we built the L3.43A/D2.63A/R2.37A receptor, a triple mutant.  This is 
the inactive L3.43A/D2.63A double mutant with an extra mutation to break the coupling between 
TM2 and TM6. 
 
Our predicted structures of the triple mutant look constitutively active based on observed salt 
bridge patterns (Figure 3.11A).  The TM2+TM6 coupling was broken, and the R3.50+D6.30 
ionic lock was also absent.  Of the ten conformations in the low energy pool, seven of them 
showed the D3.49+K4.41 salt bridge, which was observed in the inactive T3.46A and 
constitutively active WT, T3.46A/R2.37A, and T3.46A/R2.37Q receptors, but neither of the 
highly constitutively active T3.46I and L3.43A receptors.  The triple mutant also has the 
extracellular D6.58+K7.32 salt bridge, which was observed in the same receptors as the 
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TM3+TM4 salt bridge except for the constitutively active T3.46A/R2.37Q mutant.  The 
consensus of the triple mutant shows that the majority of conformations lack the R5.71+D6.30 
salt bridge observed in the highly constitutively active T3.46I mutant. 
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Figure 3.11 (A) Predicted structure of the triple mutant, the L3.43A/D2.63A/R2.37A receptor.  The 
D3.49+K4.41 salt bridge is indicated.  (B) Alignment of the lowest average energy conformations of the 
T3.46A/R2.37A (green) and L3.43A/D2.63A/R2.37A (purple) mutants.  (C) Helical backbone RMSD 
analysis for the top ten lowest average energy conformations of L3.43A/D2.63A/R2.37A with respect to 
the lowest energy conformation of T3.46A/R2.37A.  The histogram shows the number of triple mutant 
conformations within a given RMSD.  The table shows the range and average of the ten RMSD values. 
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In fact, the triple mutant looks extremely similar to the T3.46A/R2.37A double mutant.  They 
share the two salt bridges (D3.49+K4.41, D6.58+K7.32) that stabilize the receptor.  Figure 3.11B 
shows the alignment of the two mutants and visually speaking, they are very similar and are 
almost identical in six of the seven TMs.  Figure 3.11C shows how the top ten triple mutants 
ranked according to lowest average energy compare with the lowest energy T3.46A/R2.37A.  The 
average backbone RMSD for the ten triple mutants is 1.04 Å, which is smaller than the lowest 
crystal resolution for a GPCR, 1.8 Å.  The range of RMSD values is from 0.57 Å to 2.08 Å with 
nine of the ten structures having an RMSD of less than 1.50 Å.  Based on the conformational 
similarities between the two receptors, we expect the triple mutant will be constitutively active 
like the WT and T3.46A/R2.37A receptors.  Our structure predictions are confirmed with the 
GTPγS assays because the GTPγS binding level is 68.1 fmol/mg, which indicates that this triple 
mutant has a substantial level of constitutive activity (Figure 3.10).  Its level of GTPγS binding is 
significantly less than that of the WT receptor (98.5 fmol/mg), but it is more than that of the fully 
inactive mutants (~53 fmol/mg) and approximately equal to that of the constitutively active 
double mutants T3.46A/R2.37A and T3.46A/R2.37Q, 72.5 fmol/mg and 77.0 fmol/mg 
respectively.  This evidence shows that the R2.37 residue is important for preventing the 
activation of the inactive conformation of the L3.43A/D2.63A receptor. 
 
Validation of structural basis of L3.43A activity by predicting a second mutation (at position 
K3.28) aimed at eliminating constitutive activity to the L3.43A mutant 
Another way to test the importance of the D2.63+K3.28 salt bridge in stabilizing the active 
conformation is to mutate the K3.28 residue to break the TM2+TM3 coupling.  Previously, when 
we mutated D2.63 to an alanine, the resulting conformation formed an R2.37+D6.30 ionic lock 
stabilizing the fully inactive conformation.  If its partner is the K3.28 residue, than the 
L3.43A/K3.28A mutant should be fully inactive like the L3.43A/D2.63A mutant.  The predicted 
structure of the L3.43A/K3.28A mutant (Figure 3.12) has multiple stabilizing salt bridges 
including the R2.37+D6.30 ionic lock, the R3.50+D6.30 ionic lock, and the extracellular 
D6.58+K7.32 salt bridge.  The TM2+TM6 coupling was observed in the fully inactive T3.46A 
and L3.43A/D2.63A mutants, and it was experimentally proven that the R2.37 residue plays an 
important role in stabilizing the inactive state.  Both the D6.58+K7.32 and R3.50+D6.30 salt 
bridges were observed in T3.46A.  One discrepancy is that the majority of the L3.43A/K3.28A 
mutant conformations do not have the D3.49+K4.41 salt bridge, which was present in the inactive 
T3.46A and constitutively active T3.46A/R2.37A, T3.46A/R2.37Q, WT, and 
L3.43A/D2.63A/R2.37A receptors, but not the fully inactive L3.43A/D2.63A mutant.  The 
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L3.43A/K3.28A mutant shown in Figure 3.12 has the smallest average backbone RMSD, 2.14 Å, 
with respect to the L3.43A/D2.63A mutant, which is within the typical GPCR crystal resolution.  
Based on our structural predictions, we believe that L3.43A/K3.28 will be inactive like the 
L3.43A/D2.63A receptor as we had anticipated.  However, we do not have experimental 
confirmation of our hypothesis.  Site-directed mutagenesis, GTPγS assays, and ligand binding 
assays were not performed because previous experiments indicate K3.28 binds to ligands (20; 47; 
48), so our results from experiments involving ligands would be complicated because we would 
not be able to tell if the physiological consequences were due to effects with the ligand or 
structural effects from to the broken D2.63+K3.28 salt bridge. 
 
Figure 3.12 Predicted structure of the double mutant L3.43A/K3.28A.  This conformation is the third 
lowest energy pose, which best represents the consensus of the ten lowest energy structures.  The salt 
bridges are indicated with dotted black lines and arrows and are encircled in purple. 
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DISCUSSION 
 
An activation mechanism for CB1 receptor consistent with crystallographically characterized 
GPCRs and mutagenesis experiments 
By comparing the predicted salt bridge patterns for the human CB1 WT and two mutant 
receptors, T3.46A and T3.46I, we propose an activation mechanism in terms of receptor 
transformations.  Figure 3.5C illustrates the predicted patterns of four salt bridges: R2.37+D6.30, 
R3.50+D6.30, D3.49+K4.41, and R5.71+D6.30. 
• T3.46A (inactive) has the following salt bridges: R2.37+D6.30, D3.49+K4.41, and 
R3.50+D6.30.   
• During the first step of partial activation to form the weakly constitutively active WT, the 
TM2+TM6 coupling in the inactive T3.46A receptor is broken to form the TM2+TM3 
coupling of the WT receptor. Thus, the TM2+TM6 coupling appears to be essential for the 
receptor to be fully inactive.  
• The TM3+TM4 and TM3+TM6 couplings break during the second step of activation to form 
the highly constitutively active T3.46I conformation with a new TM5+TM6 coupling.  Thus, 
the breaking of the TM3+TM6 coupling appears to be responsible for full activation beyond 
WT levels. 
• Our proposed double mutants, T3.46A/R2.37A and T3.46A/R2.37Q, share salt bridge 
signatures with the WT receptor.  Based on their structures alone, we predicted that the 
receptors would be constitutively active, which was subsequently confirmed by experiments. 
 
The CB1 receptor is unusual in that the TM3+TM6 coupling, R3.50+D6.30, appears to be 
insufficient for preventing activation.  The lack of the TM3+TM6 coupling in the fully inactive 
double mutant L3.43A/D2.63A indicates that the TM2+TM6 ionic lock, not the traditional 
TM3+TM6 coupling, is necessary to stabilize the inactive CB1 conformation.  Several studies 
have questioned the importance of that salt bridge interaction in the activation mechanism of the 
CB receptors.  Site-directed mutagenesis of R3.50A in the closely related CB2 suggested that this 
mutation only weakly affects agonist binding and partially affects signaling (49).  Another 
experiment showed that this same CB2 receptor mutation prevented constitutive activation and 
downfield signaling (50), which would contradict the previous study by indicating the importance 
of R3.50 in function and signaling.  Both studies, however, do agree that the R3.50A mutation 
does not impact agonist binding.  Our modeling studies provide a structural explanation of these 
experimental results.  The R2.37+D6.30 ionic lock of the T3.46A mutant spanning the helix 
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bundle is unique while the R3.50+D6.30 ionic lock is commonly found in inactive GPCRs.  
R2.37 is present in CB1, but CB2 has a similar K2.37 residue that we suggest could form a 
similar TM2+TM6 coupling.  In other class A GPCRs residue 2.37 is most often an asparagine, a 
serine, or a threonine, which explains why this particular ionic lock has not been observed in most 
crystalized receptors. The exception is the hS1P1R crystal structure, but its R2.37 side chain was 
not resolved in the crystal structure, so it is not known how this residue interacts.  Indeed, it 
points into the center of the TM helix bundle making the TM2+TM6 coupling possible (51).  This 
unique R2.37+D6.30 interaction rather than the R3.50+D6.30 ionic lock is likely responsible for 
preventing cannabinoid receptor activation, which would explain the limited importance of the 
R3.50 residue. 
 
Validation of the role of TM2+TM6 interaction in keeping T3.46A inactive 
The predicted structures of the CB1 receptor mutants are consistent with the experimental studies 
indicating that the R2.37+D6.30 interaction may be mandatory for the maintenance of the 
inactive state in the CB1 as well as CB2 receptors.  To evaluate the importance of the TM2+TM6 
coupling in maintaining the inactive conformation, we proposed two double mutants, 
T3.46A/R2.37A and T3.46A/R2.37Q, expected to break this coupling.  We tested this prediction 
computationally and found that the TM2+TM6 coupling does not form.  Our collaborators 
experimentally assessed the consequence of breaking this predicted R2.37+D6.30 interaction by 
evaluating the level of GTPγS binding, finding a substantial increase in constitutive activity 
relative to the T3.46A receptor.  These results show that the double mutants are significantly 
more active than T3.46A just as we predicted.  
 
These results underscore the importance of the R2.37 residue in maintaining the inactive 
conformation (Figure 3.7C), confirming that the TM2+TM6 coupling is critical for constraining 
the receptor to maintain the inactive conformation. These experimental results further support our 
hypothesis that breaking the TM2+TM6, not the TM3+TM6, coupling is crucial for converting 
the inactive structure to the active conformation. 
 
Comparisons to crystallized class A GPCRs 
These conformational changes lead to helix movements consistent with those observed in the 
inactive-to-active experimentally characterized GPCRs.  For example, they agree with NMR 
studies of bRho and meta II (52), which showed that TM3 remains fairly rigid and does not re-
orient while TM6 moves significantly during activation.  Recent crystal structures of activated 
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GPCRs allow us to compare the conformational differences between the antagonist and agonist-
bound Hβ2AR (41; 45) and HA2AAR (53), or the 11-cis-retinal-bound bRho and the apo-receptor 
bOps (43), with our weakly constitutively active WT and the highly constitutively active T3.46I, 
as seen in Table 3.5.  TMs 1 - 4 are relatively fixed between bRho and bOps and inactHA2AAR 
and actHA2AAR, whereas the TMs 5 - 7 show the greatest structural changes.  For example, in 
bRho, TM6’s cytoplasmic end moves 6 – 7 Å away from the bundle interior (43), and in 
HA2AAR, the same helix shifts by 3 – 4 Å. HA2AAR’s movement is smaller than that of bOps 
because HA2AAR may be constrained by the substitution of T4 lysozyme for the third 
intracellular loop (53). 
 
Our CB1 structures show a similar change as TM6 swings outward by 6.6 Å, which agrees well 
with the bRho-bOps case (43).  In Hβ2AR, E6.30 moves by 11.40 Å when stabilized by a 
nanobody (45) or by 14.7 Å when stabilized by a Gs protein (41), while in CB1 the conserved 
residue shifts by 7.4 Å.  Also evident in crystal structures is the movement of TMs 5 and 6 
towards each other.  In the bRho-bOps activation, the two helices tilt so they become parallel 
(43).  We find the same shifts in TM5 and TM6 of CB1, as seen in Figure 3.6B.  The most 
marked differences between our predicted CB1 structures and the crystallized GPCRs occur in 
the movement of TM7.  None of the salt bridges crucial to activation in CB1 involve TM7, so its 
placement appears not to be as important as the other TMs.  Also, none of the TM7 residues 
discussed in Table 3.5 are conserved in TM7.  Thus, overall, there is agreement between our 
predicted structural changes during activation and the experimentally observed ones. 
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Table 3.5 Comparison of the alterations in CB1 during activation with features seen in crystallized GPCRs.  
The observed structural changes between the constitutively active WT and the fully active T3.46I are 
similar to those which are observed in crystal structures.  The cases where the CB1 models show deviations 
(red) from the crystal models are indicated in red. 
Crystallized GPCR Crystallized 
GPCR 
portion 
CB1 model 
portion 
Change during 
activation of 
crystallized GPCRs 
Change from WT-3 
to T3.46I-4 
bRho/bOps (43), 
HA2AAR (53) 
TMs 1 – 4 TMs 1 – 4 Not much change Not much change 
(except TM4) 
bRho/bOps, HA2AAR TMs 5 – 7 TMs 5 – 7 Large amount of 
movement 
Large amount of 
movement 
bRho/bOps TM5 TM5 
(M5.72) 
Cytoplasmic end 
moves toward 
TM6 by 2 - 3 Å 
Cytoplasmic end 
moves toward TM6 
by 4.8 Å 
bRho/bOps TM6 TM6 
(D6.25) 
Cytoplasmic end 
moves outward by 
6 – 7 Å 
Cytoplasmic end 
moves outward by 
6.6 Å 
bRho/bOps TM5 and 
TM6 
TM5 and 
TM6 
Become parallel to 
each other 
Become parallel to 
each other 
bRho/bOps TM3 and 
TM6 
TM3 and 
TM6 
Broken ionic lock Broken ionic lock 
bRho/bOps TM5 and 
TM6 
TM5 and 
TM6 
New salt bridge New salt bridge 
Hβ2AR/nano-body 
(45) 
E6.30 D6.30 Moves 11.4 Å Moves 7.4 Å 
Hβ2AR/GS (41) E6.30 D6.30 Moves 14.7 Å Moves 7.4 Å 
Hβ2AR/nano-body S5.46 V5.46 Moves inward by 
2.1 Å 
Moves inward by 
2.2 Å 
Hβ2AR/GS S5.46 V5.46 Moves inward by 
1.8 Å 
Moves inward by 
2.2 Å 
Hβ2AR/nano-body P5.50 L5.50 Moves inward by 
1.4 Å 
Moves inward by 
2.2 Å 
Hβ2AR/GS P5.50 L5.50 Moves inward by 
1.6 Å 
Moves inward by 
2.2 Å 
HA2AAR W6.48 W6.48 Moves inward by 
1.9 Å 
Moves inward by 
1.3 Å 
HA2AAR S7.42 C7.42 Moves closer to 
TM3 by 2 Å 
Moves closer to 
TM2 by 3.5 Å 
HA2AAR H7.43 L7.43 Moves closer to 
TM3 by 2 Å 
Moves away from 
TM3 by 4.8 Å 
HA2AAR N6.55 M6.55 Fixed Moves by 0.9 Å 
HA2AAR TM6 TM6 
(D6.25) 
Cytoplasmic end 
moves outward by 
3 – 4 Å 
Cytoplasmic end 
moves outward by 
6.6 Å 
HA2AAR NPxxY N7.49 Moves inward by 4 
– 5 Å 
Moves inward by 
3.5 Å 
HA2AAR Y7.53 Y7.53 Moves by 5 Å, 
rotameric switch 
Moves by 4.0 Å, no 
rotameric switch 
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We found the RMSD values of the alpha-carbons in the helical backbone of the constitutively 
active WT and double mutant receptors (T3.46A/R2.37A and T3.46A/R2.37Q) versus the highly 
constitutively active mutants (L3.43A and T3.46I) as seen in Table 3.6A.  The range of RMSDs 
is 1.62 Å (the difference between T3.46A/R2.37A and T3.46I) to 3.08 Å (the difference between 
T3.46A/R2.37Q and L3.43A) with most of the values at approximately 2.5 Å.  Tables 3.6B-D 
show the RMSD between antagonist or inverse agonist-bound and agonist-bound or putatively 
active conformations of crystallographically characterized GPCRs (10; 16; 18; 41; 42; 44; 53; 
54).  The CB1 WT receptor has RMSDs of 2.12 Å and 2.69Å with respect to T3.46I and L3.43A 
in that order.  These values are in good agreement with those of the Hβ2AR, 2.48 Å, and the 
boRho, 2.31 Å and 2.34 Å, as seen in Tables 3.6B and C.  The RMSD values for T3.46A/R2.37A 
vs. L3.43A and T3.46A/R2.37Q vs. T3.46I are also in good agreement with the experimental 
results with RMSDs of 2.57 Å and 2.31 Å respectively.  The RMSD between T3.46A/R2.37A 
and T3.43I, 1.62 Å, is a little lower than the other ones in Table 3.6A, but it matches well with 
the values from the HAA2AR, which are 1.61 Å and 1.67 Å.  The RMSDs of the CB1 predicted 
structures show that there are significant differences between the constitutively active and highly 
constitutively active conformations, and these differences are in good agreement with those from 
experiments. 
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Table 3.6 RMSDs indicating change in helical packing upon activation.  (A) Backbone RMSD comparison 
of the alpha-carbon TM regions backbone of the constitutively active (WT, T3.46A/R2.37A, and 
T3.46A/R2.37Q) and highly constitutively active (T3.46A and L3.43A) receptors.  One structure was 
selected from the top ten low energy conformations of each receptor that best represents the consensus of 
the salt bridge and hydrogen bonds.  The WT receptor is the third lowest energy conformation, 
T3.46A/R2.37A is the lowest, T3.46A/R2.37Q is the third lowest, and T3.46I and L3.43A are both the 
fourth lowest energy conformations.  (B) Backbone RMSD comparison of crystallized inverse agonist 
carazolol-bound human β2 adrenergic receptor (PDB ID: 2RH1) (18) with the agonist BI-167107 and Gs 
subunit-bound conformation (PDB ID: 3SN6) (41).  (C) Backbone RMSD comparison of crystallized 
inverse agonist 11-cis-retinal-bound bovine rhodopsin (dark-state) (PDB ID: 1U19, chain A) (16) with the 
active 11-trans-retinal-bound metarhodopsin II (PDB ID: 3PQR) (44) and the putatively active ligand-free 
bovine opsin receptor (PDB ID: 3CAP, chain A) (42).  (D) Backbone RMSD comparison of crystallized 
antagonist ZM241385-bound human adenosine A2A receptor (PDB ID: 3EML) (10) with the active agonist 
UK-432097-bound conformation (PDB ID: 3QAK) (53) and the active agonist NECA-bound conformation  
(PDB ID: 2YDV) (54). 
 
A. 
CB1 Wild-type T3.46A/R2.37A T3.46A/R2.37Q 
T3.46I 2.12 1.62 2.31 
L3.43A 2.69 2.57 3.08 
 
B 
Human β2 adrenergic receptor 2RH1 (inverse agonist-bound) 
3SN6 (agonist and Gs-bound) 2.48 
 
C. 
Bovine rhodopsin receptor 1U19 (inverse agonist-bound) 
3PQR (agonist-bound) 2.34 
3CAP (ligand free, putatively active) 2.31 
 
D. 
Human adenosine A2A receptor 3EML (antagonist-bound) 
3QAK (agonist bound) 1.61 
2YDV (agonist-bound) 1.67 
 
The RMSD between the two highly constitutively active receptors, T3.46I and L3.43A, is 2.30 Å, 
which is a discernible difference.  These dissimilar active conformations agree with the ensemble 
state theory, which suggests that each GPCR has multiple active conformations that are stabilized 
by different agonists or intracellular proteins.  For example, cAMP assays indicate the activated 
WT CB1 receptor binds to the Gi protein (55), but the L3.43A mutant binds to the Gs protein (46).  
Different receptor conformations are potentially necessary for interacting with different types of 
G proteins.  The predicted structures of T3.46I and L3.43A have different global conformations, 
so the T3.46I receptor may activate the Gi protein rather than the Gs one like the L3.43A mutant. 
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In addition to determining the backbone RMSD values, which may not be the best measure for 
comparing receptor conformations, we calculated the angle root-mean-square deviation 
(aRMSD).  One of the major components of the GEnSeMBLE methodology is sampling the helix 
tilt, sweep, and rotation angles in order to find an ensemble of low energy conformation.   Table 
3.7A shows each model of the various receptors and their corresponding angles.  Clearly, a single 
or double point mutation changes the entire packing of the helix bundle.  As shown in Table 
3.7B, the largest aRMSD values are 62.8° and 74.5°, which is the difference between the inactive 
T3.46A and active T3.46I and L3.43A receptors respectively. The difference between the 
constitutively active WT receptor and the two active mutants is not as large, with values of 29.1° 
and 32.2°.  Receptors with the same level of constitutive activity tended to have the smallest 
aRMSDs.  The WT receptor and T3.46A/R2.37A double mutant have an aRMSD of 9.1°.  Even 
though these receptors only shared one of the intracellular salt bridges, they have the most similar 
helix orientations.  A brief MD simulation is expected to relax the double mutant so that it would 
look more like the WT.  The next smallest aRMSD is 22.1°, which is the difference between the 
active mutants L3.43A and T3.46I.  Again, even though they have different salt bridge patterns, 
their helix orientations are comparable.  Overall, our results show that receptors with similar 
levels of activation have similar conformations as proven by their helix orientations.  Receptors 
with the largest discrepancies in activity had the greatest aRMSDs indicating the greatest 
structural changes that can be correlated with the observed differences in functional activity. 
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Table 3.7 Angle RMSDs indicating change in helical packing upon activation. (A) Tilt, sweep, and rotation 
angles of the consensus model representing each receptor.  The angles are calculated with respect to the 
initial inactTβ1AR (PDB ID: 2VT4) (11).  One predicted structure was selected from the top ten low energy 
conformations of each receptor that best represents the consensus of the salt bridge and hydrogen bonds.  
The WT, T3.46A/R2.37A, T3.46A/R2.37Q, T3.46I, and L3.43A receptors use the same structures as in 
Table 3.6.  The T3.46A receptor is represented by the lowest energy conformation, and L3.43A/D2.36A is 
represented by the seventh lowest energy conformation.  (B) Angle RMSD (aRMSD) comparison of the 
different receptor consensus structures. 
 
A. 
 
 
B. 
 
 
 
Straight homology models cannot explain the functional effects of single-point mutations 
By mutating a single residue, the receptors’ respective global conformations change.  In the 
T3.46I mutant, the larger hydrophobic isoleucine side chain replaces the polar threonine, breaks 
the hydrogen bond, and pushes the surrounding helices, including TM6, away in order to provide 
enough room to avoid side chain clashes.  In the T3.46A mutant, the alanine residue is smaller 
than threonine and can fit in-between TMs 2 and 6.  These two helices do not have to be as far 
away to avoid clashes as they would in the WT or T3.46I receptors.  The T3.46A residue, 
however, does not interact with S2.45, so TM2 is rotated to optimize other intracellular polar 
interactions.  In the L3.43A mutant, the threonine residue is left intact and thus so is the S2.45 
and T3.46 hydrogen bond.  The position of TM6 in relation to TM3 can change because the new 
alanine residue takes up less space than the original leucine one.  The residues in the middle of 
TM6, such as V6.43, would clash with the 3.43 residue if the WT sequence had the L3.43A 
mutant conformation.  In the L3.43A mutant, the extracellular end tilts towards TM3, but the 
intracellular end moves away breaking the R3.50+D6.30 interaction. 
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Figure 3.13 shows the results of the amino acid substitution without altering the helix packing (a 
homology model).  Figure 3.13A shows the homology model of WT based on T3.46A, obtained 
by mutating the A3.46 residue to T3.46. The larger side chain of the T3.46 residue clashes with 
the TM2 backbone and would result in extremely unfavorable energies. Therefore, TM2 and/or 
TM3 must move to accommodate the T3.46 residue, affecting the packing of other five helices. 
Similarly, Figure 3.13B shows the homology model of T3.46I based on WT, obtained by 
mutating the T3.46 residue to I3.46.  The larger isoleucine residue collides with S2.45.  Thus, 
TM3 must shift to accommodate the presence of the larger side chain.  However, it only moves 
slightly, sweeping away from TM2 by 15°.  These helix movements cause large changes in the 
rest of the TM helix bundle in order to maximize favorable interactions, which cannot be captured 
by homology models even after relaxation by MD methods. 
 
 71 
 
Figure 3.13 Effect of the amino acid at position 3.46 on the helical interactions in the human CB1 receptor.  
(A) Comparison of the T3.46A model versus the WT homology model (based on the T3.46A 
conformation).  (B) Comparison of the WT model versus the T3.46I homology model (based on WT 
conformation).  In each case, the residue (T in (A) or I in (B)) is too large for their respective positions, 
which explains why the receptor structures must change to accommodate the mutations. 
 
Comparison to previous CB1 modeling studies 
Previous CB1 modeling studies used homology modeling to bRho or other crystallized GPCRs as 
templates, followed in some cases by MD (20; 46; 56-60).  Initial studies by Reggio and co-
workers used the bRho template to develop homology models of CB1 (20; 56-58).  Significantly 
kinked TM6 conformations (61) were added to the predicted 7-helix bundle, forming the 
R3.50+D6.30 that had been observed in the crystallographically characterized structure of bRho. 
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This predicted structure included another TM3+TM6 coupling between extracellular residues 
K3.28 and D6.58 (20).  The CB1 active conformation was created by using activation hints from 
bRho: TM6 was straightened, and TMs 3 and 6 were rotated counter-clockwise with respect to 
the extracellular side.  These motions broke both TM3+TM6 couplings (20). 
 
A more recent model has used the inactHβ2AR crystal structure as a homology template to 
provide secondary structure information.  Only two salt bridges were observed—one between 
R3.50 and D6.30 as in the models discussed above and another between K3.28 and D2.63 (60) 
rather than D6.58 as proposed from the bRho homology structure (20).  In general, these previous 
models agree that the conserved R3.50+D6.30 interaction is present in the constitutively active 
state.  Shim’s 2010 review (59) proposes that the activation mechanism CB1 consists of the 
agonist binding to EC2, which causes this loop region to couple to the aromatic microdomain in 
TMs 5 and 7, thereby forcing W6.48 to undergo a toggle switch. This movement, in turn, causes a 
cascade of interactions between hydrophobic or polar residues in the intracellular direction 
resulting in the breakage of the R3.50+D6.30 interaction (59).  This mechanism has yet to be 
experimentally verified. 
 
Software programs such as Modeller (62) have also been used previously to predict CB1’s 
structure. The ModBase dataset (http://modbase.compbio.ucsf.edu/modbase-cgi/index.cgi) 
contains multiple CB1 structure predictions constructed from Modeller software (63).  One of its 
more reliable conformations, according to its MPQS score, is based on the agonist-bound 
actHA2AAR crystal (PDB ID: 2YDV chain A) (64) homology model.  In this predicted 
conformation R3.50 does not form an ionic lock with D6.30 even though both residues are 
conserved.  As mentioned above, this particular interaction has been observed in multiple class A 
GPCRs.  Furthermore in these homology-built structures, ligand-binding residues are not 
accessible to the binding site (20; 57).  For example W5.43A leads to a ~1000 fold drop in 
binding affinity for the inverse agonist/antagonist rimonabant (57), but in the ModBase 
prediction, this residue faces into the lipid membrane region.  In our predicted structures, 
however, this residue points into the binding site.  Thus, the homology-based structures do not 
account for the essential characteristics of the CB1 receptor.  None of the previous structures have 
implicated the TM2+TM6 coupling as being critical for the fully inactive CB1 receptor. 
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CONCLUSIONS 
 
Using the CB1 receptor as the model, we provide the first complete picture of the GPCR 
activation mechanism from the inactive form (T3.46A) through the weakly constitutively active 
form (WT) to a highly constitutively active form (T3.46I).  Some molecular signatures of our 
mechanism have been observed in crystal structures of inactive and active forms, while others are 
novel and may be specific to the cannabinoid family.  Based on our understanding of the unique 
interaction observed between TMs 2 and 6 in the inactive T3.46A receptor, we designed double 
mutants expected to be constitutively active, and subsequently confirmed this with GTPγS assays.  
This lays the groundwork for predicting inactive and active mutations for this and other GPCRs, 
which may be used to determine new ligands to have specific activity for activating particular G 
proteins, β arrestins, and perhaps other functionalities. 
 
The ability of our first principles-based ensemble methods to predict structures that explain 
experiments and to predict novel mutations with specific functionality, subsequently validated by 
experiments, suggests that these methods may be very useful in understanding activation and 
specific ligand-GPCR interactions for other systems. 
 
Our experimental and computational studies show that dramatic changes in the global receptor 
conformations can be caused by the mutation of a single residue. This invalidates the implicit 
assumption in using mutation-binding studies to validate a model ligand-receptor structure, where 
it is assumed that the overall global structure of the receptor changes little.  Our study shows 
cases in which this assumption is wildly invalid, requiring careful reinterpretation of all such 
GPCR binding-mutagenesis studies. 
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ABSTRACT 
 
The human cannabinoid type 1 (CB1) G-protein coupled receptor (GPCR) is a potential anti-
obesity drug target, but the structure remains unknown.  Using the Monte Carlo GEnSeMBLE 
method, we previously predicted the optimum ensemble of conformations for CB1, which we 
used to explain the observed changes in the receptors’ G protein coupling activity upon single-
point mutations.  Our predictions were validated by predicting double and triple mutants that 
reversed activity either by gaining or decreasing function depending on the initial constitutive 
activity level.  The mutations were subsequently validated experimentally.  Here, we use these 
substantiated CB1 conformations to predict the binding sites and energies of a series of known 
CB1-selective inverse agonists.  Our results agree with available site-directed mutagenesis data 
and predict new interactions that can be tested experimentally.  In the lowest energy complex, the 
ligand is anchored via hydrogen bonds with K3.28 and a tryptophan on the TM5 (W5.43), which 
is different from previously published pharmacophores.  Seven derivatives of rimonabant were 
docked to CB1, and the calculated binding energies were compared with the experimental binding 
affinity resulting in a ~90% correlation.  This excellent agreement between the calculations and 
experiments gives credence to our predicted CB1 structures and inverse agonist binding site.  
Using this binding pose, rimonabant was reimagined so that it could exploit interactions with 
residues in the binding site.  Based on our predicted rimonabant-CB1 pharmacophore, we propose 
new anti-obesity drug candidates that are expected to be strong CB1-targeting inverse agonists 
that can be tested by experimentalists. 
 
INTRODUCTION 
 
G-protein coupled receptors (GPCRs) are located in the cellular membrane and act as mediators 
for cell signaling making them popular targets for medication, but drug design for GPCRs has 
been challenging due to the paucity of structures.  These integral membrane proteins are 
extremely difficult to crystallize—only ~26 GPCRs have been done so successfully.  Despite 
recent advances in structure determination methods (1), little is known about GPCR structures, 
especially their activation mechanisms.  Only six GPCRs, bovine rhodopsin (bRho) (2-5), human 
β2 adrenergic receptor (Hβ2AR) (6; 7), human adenosine A2A receptor (8-11), human muscarinic 
M2 receptor (12), human neurotensin NTS1 receptor (13), and human P2Y12 receptor (14) have 
been crystallized in the active or partially active conformations, of which only the Hβ2AR has 
been co-crystallized with the full heterotrimeric Gs protein (6). 
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The human cannabinoid 1 (CB1) receptor is an example of one of the many GPCRs that have not 
been crystallized, and therefore its spectrum of conformations, from a fully inactive state to 
various active states, remain unknown.  CB1 has high therapeutic potential as a drug target.  This 
receptor is activated by marijuana and its synthetic versions that had been developed to alleviate 
pain and increase appetite for AIDS and cancer patients.  The CB1-selective inverse 
agonist/antagonist rimonabant (15) is an anti-obesity drug that was available in Europe and was in 
phase III of US FDA clinical trials, but had to be withdrawn from the European market due to 
serious side effects of depression and suicide.  By determining a realistic binding site, we can 
develop drugs specifically for CB1 and decrease the probability of off-target interactions and 
subsequent unfortunate side effects.   
 
In previous studies, we used the Monte Carlo GEnSeMBLE (GPCR Ensemble of Structures in 
Membrane Bilayer Environment) method to predict an ensemble of low energy CB1 
conformations (16; 17).  Briefly, the GEnSeMBLE method consists of sampling the energies of 
trillions of seven helix bundles by rotating and tilting the transmembrane (TM) helices. This 
method is unique for its ability to predict multiple conformations, unlike homology modeling.  It 
is important to generate multiple conformations because receptors are dynamic and flexible.  A 
single GPCR can bind to multiple types of intracellular proteins suggesting that it may undergo 
conformational changes to do so.  Furthermore, different ligands bind to and stabilize different 
GPCR conformations (18-20).  Previously, we used GEnSeMBLE to identify ten low energy CB1 
conformations that are predicted to be energetically accessible.  This current study focuses on 
validating our proposed CB1 receptor conformations by docking a known inverse agonist to them 
and analyzing our docked poses in light of the site-directed mutagenesis data (21-30) and 
structure-activity relationship (SAR) data (31; 32). 
 
Site-directed mutagenesis data of residues around a ligand binding site indicate which ones have a 
large impact on a particular ligand’s binding affinity and can perhaps identify ones that are in the 
binding site and interact with the ligand.  If the mutated residues are located in the ligand’s 
binding site, then we can postulate that the changes in ligand binding affinity are a result of the 
changes in the mutated residues’ interactions with the ligand.  A correlation between large 
changes in binding affinity and strong interactions with the ligand is expected.  Table 4.1 shows 
the side-directed mutagenesis data for rimonabant (Figure 4.1).  Binding affinities are measured 
by Ki and Kd values.  The mutations that have a significant impact on binding affinity to 
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rimonabant are W5.43A, F3.36A, and K3.28A, which cause >1000-fold (21), 20-fold (22), and 
17-fold (23) decreases respectively.   
 
Table 4.1 Compilation of site-directed mutagenesis data for CB1 residues.  
Ligand Mutation TM# Initial Ki or 
Kda(nM) 
New Ki or 
Kda (nM) 
Fold Change 
Rimonabant W5.43Ac 5 4.8 46% at 
5mm 
>1000b 
Rimonabant F3.36Ad 3 3.7 75.5 20.4 
Rimonabant K3.28Ae 3 2.3a 39.6a 17.2 
Rimonabant I2.62T-
D2.63Nj 
2 3.3 22.7 6.9 
Rimonabant W6.48Ac 6 4.8 33 6.9 
Rimonabant D2.63Nj 2 3.3 17.6 5.3 
Rimonabant C7.42Mk 7 39 194 5.0 
Rimonabant F2.61Al 2 2.3a 11.0a 4.8 
Rimonabant F7.35Al 7 2.3a 8.4a 3.6 
Rimonabant S2.60Ai 2 7.2 22.8 3.2 
Rimonabant L3.29Al 3 2.3a 7.2a 3.1 
Rimonabant M6.55Al 5 2.3a 6.8a 3.0 
Rimonabant F3.36Ac 3 4.8 14 2.9 
Rimonabant T3.33Al 3 2.3a 6.5a 2.8 
Rimonabant I2.62Tj 2 3.3 8.8 2.7 
Rimonabant F3.36Ld 3 3.7 7.3 2.0 
Rimonabant F3.25Ac 3 4.8 9.6 2.0 
Rimonabant S7.39Ai 7 18.4 14.2 0.77 
a Kd value. b Italicized rows indicate large changes (greater than 10-fold) in binding affinity upon 
mutation. c See Ref.(21). d See Ref.(22). e See Ref.(23). f See Ref.(24). 
g See Ref.(25). h See Ref.(26). i See Ref.(27). j See Ref.(28). k See Ref.(29). l See Ref.(30). 
  
 
 
 
Figure 4.1 Schematic illustrations of the CB1-selective inverse agonist and anti-obesity drug rimonabant. 
 
In order to validate our predicted CB1 receptor conformations, we docked rimonabant with the 
hierarchical programs, DarwinDock and GenDock (33-37), developed within our lab, so that we 
might determine a correlation between our calculated residue interactions and the change in 
binding affinity upon mutation.  Our predicted ligand-receptor complexes can accurately explain 
site-directed mutagenesis data and, for the most part, the experimental trends in binding affinity.  
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These predicted binding sites were used to design and identify new ligands that we believe would 
act as inverse agonists and strongly interact with the CB1 receptor.  In this study, we propose a 
binding site for rimonabant that has differences from what has been previously published (21; 23; 
30; 38-40).  The docked rimonabant pose serves as an inspiration for recommending potential 
CB1-selective inverse agonists. 
 
METHODS 
 
(For more details about ligand docking methodology, see Chapter II.) 
 
We predicted an ensemble of CB1 receptor structures based on first principles using the 
GEnSeMBLE method developed within the lab (34; 41-44).  Details of the procedure for 
structure prediction have been published previously (16; 17; 44).  The procedure for docking 
rimonabant and other inverse agonists to the CB1 receptors are outlined below.  All the 
simulations used the Dreiding III force fields (FF) (45) [with exponential-6 (exp6) or Lennard-
Jones (LJ) forms for the van der Waals (vdW) term], unless otherwise noted. 
 
Ligand preparation 
For rimonabant, we constructed each ligand with Maestro software (46) and performed a 
conformational search with MacroModel software (47).  A total of 83 ligand conformations were 
saved for rimonabant.  Nine conformations remained after two rounds of clustering.  One 
conformation was constructed from existing coordinates from the crystallized molecule in 
methanol solvate (48).  Each ligand was minimized with SGB solvation (49) for 100 steps or to a 
convergence threshold of 0.2 kcal/mol/Å RMS force with MPSim software (50). 
 
Docking of rimonabant to CB1 receptors 
We docked ten conformations (nine from conformational search and one from a crystal) of 
rimonabant to the selected putative binding regions of all ten low energy structures for the CB1 
receptor using the programs DarwinDock and GenDock (33-37). 
 
DarwinDock 
This program combined the completeness of generating poses for the binding pocket, indicated by 
the sphere regions, and the clustering of similar poses together to reduce the computational cost 
of energy scoring for the possible candidates.  Darwin Dock consisted of using Dock6 (51) to 
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generate 5000 ligand poses in the alanized receptor for multiple steps.  The W5.43 residue is the 
only hydrophobic, bulky residue not replaced with alanine because this tryptophan is deemed 
critical for ligand interaction by site-directed mutagenesis data (see Table 4.1), so it remains 
unchanged during docking.  A ligand pose was deemed acceptable if it clashed or bumped the 
receptor residues at six positions or less.  The complexes are clustered so that every family 
member was within a 2.00 Å RMSD of another.  These steps are repeated until the number of 
new families created is less than 2% of the number of existing families.  The program scores the 
energies of the family heads and selects the 10% of family heads with the lowest energies.  All 
the members of these respective families are scored energetically.  One hundred and fifty 
receptor-ligand poses are chosen according to the lowest phobic, polar, and total energy for 
enrichment in GenDock.  
 
GenDock  
GenDock refined and enriched the 150 docked ligand-receptor poses generated by DarwinDock.  
In the SCREAM module (45) alanine residues  were replaced with the original hydrophobic 
residues, and the side chain rotamers of binding site residues were sampled before the entire 
complex was minimized for 10 steps.  In the next module, the receptor was neutralized and 
minimized for 60 steps using the exp6 vdW term in the Dreiding FF.  A final complex was 
selected for each receptor and ligand conformation (300 complexes total) according to the lowest 
binding energy with strain and ligand solvation, which we believe best represents the binding 
affinity.  The binding energy with strain and ligand solvation is defined as the energy difference 
between the complex and the sum of the receptor and ligand energies with ligand strain and 
ligand solvation added in.  The selected complex was minimized with the Dreiding III FF with 
the LJ vdW term (Dreiding III-LJ FF) in vacuum for 50 steps or to an RMS force threshold of 0.5 
kcal/mol/Å using MPSim software (50). 
 
Validation of predicting binding sites 
Building and docking rimonabant derivatives for SAR studies 
We took the lowest energy CB1 receptor-rimonabant complex shown in Figure 4.2, extracted the 
rimonabant ligand, modified it with Maestro software to look like the respective derivative, 
calculated the charges with Jaguar software, minimized it with for 100 steps or a threshold of 0.2 
kcal/mol/Å with MPSim, and docked it using the same procedure described above with a few 
exceptions.  Instead of docking to ten receptor conformations, we docked to one—the alanized 
CB1 receptor conformation WT6 because that produced the lowest energy complex with 
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rimonabant shown in Figure 4.2.  We also docked a single ligand conformation derived from the 
docked rimonabant pose.  We repeated these steps for seven derivatives and the original 
rimonabant ligand.  For rimonabant, we did not alter the ligand structure and only docked the 
optimized ligand conformation.  The final complexes were chosen according to the lowest 
binding energy with strain and ligand solvation.  For comparison of the experimental binding 
affinities with the computational energies, we used the binding energy, or the difference in energy 
between the receptor-ligand complex and the receptor and the ligand structures separately.  The 
ligand strain and ligand solvation were ignored since we are comparing energetics across 
different ligands.  
 
Free energy and binding affinity calculations 
The experimental change in free energy upon ligand binding to the receptor, ΔGbindExp , is obtained 
from the pKi (52) in Equation 4.1: 
ΔGbindExp = −RT  ln 10− pKi( ) . (4.1) 
The ΔΔG exp , or the difference in the change in experimental free energy upon ligand binding for 
a given inverse agonist (ΔGbindExp ) with respect to the corresponding value of rimonabant, is 
determined by Equation 4.2: 
 ΔΔG exp= −RT  ln Ki Inverse agonist( )Ki Rimonabant( ) .
 (4.2) 
 
Discovery of novel CB1 ligands 
Exploiting the ligand binding site to define a new scaffold 
Our predicted rimonabant-CB1 binding site was used to identify new potential CB1-selective 
inverse agonists.  We performed a crude search in PubChem (53) looking for ligands that are 
comparable to rimonabant according to the Tanimoto coefficient (54), which indicates how 
similar the 2D structures of the ligands are to one another.  The Tanimoto coefficient ranges from 
0 to 1, with 0 being no resemblance between the molecules and 1 being identical resemblance 
between the molecules.  We wanted ligands that are modifications of rimonabant to exploit 
interactions with underused polar and aromatic residues in the predicted binding site.  For 
example, K7.32 is located near rimonabant, but does not form a hydrogen bond with it, so we 
searched for a ligand with an appropriately placed functional group to create a desired polar 
interaction.  We also wanted a ligand that is commercially available, so that experimentalists can 
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easily test our predictions, and one that has not been previously tested with the CB1 receptor.  
Once we had identified a ligand (MSC1, see Figure 4.6) that met the above criteria, we 
performed a search in PubChem to identify ligands that scored a 0.90 on the Tanimoto 
coefficient, or those that have a 2D structure that is 90% similar to the new PubChem ligand 
MSC1.  The ligands found in PubChem are denoted by the acronym ‘MSC’ followed by a 
number (MSC1 through MSC16). 
 
RESULTS AND DISCUSSION 
 
Docking inverse agonist rimonabant to CB1 
The lowest energy pose for the CB1-rimonabant complex agrees with site-directed mutagenesis 
data because the ligand is anchored by hydrogen bonds with W5.43 and K3.28 (Figure 4.2).  
These residues have the largest impact by decreasing experimental binding affinity upon mutation 
as seen in Table 4.1.  The breakdown of calculated binding energies for the complex is shown in 
Table 4.2.  W5.43 has the largest non-bonding energy of all the residues in the receptor with  
-9.36 kcal/mol.  As stated above, Table 4.1 shows that the W5.43A mutation has a major effect 
on rimonabant binding.  The experimental mutation indicates a significant decrease in binding 
affinity of >1000-fold.  Thus, our docking studies agree with experimental data because 
rimonabant has significant polar and phobic contacts with the CB1 receptor.   
 
 
Figure 4.2 Inverse agonist rimonabant docked to CB1 receptor.  Rimonabant is anchored to CB1 by the 
two hydrogen bonds: one with W5.43 and the other hydrogen bond with K3.28.  Hydrogen bond 
heteroatom distances are labeled in black. 
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Table 4.2 Cavity analyses for the CB1 WT in complex with rimonabant. 
Residuea Numberb VdWc Coulombc H-Bondc NonBondc,d 
TRPe 5.43 -3.146 -2.085 -4.129 -9.360 
MET 6.55 -6.043 -0.756 0 -6.799 
LYS 3.28 -0.833 -1.410 -3.322 -5.566 
PHE 3.36 -3.841 -0.054 0 -3.896 
VAL 3.32 -2.904 -0.363 0 -3.267 
THR 5.47 -1.912 -0.048 0 -1.960 
LEU 6.51 -2.100 0.193 0 -1.907 
TRP 6.48 -1.844 0.008 0 -1.837 
THR 3.33 -1.889 0.093 0 -1.797 
ILE 2.56 -1.449 0.000 0 -1.449 
LEU 7.43 -1.382 0.119 0 -1.263 
PHE 7.35 -0.959 -0.174 0 -1.134 
SER 3.35 -1.385 0.302 0 -1.083 
a Only residues with energies whose absolute values are greater than 1.0 kcal/mol. 
b Residues are numbered according to the Ballesteros-Weinstein scheme (55). 
c All energies are in units of kcal/mol. 
d The non-bonding (NonBond) energy in the far right column is the sum of the van der Waals (VdW) 
energy, coulombic (Coulomb) energy, and hydrogen bond (H-bond) energy. 
e Residues with hydrogen bonds are highlighted in bold red.   
 
According to our docking cavity analysis in Table 4.2, K3.28 has the third largest non-bonding 
interaction energy, -5.566 kcal/mol, with rimonabant due to its hydrogen bond with the amide 
carbonyl of the ligand.  This docking pose is supported by a previous SAR study (23), which 
showed that the binding affinity decreased by 17-fold by mutating K3.28 to alanine.  However, 
the same experiments with the rimonabant derivative VCHSR, a version of rimonabant with 
hydrocarbons replacing the amide and piperdine groups, showed its the binding affinity relative to 
rimonabant did not change for the K3.28A mutant.  This study suggests that K3.28 interacts with 
the polar atoms of the amide group or piperdine ring, including the carbonyl (23), which agrees 
with the predicted docked ligand pose. 
 
In our docked pose of rimonabant with the WT receptor, the F3.36 residue has a significant 
interaction with the ligand consisting of a van der Waals interaction energy of -3.896 kcal/mol.  
In binding assays, the F3.36A mutation decreased this inverse agonist’s binding affinity by 20-
fold (22), or 1.78 kcal/mol, for the human CB1 receptor.  An earlier study done with the mouse 
sequence showed that F3.36A only decreases the binding affinity by 3-fold (21), which is not a 
significant amount (Table 4.1).  Returning to the human sequence studies, the F3.36L mutation 
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decreased the binding affinity by only 2-fold indicating the importance of the bulky hydrophobic 
residue for receptor-ligand interaction (22). 
 
We notice that M6.55 has a strong interaction with rimonabant, but that is not explained by the 
site-directed mutagenesis data.  This residue has the second strongest interaction with CB1 with a 
non-bonding energy of -6.8 kcal/mol, which is almost entirely hydrophobic in nature (Table 4.2).  
When methionine is mutated to an alanine, however, the binding affinity only decreases slightly, 
by 3-fold (30), or by 0.65 kcal/mol in energy, for the CB1 receptor.  The predicted binding site 
cannot explain this site-directed mutation. 
 
Our predicted rimonabant binding site in CB1 is different from previous computational studies 
that examined rimonabant docked to bRho templates of human CB1 (21; 23; 39; 40).  Figure 4.3 
compares this rimonabant pharmacophore published by Lange and Kruse (38) (Figure 4.3A) with 
the corresponding pharmacophore from this study (Figure 4.3B).  Our models are basically 
perpendicular to one another.  Rimonabant in the previous models (Figure 4.3A) spans the width 
of the binding site with the chlorophenyl rings near TM5 and the piperdine ring near TM3.  In 
Figure 4.3B, the ligand is lying parallel to the z-axis passing from the extracellular to 
intracellular side of the membrane.  Both agree that a hydrogen bond forms between K3.28 and 
the amide carbonyl of rimonabant.  However, the earlier models show that K3.28 also participates 
in a salt bridge with D6.58 (21; 23; 39), which we do not observe.  In addition, in previous 
models, the W5.43 residue is sandwiched by rimonabant’s two chlorophenyl groups and thus has 
strong aromatic interactions.  Furthermore, multiple other aromatic residues in the binding pocket 
(F3.25, F3.36, W4.64, Y5.39, W6.48) participate in stacking with the ligand (21; 39; 40), whereas 
in our predicted binding site, the W5.43 residue’s impact on binding affinity comes from its 
ability to form a hydrogen bond with rimonabant.  Instead of W5.43, the F3.36 residue is 
sandwiched by the chlorophenyl groups.   
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Figure 4.3 CB1-rimonabant pharmacophores with side chains important for receptor-ligand interactions 
labeled.  (A) Lange and Kruse published a pharmacophore (38) based on prior docking studies (21; 23; 39; 
40) involving the human CB1 receptor predicted using homology modeling with bRho.  These studies find 
that rimonabant forms one hydrogen bond with K3.28 and sandwiches W5.43.  [Figure 4.3A is based on 
the previously published Figure 4 from Lange and Kruse, 2005 (38).]  (B) Our predicted pharmacophore 
shows that rimonabant has a different binding site in our GEnSeMBLE-derived CB1 structure that allows it 
to form two hydrogen bonds, including one with W5.43, and have strong aromatic interactions with the 
receptor.  Residues in the binding site are labeled in both Figures 4.3A and 4.3B.  Residues labeled in red 
in Figure 4.3B are unique to that particular pharmacophore and are not found in the binding site shown in 
Figure 4.3A. 
 
A recent paper from Shim et al. based its CB1 model on the Hβ2AR (30), and the authors 
identified a similar binding site compared to the one discussed above that was published by 
Lange and Krause (38).  The ligand does lie perpendicularly to the model presented in this study, 
in that the piperdine ring points to the TM1-2-7 binding pocket and the chlorophenyl rings point 
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towards TM5 where they form aromatic stacks with W5.43 and W6.48.  However, rimonabant’s 
binding site is markedly different from the others because this particular ligand pose does not 
form a direct hydrogen bond with K3.28.  Also, the monochlorophenyl and dichlorophenyl rings 
are switched compared to the previous models. 
 
It is reasonable for our predicted rimonabant binding site to disagree with the previously 
published ones since our predicted receptor structures are different.  Details on prediction 
methods and a structural comparison have been published previously (16; 17; 44), but in general, 
we based our structure on the turkey β1 adrenergic receptor and performed a 360° rotation of all 
the helices and additionally sampled helix tilt and sweep angles.  To reiterate, the previous studies 
used homology models based on the bRho or Hβ2AR structure templates.  These three GPCRs 
have very similar global conformations, but we preformed considerable sampling to obtain CB1 
receptor conformations that were significantly different than the starting template.  The method 
we used to identify our final receptor-inverse agonist complex is also different.  The most recent 
study from Shim et al., (30) used the selection criterion that one of the two chlorophenyl rings 
should be near the TM3-5-6 hydrophobic site, so their final pose was chosen based on 
rimonabant’s interactions with residues for which there was site-directed mutagenesis data, 
whereas we selected our complex based on the lowest energy complex, which agrees with 
experimental data.   
 
The conformation that produced a rimonabant binding pose most similar to ours came from 
another study where the ligand was docked to a bRho homology model (56).  This predicted 
binding site is similar to the other bRho-based models mentioned above in that it has a 
K3.28+D6.58 salt bridge, but in contrast with those studies and in agreement with ours, 
rimonabant sits vertically in the binding pocket—the piperdine ring points towards the 
extracellular end and the chlorophenyl rings point towards the intracellular end.  The oxygen 
atom of rimonabant’s amide carbonyl forms a hydrogen bond with K3.28, but unlike ours, the 
ligand does not form any hydrogen bonds with W5.43.  The amide carbonyl points toward TM5, 
while the amide proton points to the TM1-2-7 pocket.  They predict that the pyrazole nitrogen on 
rimonabant forms a hydrogen bond with Y5.39, which we do not observe in our complexes. 
 
Analysis of the conformational ensemble of CB1 structures 
Our structure prediction methodology is unique in that we can predict an ensemble of 
energetically accessible conformations.  This procedure is a more realistic approach than 
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homology modeling because the receptors are flexible and dynamic, and experimental evidence 
suggests that different ligands can stabilize different receptor conformations that can potentially 
interact with various intracellular proteins.  Surprisingly, rimonabant does not have its most 
favorable binding energies with the lowest energy CB1 receptor conformation (called WT1) 
(Table 4.3).  Instead, rimonabant has a slightly better binding affinity with the conformation 
ranked sixth in energy (WT6).   
 
Table 4.3 Comparison of receptor conformations selected by the inverse agonist rimonabant. 
Energy Rank WT Conf. # bound to 
Rimonabanta 
Binding Energy with strain and 
Rimonabant solvation 
1 WT6b -59.10 
2 WT1 -57.24 
3 WT9 -55.44 
4 WT5 -54.39 
5 WT2 -50.97 
6 WT7 -50.12 
7 WT4 -50.05 
8 WT10 -49.59 
9 WT8 -49.35 
10 WT3 -48.63 
a The complexes are ranked according to best binding energy with strain and ligand solvation included. 
b Receptor conformation numbers that do not contain the conserved R3.50 and D6.30 salt bridge are in bold 
red. 
 
Even more surprising is that the inverse agonist rimonabant preferentially binds to receptor 
conformations that lack the R3.50 and D6.30 ionic lock, which is believed to be important for 
preventing activation (Table 4.3).  Experiments have shown that rimonabant inactivates the CB1 
receptor (15; 32), but the inverse agonist has the best binding energies with those that look 
activated.  When comparing the lowest energy complex for each receptor conformation, the three 
conformations that lack the conserved R3.50 and D6.30 ionic lock are ranked in the top four 
rimonabant-CB1 complexes, which is not what we had anticipated.   
 
There have been, on the other hand, several studies that suggest this R3.50 and D6.30 salt bridge 
is not necessary for maintaining the inactive conformation.  It is possible for antagonists to bind 
to the inactive state without the ionic lock (57; 58).  For example, Audet and Bouvier have shown 
that the R3.50 and D6.30 salt bridge is broken in the crystallized complex of Hβ2AR bound to the 
antagonist carazolol.  They also note that as of 2012, of the 36 crystallized GPCR structures 
bound to antagonists and inverse agonists, only three contain this intact salt bridge, which was not 
observed across all structures for these particular receptors (57).  In previous work with the 
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human CB1 receptor, we had shown that a different residue, R2.37, plays an important role in 
preventing receptor activation (16; 17; 44).  We believe that this residue forms an ‘ionic lock’ via 
a salt bridge interaction with D6.30 to stabilize the inactive conformation.  Thus, the traditional 
R3.50 and D6.30 salt bridge seems unnecessary for stabilizing the inactive CB1 conformation, 
and the inverse agonist would not preferentially bind to a conformation that contained this 
signature contact.  We did not dock rimonabant to the CB1 WT conformation containing the 
R2.37 and D6.30 salt bridge that we believe to be the ionic lock for this receptor because none of 
the low energy WT conformations contain this contact. 
 
In its current state, the rimonabant-bound CB1 receptor conformation WT6 does resemble the 
predicted structure of a constitutively active mutant, T3.46A/R2.37A, which too lacks the R3.50 
and D6.30 ionic lock (16; 17).  Their alpha-carbon backbone RMSD is 1.2 Å, which is smaller 
than all crystal structure resolutions (11) and indicates that the two conformations are very 
similar.  For comparison, the difference between the WT receptor conformations WT2 (which 
contains the R3.50+D6.30 salt bridge) and WT6 (which does not) is 1.8 Å. 
 
Analysis of structure-activity relationship (SAR) with rimonabant derivatives 
In order to validate our proposed binding site, we docked known derivatives of rimonabant 
(Figure 4.4A) to the CB1 receptor conformation and plotted our calculated binding energies 
against the experimental binding affinity, pKi, to find the correlation between the two data 
(Figure 4.5).  In all of the complexes, the ligand bound to the same site as rimonabant originally 
did (Figure 4.4B).  Figure 4.5A shows a comparison between the pKi of the inverse agonists 
from Hurst et al. (31) and our calculated binding energies.  We observe a very high correlation of 
93.4%, which shows there is good agreement between the trends observed in experimental 
binding affinities and our own calculated binding energies.   
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Figure 4.4 Rimonabant derivatives used in SAR study.  (A) Rimonabant and the seven derivatives used in 
the SAR study.  The portions of the ligand that are different from rimonabant are colored in red.  The 
derivatives in the first two rows were used in the Hurst et al., 2006 study (31), and the derivatives in the 
third row were used in the D’Antona et al., 2006 studies (32; 59). (B) Rimonabant and seven derivatives 
docked to the CB1 complex.  Rimonabant has carbon atoms colored in cyan.  The other derivatives have 
carbon atoms colored in grey. 
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Figure 4.5 Comparison of experimental binding affinities and computationally calculated energies between 
receptor and inverse agonists.  (A) Plot showing the correlation of the experimental binding affinity, pKi, 
for inverse agonists in Hurst et al. (31) versus our calculated binding energy (red circles).  R2 values are 
indicated on the plot.  (B) Plot showing the correlation of the ΔΔG exp  of previously published inverse 
agonists with respect to that of rimonabant (31; 32) versus the calculated binding energy.  R2 values are 
indicated on the plot.   
 
For the inverse agonists from D’Antona et al. (32; 59), we compared these calculated energies 
with the ΔGbindExp determined from Equation 4.1.  The ΔGbindExp  values are within 1 kcal/mol of each 
other since the energies are -9.33 kcal/mol for AM-281, -10.0 kcal/mol for AM-251, and -9.70 
kcal/mol for rimonabant.  Similarly, both the calculated cavity and binding energies for the three 
ligands are approximately within 1 kcal/mol.  The binding energies are -67.4 to -69.0 kcal/mol, 
which are very similar and agree with the experimentally observed negligible change in free 
energy upon binding.  This excellent correlation is surprising because the predicted energies are 
based purely on enthalpy and do not include entropy.  However, the entropy change upon binding 
of all the ligands should be similar since they all have the same number of rotatable bonds. 
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Figure 4.5B combines the results from Figure 4.5A with those regarding the inverse agonists 
from D’Antona et al. (32) for a single comparison of our calculated binding energies and the 
binding affinities from the two experiments.  The respective ΔΔG exp  values from Equation 4.2 
are plotted against the calculated binding energies for all eight ligands, and we observe an 89.4% 
correlation.  The excellent agreement between our predicted energies and the experimental 
binding affinity shown in Figure 4.5 provides confidence that we predicted a very reasonable 
binding site for rimonabant.  
 
Discovery of novel CB1-targeting inverse agonists 
With a reliable rimonabant binding site pharmacophore for CB1, which is supported by site-
directed mutagensis and SAR data, we developed a new, more selective CB1 inverse agonist.  
After an informed search in PubChem (53), we selected Zinc08587042, which we will refer to as 
MSC1 (Figure 4.6), a ligand with a 68% similarity to rimonabant according to the 2D Tanimoto 
coefficient (54).  Rather than relying on PubChem’s search algorithm, which looks for molecules 
based on a 0.90 Tanimoto similarity score with respect to rimonabant, we used the predicted CB1 
binding site and searched for a ligand that maintained key structural aspects of rimonabant and 
additionally took advantage of underused residues in the binding site.  For example, it was 
important to find a ligand that had the same amide and pyrazole functional groups to maintain the 
hydrogen bonds with K3.28 and W5.43 respectively.  Yet, we wanted to replace rimonabant’s 
piperidine ring with a phenyl and a substituted polar group to improve the interactions with the 
aromatic residues and gain an additional hydrogen bond with K7.32, which is in rimonabant’s 
binding site.  Furthermore, we wanted to replace the methyl group of the pyrazole group with a 
polar substitute to form a hydrogen bond with S7.39.  MSC1 is attractive because it contains an 
acetylphenyl group, which we predicted would reach into the aromatic pocket of the extracellular 
end, and a triazole, which would replace a methyl group with a nitrogen atom.  However, we also 
wanted a small molecule that was commercially available and that had not been previously tested 
with CB1 in bioactivity assays.  MSC1 met all of the above criteria. 
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Figure 4.6  Proposed CB1 inverse agonist MSC1 (Zinc08587042).  Structure comparison of rimonabant 
(top) with MSC1 (bottom).  MSC1 has a 2D structure that is 68% similar to rimonabant’s.  Portions of 
MSC1 highlighted in red are different from the corresponding parts in rimonabant. 
 
PubChem subsequently identified 15 small molecule ligands that have a 2D structural similarity 
Tanimoto score of 0.90, or have 2D structures that are 90% similar to that of MSC1 (Figure 4.7).  
We plan to dock these 16 ligands to the ensemble of predicted CB1 structures, find their 
corresponding binding energies, and predict their respective pKi values using the relationship in 
Figure 4.5.  Of the 16 MSC small molecules, 14 of them, MSC1 - MSC6, MSC8 – MSC11, and 
MSC13 – MSC16 are commercially available. 
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Figure 4.7 Proposed CB1-selective inverse agonists based on PubChem (53) similarity search with MSC1.  
PubChem identified 15 ligands that have 2D structures similar to MSC1. 
 
CONCLUSIONS 
 
The CB1 receptor inverse agonist rimonabant, along with its structurally related molecules, were 
docked to previously predicted CB1 receptor conformations.  The CB1-rimonabant complex 
explains site-directed mutagenesis because this inverse agonist is anchored to the receptor via a 
hydrogen bond with W5.43 rather than just hydrophobic interaction.  We confirmed our receptor 
structure with SAR data, involving rimonabant-related inverse agonists, and our calculated 
binding energies for the various inverse agonists show excellent, 93%, agreement with the 
experimentally determined binding affinities.   
 
Understanding how rimonabant interacts with the receptor, we searched for ligands with specific 
traits that we predicted would enhance its affinity for the binding site.  We should note that we 
did not rely on a PubChem search algorithm based solely on the Tanimoto coefficient to identify 
potential CB1 inverse agonists.  We analyzed rimonabant’s binding site in CB1 and predicted 
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which residues are not being engaged and how structural alterations in rimonabant could 
maximize interactions with residues in the receptor.  We have selected a small molecule that met 
specific criteria and found another 15 based on a PubChem similarity search.  Of these 16 small 
molecules, 14 ligands are commercially available making it easier for experimentalists to verify 
our predictions.  Our next step is to dock these proposed ligands to calculate the binding energies 
and provide an estimation of the experimental binding affinities. 
 
It is extremely important to learn if MSC1 and the other small molecules discussed above are 
CB1-selective strong binding inverse agonists because they could be new candidates for anti-
obesity drugs that target CB1.  Rimonabant, while effective, is not on the market due to its side 
effects.  Our proposed new inverse agonists based on a realistic binding site might bind almost 
exclusively to CB1, decreasing the probability of undesirable side effects resulting from off-target 
interactions. 
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Chapter V 
 
CB1 RECEPTOR STRUCTURAL CHANGES UPON DYNAMICS WITH AND 
WITHOUT THE PRESENCE OF AN INVERSE AGONIST 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted partially from Anton Proposal entitled “Activation of the Gi and Gs proteins via 
coupling with the human cannabinoid type 1 (CB1) G protein-coupled receptor;” 
submitted in 2013. 
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ABSTRACT 
 
G protein-coupled receptors (GPCRs), like the human cannabinoid type 1 (CB1) receptor, are 
flexible macromolecules that can bind to various intracellular receptors and ligands, but little is 
known about the ensemble of possible conformations due to the scant number of crystallized 
GPCRs.  Here, we used NAnoscale Molecular Dynamics (NAMD) version 2.9 software to run 50 
ns NPT molecular dynamics (MD) simulations on the predicted CB1 receptor in the apo and 
inverse agonist rimonabant-bound forms inserted into solvated lipid bilayers.  We find that the 
apo-CB1 receptor (without the ligand present) is stable with its R3.50+D6.30 salt bridge intact for 
50 ns.  We also see the formation of a salt bridge between R148 of the first intracellular loop and 
D6.25.  We expect that both of these salt bridges would stabilize the inactive form since they 
would prevent the binding of the G protein to the intracellular end.  Surprisingly, the inverse 
agonist rimonabant bound to a conformation of the CB1 receptor that is missing the R3.50+D6.30 
salt bridge.  However, this polar contact forms during MD and is stable for the final 40 ns of the 
simulation.  We hypothesize that rimonabant conforms the CB1 receptor to take the inactive 
conformation in an ‘induced fit’ manner.  However, it is necessary to extend the lengths of these 
simulations to see if the rimonabant-bound receptor conformation becomes fully inactive and 
stable. 
 
INTRODUCTION 
 
G protein-coupled receptors (GPCRs) are transmembrane (TM) proteins that mediate intracellular 
signals.  Due to their penchant for existing in the hydrophobic lipid bilayer, they are difficult to 
isolate and crystallize, but thanks to recent technical and methodological advances, there has been 
an explosion in the number of crystallized GPCRs.  However, only four receptors have been 
crystallized in the activated form (1-11), and even then, crystallizations of these receptors only 
capture a snapshot of a very dynamic and flexible macromolecule.  GPCRs have the ability to 
exist in multiple active and inactive conformations (12-15), so molecular dynamics (MD) 
simulations of these receptors are necessary in helping us to understand their activation 
mechanism and which different conformations are energetically accessible.  Figure 5.1 shows a 
schematic illustration inspired by Kobilka and Deupi (14) relating the activity levels of receptor 
conformations and their respective energies.  For the apo-receptor, or receptor without a bound 
ligand, inactive conformations are the lowest or most favorable in energy and are thereby the 
most populated according to the Boltzmann distribution.  As the receptor activates, it undergoes a 
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conformational transition indicated by the energetic barrier followed by adoption of the activated 
conformation, which is higher in energy and therefore less populated and less likely to be 
obtained with crystallization procedures. 
 
Figure 5.1 Schematic illustration relating energy to receptor level of activation.  The red line corresponds 
to the apo-receptor (receptor alone), and the blue line corresponds to the receptor bound to an inverse 
agonist.  Adapted from Figure 1 in (14). 
 
When an inverse agonist is added to the receptor, the inactive receptor conformation becomes 
increasing stabilized while the transition barrier becomes larger, indicating that activation is more 
energetically difficult.  In addition, the activated state becomes higher in energy, so it is less 
accessible at room temperature.  Fluorescence lifetime spectroscopy experiments of the human β2 
adrenergic receptor (Hβ2AR) support this model because the apo-receptor has one conformational 
state, but in the presence of a neutral antagonist, there are fewer structural fluctuations meaning 
that this conformation is stabilized (16). 
 
Our aim is to use MD simulations to provide direct information on the atomistic structural 
changes of the GPCR over time and how these structural changes are impacted by the presence of 
an inverse agonist.  One of the best systems for studying multiple GPCR conformations is the 
human cannabinoid type 1 (CB1) receptor because it has been experimentally proven to bind to 
different types of G proteins (17-20) suggesting a structural and functional flexibility, and it has 
multiple predicted inactive and active conformations (21; 22).  It is activated by the psychoactive 
component of marijuana, and plays an important role in pain and hunger regulation.  It is also a 
 105 
potential target for anti-obesity drugs.  But in order to design drugs to interact specifically with 
CB1, we must understand the receptor structure and the corresponding conformational changes 
underlying receptor activation that lead to downstream physiological effects.   
 
Our lab routinely carries out MD simulations on large proteins solvated in water with appropriate 
levels of salt, often on GPCRs (23-39), but also on serine proteases (40), DNA (41-44), RNA 
(45), peptides on silica surface (46), outer membrane protein A (OmpA) (47), and antifreeze 
proteins (48).  Typically such calculations have ~50,000 atoms per periodic cell.  We use such 
MD software packages include NAMD (49-51), MPSim (52), LAMMPS (53), and AMBER7 (54; 
55). 
 
Here, we used NPT MD simulations with NAMD software to understand how our predicted apo-
CB1 receptor structure changes in the solvated bilayer, a biologically relevant condition, and in 
the presence of an inverse agonist.  For the apo-receptor, we observe that the structure is stable 
for 50 ns, but this simulation needs to be lengthened to understand if it adopts a fully inactive 
conformation.  Surprisingly, the inverse agonist rimonabant bound to what appears to be a pre-
activated CB1 receptor conformation.  However, with dynamics, the receptor starts to form 
contacts that would resemble an inactive structure.  These results suggest that these receptors 
preferentially adopt the inactive structure, but longer simulations are necessary to confirm this 
hypothesis. 
 
METHODS 
 
In previous work, we predicted the structures of an ensemble of low energy structures using the 
GEnSeMBLE method (21; 22) followed by re-docking an optimized version of known CB1-
selective inverse agonist rimonabant to the sixth lowest energy structure to obtain a complex with 
favorable binding energy with strain and ligand solvation (see Chapter IV).  The apo-receptor 
structure discussed throughout this chapter is the second lowest CB1 receptor in terms of average 
energy because this is the lowest energy structure of the ten that contains the R3.50+D6.30 ionic 
lock.  (By convention, salt bridges are indicated by a ‘+’, hydrogen bonds are indicated by a ‘-’, 
and residues will be referred to with Ballesteros-Weinstein numbering (56).)  Here, we add loops 
and helix 8 before running MD on the apo-receptor or receptor-ligand complex in a solvated and 
neutralized lipid bilayer.   
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Adding loops to the TM bundle 
The steps below use the all-atom Dreiding force field (FF) (57) unless otherwise noted. 
 
Constructing the loop scaffolds 
Loops were added and optimized for the two different receptor structures—one of which 
contained a bound rimonabant ligand.  Each of the six loops were grown in the TM bundle 
without the other five loops present using a software program called ‘growloop’ written by 
Vaclav Cviek of the Goddard lab.  The loop scaffolds are initially constructed entirely out of 
glycine residues with secondary structure dihedral angles for the backbone if indicated (Table 
5.1).  The glycines are grown in one-residue increments from both ends of the start/stop loop 
residues at the TM termini.  We used a tolerance distance of 0.4 Å per residue with a bump cut-
off distance of 2.5 Å.  The tolerance is the amount of ‘space’ allotted per residue, so that the 
distance between the two growing ends of the loop does not exceed m (tolerance) with m = 
number of residues left to grow in the loop.  The bump cut-off is the acceptable distance between 
the loop and TM backbone atoms.  The number of conformations that were generated for each 
loop was 10n2, with n = number of residues in the loop.  Secondary structure of the loops was 
predicted with online servers: Porter Protein Secondary Structure Prediction Server (58; 59), 
APSSP2: Advanced Protein Secondary Structure Prediction Server (60; 61), and PSIPRED: 
Protein Prediction Server (62-64).  The lengths of TM2 and TM3 were shortened by two residues 
each on the extracellular (EC) ends in order to generate enough EC1 loops that could span the 
distance between the TMs without being too strained. 
 
Table 5.1 CB1 loop building.  The respective start and stop residues and respective loop sequences for each 
of the three intracellular (IC) and three extracellular (EC) loops are shown.  Secondary structure prediction 
(SSP) for the loop backbone based on three online servers (58-64) is shown with S=beta sheet and 
C=random coil.  a=Modified start residue for EC1 loop.  b= Modified stop residue for EC1 loop.  Originally 
they were 183 and 186 respectively, but the program could not generate enough loops because of too much 
strain. *= ‘dummy’ residue, place holder for the seven-residue EC2-bulge sequence. 
Loop Start 
Residue 
Stop 
Residue 
Sequence SSP 
IC1 144 149 SRSLRC None 
EC1 181a 188b HRKDSRNV None 
IC2 217 229 SIHRPLAYKRIVT None 
EC2 255 271 WNCA*CSDIFPHI None 
EC2-
bulge 
258 263 EKLQSV None 
IC3 309 322 IQRGTQKSIIIHTSEDGKVQVTRP CCCCCSSSSSSSSCCCSSSSSSCC 
EC3 369 375 GKMNKLI None 
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Modifying the loop scaffolds 
In a subsequent script, written by Caitlin E. Scott and Professor Ravinder Abrol, the individual 
loops are merged with the TM bundle and modified to have the correct target sequence.  First, the 
individual loop plus the four terminal residues at the loop-TM junction in the TM bundle are 
minimized 10 steps with SGB solvation (65) using MPSim software (52), and the top 10%, 
according to energy, are kept for subsequent steps.  Then, the glycine, proline, and cysteine 
residues, which affect the shape of the loop backbone (66), are mutated into the loops with 
SCREAM software (67).  Alanines replace all the other glycine residues.  The loop regions and 
the terminal TM residues are minimized for 10 steps with SGB solvation.  The correct sequence 
is mutated with SCREAM software into the loop scaffolds before the loops and adjacent TM 
residues are minimized again for 10 steps with SGB solvation.  The top 10% of conformations are 
chosen according to energy, and these loops and the adjoining terminal TM residues are 
minimized 50 steps with SGB solvation.  Any loop-receptor structure that is greater than 50 
kcal/mol from the lowest energy structure is discarded from subsequent steps listed below. 
 
Building EC2 loop and an intra-loop disulfide bridge 
The EC2 loop was particularly challenging to construct given the presence of a disulfide bridge 
(DSB) between cysteine residues 257 and 264 (68).  To ensure that the two cysteine residues are 
close enough to form an intra-loop DSB, we replace the seven residues separating the cysteines 
with a ‘dummy’ alanine residue.  The procedure for inserting the EC2 loop scaffold into the TM 
bundle follows the same method outlined above, with some exceptions.  After attaching the loop 
scaffold to the TM bundle, the distance between the alpha-carbons of the DSB cysteine residues 
is calculated.  If the distance is greater than 7.5 Å, the loop is discarded.  Second, after keeping 
the top 10% of loops according to energy and mutating the cysteine, proline, glycine, and alanine 
residues with SCREAM, the distance between the two sulfur atoms in the DSB cysteine residues 
is calculated.  If this distance is greater than 7.0 Å, the loop is discarded.  Then, the dummy 
alanine residue is removed, and the DSB is formed.  The charges are corrected for the oxidized 
cysteines in the DSB, and these residues and their adjacent neighbors are minimized 10 steps with 
SGB solvation.  Subsequently, the entire loop and the terminal TM residues are minimized 10 
steps with SGB solvation before completing the rest of the procedure described above by using 
SCREAM to replace the alanines with the target sequence residues, minimizing the solvated 
loops and adjoining residues, keeping the best 10% of low energy structures, and finally 
minimizing the loops and adjoining residues for 50 steps with SGB solvation. 
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After constructing the DSB and removing the dummy residue, it is necessary to complete the loop 
by building the portion referred to here as the ‘EC2-bulge,’ or the loop residues separating the 
two cysteines in the DSB.  For each of the receptor-EC2 loop portions generated in the step 
above, we use growloop to generate the EC2-bulge portion and insert it into the receptor-EC2 
loop.  The bulge residues and the four residues connecting the DSB cysteine residues to the 
previously constructed loop are minimized for 10 steps with SGB solvation.  For the loops with 
the top 10% according to energy, these residues are mutated with SCREAM software into 
alanine, cysteine, proline, or glycine residues and minimized 10 steps using SGB solvation.  The 
correct target sequence replaces the alanine residues using the SCREAM program before being 
minimized 10 steps with SGB solvation.  The bulge and adjoining loop residues are minimized 
for 50 steps with SGB solvation.  All the TM bundles with the complete EC2 are ranked 
according to their energies, and the top (n2/10) loops or those within 50 kcal/mol of the lowest 
energy structure are selected for subsequent steps. 
 
Merging the loops and attaching them to the TM bundle 
In this section, we will first test combinations of first the EC loops to see which three loop 
conformations produce the lowest energy combination.  EC1 and EC3 are extracted from the TM 
bundle-loop conformations and attached to the TM bundle containing EC2.  All the residues in 
the loops and any residue in the TM bundle within 5 Å of the loops’ rotamers are sampled with 
SCREAM software.  The single point energies of loop portion and close residues of the TM-EC 
loop bundle are determined in vacuum and with SGB solvation.  These portions are then 
minimized for 10 steps in vacuum and 10 steps with SGB solvation.  All the combinations of 
EC1, EC2, and EC3 loops are sorted and ranked according to these four different energy criteria.  
For the apo-CB1 receptor, the second lowest energy structure after minimization with SGB 
solvation was selected for subsequent steps because its energy was within several hundredths of 
the lowest energy complex, it had a lower RMS force, and it ranked first in the other three energy 
categories.  For the CB1-rimonabant receptor, the structure with the best minimized energy with 
SGB solvation was selected since this type of energy is the most accurate representation. 
 
The TM bundle with the three ECs acted as input for attaching the three intracellular (IC) loops.  
The IC loops are extracted from the TM bundle-IC loop complex, so that they are individually 
attached to the TM bundle containing the EC loops.  The IC loop residues and any residue within 
5 Å have their various rotamers sampled with SCREAM.  Then, the loops and surrounding 
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residues’ single point energies are calculated in vacuum and with SGB solvation.  These loops are 
minimized for 10 steps in vacuum and with SGB solvation, and are ranked according to these 
four energies.  The lowest energy structure after minimization with SGB solvation is selected for 
MD. 
 
Adding helix 8 to the TM bundle 
For helix 8, the helix that lies perpendicular to the helical bundle with half of itself exposed to the 
solvent and the other half exposed to the bilayer, we used a homology model form the human 
adenosine A2A receptor (HAA2AR) bound to an agonist (PDB ID: 3QAK) (8) because its TM7 
was oriented closest to TM7 in CB1.  We aligned the NPXXY motifs of TM7 for the two 
receptors, then using Maestro software (69) rotated helix 8 so it does not clash with CB1’s TM1, 
and then used SCREAM software to mutate the residues with those that match the CB1 sequence.  
Then, the residues consisting of helix 8 (#399 to 413) are attached to the TM-loop bundle and 
minimized 50 steps in vacuum.  
 
CB1 receptor molecular dynamics 
MD simulations were conducted on two systems—one of the apo-CB1 GPCR and one of the CB1 
receptor bound to the inverse agonist rimonabant.  This receptor was inserted into a periodic 
POPC lipid bilayer in a TIP3P water box with a tetragonal periodic cell 85Å x 85Å x 107Å.  We 
added 15 chloride ions to neutralize the systems and to match physiological pH.  The apo-CB1 
receptor system consisted of a total of 64,197 atoms including 4918 atoms for the receptor, 
19,381 membrane atoms, 39,883 water atoms, and 15 chloride atoms for neutralization (Table 
5.2).  For the CB1-rimonabant system, there are 63,242 total atoms including 4918 atoms for the 
receptor, 18,416 membrane atoms, 39,842 water atoms, 15 chloride atoms for neutralization, and 
51 atoms for the ligand.  
 
Table 5.2 Size of the CB1 MD systems  
 Number of atoms 
MD system Receptor Membrane Water Ions Ligand Total 
Apo-CB1 4918 19,381 39,883 15 0 64,197 
CB1+Rimonabant 4918 18,416 39,842 15 51 63,242 
 
We performed NPT simulations with the NAnoscale Molecular Dynamics (NAMD) version 2.9 
software (49-51) with the CHARMM22 FF (70; 71) for the receptor atoms, the CHARM27 FF 
(72) for the lipids, the AMBER9 FF (73) for the ligands.  For the non-bonded FF parameters, we 
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set the cut-off distance for electrostatic and van der Waals (vdW) calculations to be 12 Å.  The 
pairlist distance is 13.5 Å.  At this distance, the energies between pairs of atoms will not be 
calculated, but this pair will be included in the list of interacting atoms in case these two atoms 
move closer than the cut-off distance later in the simulation.  The switching function was 
selected, so smoothing functions, not truncated cut-off functions were applied to the electrostatic 
and vdW forces.  The switching distance, or when the smoothing function takes effect, is at 10 Å.  
We excluded atoms connected by two or three bonds from non-bonding interactions. 
 
First we minimized the system, while the TMs, loops, and ligand (if present) are fixed, and the 
water, ion, lipid, and helix 8 atoms are movable.  Minimization lasted for 5 ps with a timestep of 
1 fs.  There were 20 timesteps per cycle, or 20 fs, before atoms were reassigned to the non-
bonded pair list, or list of atoms to calculate pairwise non-bonded energies.  The system had 
periodic boundary conditions that are defined by three vectors : <85Å 0 0>, <0 85Å 0>, <0 0 
107Å>, to match the size of the cell.  Water molecules were wrapped, or translated, to the other 
side of the cell if they exited the cell’s boundaries.  Particle Mesh Ewald (PME) was applied to 
electrostatics (74; 75).  The PME grid had 87 points in the x and y directions and 110 points in the 
z-direction.  Full electrostatic evaluations and short-range non-bonding interactions occurred 
every timestep or every femtosecond. 
 
Second, we equilibrated the system using the same set of movable atoms.  Dynamics lasted for 
500 ps at a timestep of 1 fs.  The FF parameters, the PME, and many of the integrator parameters 
were the same as for those used during minimization.  Differences included: full electrostatic 
evaluations occurred every 4 fs, and non-bonding interactions were calculated every 2 fs rather 
than every femtosecond as during minimization.  To maintain a constant pressure of 1.01325 bar 
(1 atm) and temperature at 310 K for our NPT simulation, we used the Nosé-Hoover Langevin 
piston control and Langevin thermostat with Langevin dynamics (76; 77).  To maintain a constant 
pressure, we used a flexible cell with constant area in the x and y directions, thus allowing 
fluctuations in the z-direction.  The Langevin piston oscillation period was 200 fs, the Langevin 
piston decay or damping timescale was 200 fs, and the Langevin piston temperature or noise 
temperature was equal to the target temperature (310K).  We initialized the temperature to equal 
0K, and the system was heated to 310K.  To maintain a constant temperature, we used a damping 
coefficient of 5 ps-1, and Langevin dynamics did not apply to the hydrogen atoms.  All the atoms, 
not just the waters’, are wrapped around the cell.  In this case, we applied a margin of 5 Å to 
partition the cell into smaller cubes.  Trajectory coordinates, unit cell information, and details 
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about the extended system were written out and saved every picosecond, and energies were 
written out every 100 fs. 
 
Third, we performed a 5 ps minimization on the entire system including all receptor atoms.  Since 
the size of the box changed during dynamics, in this step the PME grid had 84 points in the x and 
y directions and 96 points in the z-direction, which was smaller than what it was during the first 
minimization.  Also, the full electrostatic evaluations occurred every 4 fs.  All the atoms, not just 
the waters’, were wrapped around the cell, and the cell basis vectors were not defined.  
Everything else matched the parameters for the first minimization. 
 
Fourth, we performed a simulation of the entire system with every atom movable.  There is a 250 
ps equilibration period followed by 50 ns of NPT dynamics with a timestep of 1 fs.  The 
parameters for the portion are the same as for the first equilibration period except the PME grid 
size was smaller, matching the dimensions used for the second minimization step.  Here, the cell 
basis vectors and margin for periodic boundary conditions were not defined.  Also, in this step, 
the cell was kept at a constant area throughout the simulation.  Finally, the trajectory coordinates 
were written out every picosecond rather than every 100 fs. 
 
RESULTS AND DISCUSSION 
 
Apo-CB1 receptor dynamics: Structure is stable; see inactive traits start to form 
To ensure the stability of the predicted CB1 structures, we ran 50 ns of MD simulations of the 
apo-CB1 receptor, second lowest in energy in the ensemble, in a neutralized solvated bilayer.  
The average root-mean-square deviation (RMSD) per residue during the simulation is rather high 
at 4.01 Å, but many of the important polar contacts are stable.  The loop regions and TM1 are 
flexible, but the other TMs are stable as indicated by the RMSD per residue shown in Figure 5.2 
and Table 5.3.  The RMSD per residue averaged over the seven TMs is 2.98 Å, which is much 
lower than the corresponding value for the six loop regions—6.11 Å.  The R3.50+D6.30 salt 
bridge is intact during the entire simulation, and after 5 ns, a new salt bridge between R148 of 
IC1 and D6.25 forms (Figure 5.3). This R148+D6.25 salt bridge is similar to the R2.37+D6.30 
ionic lock observed in the fully inactive T3.46A and L3.43A/D2.63A mutants (21; 22).  After 
some dynamics, the constitutively active CB1 apo-receptor starts to resemble the fully inactive 
T3.46A mutant structure since there are two salt bridges that span the interior of the bundle.  This 
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R148+D6.25 salt bridge would also be effective at preventing G protein coupling to the CB1 
receptor and subsequent activation. 
   
 
Figure 5.2 RMSD per residue (Å) plotted against all residues in the CB1 receptor.  The RMSD values for 
the apo-CB1 residues are in red, and the corresponding values for the CB1-rimonabant residues are in blue.  
The seven TMs, three intracellular loops (ICs), three extracellular loops (ECs), and helix 8 are indicated on 
the plot. 
 
Table 5.3 RMSD per residue averaged over the TM, loop, and helix 8 regions for the apo-CB1 receptor and 
the CB1-rimonabant complex. 
TM# Apo-CB1 
Ave. RMSD 
(Å) 
CB1-
Rimonabant 
Ave. RMSD (Å) 
Loop Apo-CB1 
Ave. RMSD 
(Å) 
CB1-
Rimonabant 
Ave. RMSD 
(Å) 
1 3.65 2.51 IC1 3.74 2.69 
2 2.10 1.74 EC1 5.43 3.43 
3 2.29 1.48 IC2 7.53 3.82 
4 3.04 1.69 EC2 5.77 3.85 
5 3.91 2.45 IC3 8.81 7.88 
6 2.74 2.29 EC3 5.39 3.59 
7 3.09 1.88 Helix8 5.16 3.62 
TM 
average 
2.98 2.01 Loop 
average 
6.11 4.21 
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Figure 5.3 Apo-CB1 receptor after 50 ns of MD.  Important intracellular salt bridge residues [R148 (IC1), 
R3.50, D6.25, and D6.30] are labeled in the insets.  Salt bridges are indicated with black dotted lines, and 
their heteroatom distances are labeled.  The RMSD distances are plotted with respect to time in the upper 
graphs for the R148+D6.25 salt bridge (left) and the R3.50+D6.30 salt bridge (right). 
 
Also, the R2.37+D3.49 salt bridge observed in the predicted structures of constitutively active 
and highly constitutively active receptors is stable for almost 50 ns (Figure 5.4).  At 
approximately 49.5 ns, this polar contact breaks.  The simulation needs to be extended to see if 
this salt bridge reforms or if it is permanently broken.  Perhaps by breaking this TM2+TM3 salt 
bridge, there will be an opportunity for the R2.37+D6.30 ionic lock to form.  The R148 residue, 
in close proximity to R2.37, interacts with D6.25 in a stable salt bridge, so the intracellular end of 
TM2 is being drawn towards TM6 making the formation of the ionic lock highly likely. 
 
This simulation shows that the constitutively active CB1 receptor structure starts to resemble the 
fully inactive structure, which agrees with previous analysis of Hβ2AR (12; 14-16), in that in the 
absence of a stabilizing agonist or G protein, the inactive conformation of the receptor is most 
energetically favorable and, according to the Boltzmann distribution, most populated.  
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Surprisingly, we begin to observe such significant conformational changes over a short timescale.  
It is necessary to run these simulations longer—for a microsecond trajectory perhaps—to see the 
formation of the R2.37+D6.30 ionic lock and to ensure that these traits are stable. 
 
 
Figure 5.4 Intracellular end of apo-CB1 receptor after 50 ns of MD.  Important charged residues [R148 
(IC1), R2.37, D3.49, R3.50, D6.25, and D6.30] are labeled.  Salt bridges are indicated with black dotted 
lines.  The RMSD distances between the heteroatoms of residues R2.37 and D3.49 are plotted with respect 
to time in the bottom graph. 
 
CB1-rimonabant dynamics: Inverse agonist induces formation of inactive structure traits 
Surprisingly, when we docked the inverse agonist/antagonist rimonabant (78) to the ensemble of 
low energy constitutively active CB1 structures, the ligand preferentially bound to structures 
lacking the R3.50+D6.30 ionic lock, which helps stabilize the inactive structure (for more 
information, see Chapter IV).  We ran MD on the CB1-rimonabant complex in a physiological 
system to see how the presence of the inverse agonist affects the constitutively active 
conformation (Figure 5.5).  The CB1-rimonabant complex is more stable than the apo-CB1 
receptor since its average RMSD per residue is 2.82 Å as compared to 4.01 Å (Figure 5.2 and 
Table 5.3).  The R2.37+D3.49 salt bridge, which broke at the end of the apo-CB1 simulation, is 
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intact for the 50 ns.  After 10 ns, however, a salt bridge between R3.50 and D6.30 forms and is 
stable for the final 40 ns of the simulation.  Much like the apo-CB1 receptor case, certain contacts 
form, which resemble those indicative of the inactive conformation.  Perhaps the presence of the 
inverse agonist induces the formation of the R3.50+D6.30 ionic lock and other inactive traits.  In 
addition, the formation and breakage of this ionic lock has been observed in long-scale MD 
simulations of Hβ2AR.  The crystallized form of this receptor bound to the partial inverse agonist 
carazolol lacks this TM3+TM6 coupling, but this contact forms easily during MD.  For the micro-
second length simulation of the receptor with and without the inverse agonist bound, the ionic 
lock forms and breaks multiple times and stays broken for tens of nanoseconds.  These data 
suggest that there are two distinct inactive states for Hβ2AR—one with the ionic lock and one 
without (13).  We may be observing a similar phenomenon here for the CB1-rimonabant complex 
in that the receptor can be inactive with or without the intact R3.50+D6.30 ionic lock.  The 
simulations will need to be extended to see if the R2.37+D6.30 ionic lock, which is particularly 
important for preventing CB1 activation (21; 22), forms and is stable in this complex. 
 
Figure 5.5 CB1-rimonabant complex after 50 ns of MD.  Important intracellular salt bridge residues 
(R3.50and D6.30) are labeled in the inset.  The salt bridge is indicated with a black dotted line, and the 
heteroatom distance is labeled.  The RMSD distances are plotted with respect to time in the upper graph for 
the R3.50+D6.30 salt bridge. 
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This CB1-rimonabant complex is evidence for both the conformational selection and induced fit 
theories (discussed in Chapter I) (12).  We docked ten conformations of the inverse agonist to ten 
CB1 structures, and the ligand had the lowest binding energy with strain and ligand solvation 
with the receptor structure that is sixth lowest in energy and missing the R3.50+D6.30 ionic lock. 
The inverse agonist preferentially binds to a receptor structure that is not only high in energy but 
looks pre-activated.  During the MD simulation, the R3.50+D6.30 ionic lock forms suggesting 
that rimonabant is inducing the receptor to look inactivated.  Longer simulations are needed to see 
if the receptor becomes fully inactive and if it is stable in that conformation. 
 
Comparison between apo-CB1 and CB1-inverse agonist MD simulations 
The CB1 receptor bound to the inverse agonist is more stable during simulations than when it is 
in its apo form (Figure 5.2 and Table 5.3).  Nearly every section of the receptor has a higher 
RMSD in the apo-receptor than in the inverse agonist-bound form.  Surprisingly, the major 
differences in RMSD are in the loops—especially IC2, which is not near the ligand binding site.  
The RMSD averaged over all loop residues in IC2 is 7.53 Å in the apo-receptor, but 3.82 Å in the 
CB1-rimonabant complex.  The inverse agonist might have a stabilizing effect on the TM regions 
and the EC loops, but the connection between rimonabant and its impact of IC2 is not obvious.  
TM5 of the apo-receptor has a higher RMSD of 3.91 Å compared to 2.45 Å of TM5 of the CB1-
rimonabant complex.  Rimonabant interacts with TM5, maybe stabilizing it and the connected 
IC2.  The receptor structures themselves, however, are different, and the loops were generated 
and optimized for the two receptors’ structures, so perhaps the cause of the stabilizing effect is 
from the structure itself, not the inverse agonist.  To test this hypothesis, we will need to run MD 
simulations of the second lowest energy structure (apo form) in complex with rimonabant and of 
the sixth lowest energy structure (ligand-bound form) without rimonabant present.  The results 
will indicate what effect rimonabant has on these receptors’ structures and their relative 
stabilities.  It seems that the CB1 receptor structure of the CB1-rimonabant complex is more 
stable after MD since the polar contact R3.50+D6.30 is formed, which is absent in the initial 
conformation.  In future work, we will remove rimonabant from the CB1-rimonabant complex 
and run MD to see if the CB1 structure is stable without the presence of the inverse agonist. 
 
Neutralization issues to address 
In this study, we added just the number of chloride ions to neutralize the entire protein, but we 
have shown in our DNA calculations that it is best to add additional sodium and chloride ions to 
match the experimental salt concentration (44).  For future simulations, we will use TLeap to add 
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sodium ions to negatively charged residues lacking a salt bridge partner and chloride ions 
unpartnered with positive residues.  Thus, we will neutralize the receptors on a residue-by-residue 
basis rather than the entire macromolecule. 
 
CONCLUSIONS 
 
We ran MD simulations to see how predicted receptor structures and inverse agonist-bound 
complexes change over time in biologically relevant conditions.  For the apo-CB1 receptor, we 
see that the intracellular R3.50+D6.30 ionic lock is stable, and another salt bridge between IC1 
and D6.25 forms.  These observations, along with the breaking of the R2.37+D3.49 salt bridge, 
might be early signs of the formation of the R2.37+D6.30 ionic lock, which is important for 
stabilizing the fully inactive form of the receptor.  Similarly, the CB1-rimonabant complex forms 
the TM3+TM6 ionic lock, which is then stable during the simulation.  Thus, in the presence of 
the inverse agonist, the receptor acquires traits that are indicative of the inactive receptor.  
Perhaps the inverse agonist induces these conformational changes, which would support the 
conformational selection model (because rimonabant binds preferentially to a pre-activated 
conformation) and the induced fit model (because after binding, the receptor starts to look 
inactive).  These simulations agree with previous analysis of the Hβ2AR experiments because we 
observe two different inactive structures of the receptor bound to an inverse agonist, and the 
inactive states are more populated even without the presence of an inverse agonist.  Longer 
simulations of the CB1 receptor complexes are necessary to see if they can achieve stable forms 
of the fully inactive conformations. 
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Chapter VI 
 
STRUCTURAL PREDICTION OF THE HUMAN CANNABINOID TYPE 2 (CB2) 
RECEPTOR AND COMPARISON WITH ITS SISTER CB1 RECEPTOR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The majority of the CB2 WT and T3.46A structure prediction computational experiments 
were performed by Kyle Tejada as part of the Caltech Freshman Summer Research 
Institute (FSRI). 
 
The ligand binding assay results shown herein were preformed by Dr. Kwang Hyun Ahn 
and other members of Professor Debra Kendall’s lab. 
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ABSTRACT 
 
The human cannabinoid type 2 (CB2) receptor is an attractive target for pain medication.  Since it 
is located in the peripheral nervous and immune systems, drugs that act on this receptor are less 
likely to cause unwanted psychoactive side effects.  However, drug design is difficult because 
CB2 has never been crystallized, and its structure remains unknown.  Previously, we predicted 
the structure of its sister receptor, human cannabinoid type 1 (CB1), using the GEnSeMBLE 
computational programs and explained the functional differences caused by structural changes 
resulting from the mutation of a single threonine residue 127 (T3.46) on the intracellular end of 
the third transmembrane region (TM).  In the CB1 receptor, changing this threonine to an alanine 
(T3.46A) causes the receptor to become fully inactive.  Changing this same threonine to an 
isoleucine (T3.46I) causes the receptor to become highly constitutively active.  We predicted, and 
subsequent experimental evidence supported our claim, that a salt bridge between an arginine on 
TM2 and an aspartic acid on TM6 stabilizes the inactive CB1 conformation.  Using the predicted 
structure of CB1 WT as a template, we predicted the structures of the CB2 wild-type (WT) 
receptor plus two threonine mutants (T3.46A, T3.46I).  Surprisingly, the resulting CB2 receptor 
structure predictions are significantly different from its CB1 counterparts.  For example, the 
threonine to alanine (T3.46A) mutant lacked the TM2 and TM6 salt bridge indicating that the 
CB2 version is constitutively active like the CB2 WT receptor.  The threonine to isoleucine 
(T3.46I) mutant also is missing the TM2 and TM6 salt bridge as well as the signature polar 
contacts of the highly activated CB1 structures.  Thus, we predict all three receptors are 
constitutively active, which is different from what was predicted for the CB1 receptor and its 
corresponding mutants.  However, subsequent agonist binding assays performed by Professor 
Debra Kendall and her lab support our conclusions based on our structural predictions.  With this 
information, we propose a double mutant, G2.48V/T3.46A, that we believe will contain the TM2 
and TM6 salt bridge and thus will be fully inactive. 
 
INTRODUCTION 
 
There are few options available for the treatment of multiple and chronic types of pain.  The 
human cannabinoind type 1 (CB1) receptor, which is activated by cannabis, is an attractive target 
for pain medication, but its usefulness is hampered by the psychoactive side effects including 
hyperthermia, anxiety, sedation, and catalepsy [for review, see (1)].  CB1 is located primarily in 
the central nervous system (CNS) (2-6) and less significantly in the peripheral nervous system (7-
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9).  A more attractive target is the human cannabinoid type 2 (CB2) receptor.  Unlike its sister 
receptor, CB2 is expressed to a much smaller extent in the CNS (10) and is located primarily in 
peripheral nervous system and immune tissues including the spleen and tonsils where its mRNA 
concentration is 10 to 100 times greater than that of CB1 mRNA (7).  Due to limited expression 
in the CNS, pain medication that targets CB2 will be less likely to have the same psychoactive 
side effects exhibited by those that interact with CB1.  The CB2-selective agonist AM1241 
reduces nocieption (sensitization to pain), inflammation, and neuropathic pain in animal models 
(11-21).  The antinocieption effect is reversed by the CB2-selective antagonist AM630, but not by 
the CB1-selective antagonist AM251 proving that this sensation is mediated by the CB2, not the 
CB1 receptor (11; 22).  Furthermore, agonists like WIN55212-2 and CP55940, which 
preferentially bind to CB2 but have a significant affinity for CB1, have been proven to cause pain 
reduction mostly through the CB1 receptor (12; 23-26).  Unlike CB2-selective AM1241, 
WIN55212-2 has also been shown to cause the undesirable CNS side-effects listed above (7), 
thus indicating the importance for discovering a highly selective-CB2 agonist.  As of 2013, a CB2 
agonist has not been FDA-approved for pain treatment (27). 
 
While CB2 agonists like AM1241, have shown therapeutic promise, drug design for CB2 has 
been especially difficult considering that CB2 has never been crystallized, and its structure 
remains unknown.  However, our lab has been developing GEnSeMBLE (GPCR Ensemble of 
Structures in Membrane BiLayer Environment) methodology to successful predict the structures 
of GPCRs (28-32) and have applied these techniques to CB2’s sister receptor, CB1 (32-34).  In 
previous studies, Professor Debra Kendall and her lab at the University of Connecticut showed 
that mutating a single threonine residue 210 [T3.46 according to Ballesteros-Weinstein 
numbering (35)] on the third transmembrane region (TM) causes significant changes in the 
receptor’s function.  When this threonine is mutated to an alanine (T3.46A), the receptor shows a 
significant decrease in binding affinity for the agonist, but a slight increase in binding affinity for 
the inverse agonist/antagonist.  Conversely, when this threonine becomes an isoleucine (T3.46I), 
the receptor has a slight increase in binding affinity for the agonist, but a significant decrease in 
binding affinity for inverse agonist/antagonist.  Thus, the T3.46A was believed to be the fully 
inactive form of the receptor, and T3.46I was the constitutively active mutant (36; 37).  
Subsequent GTPγS assays conducted without the ligands present confirmed these conclusions 
about the functional states of the receptors (33; 34).  Based on our structural predictions of the 
wild-type (WT) CB1 receptor and these two single mutants, we suggested that a salt bridge 
between an arginine on TM2, R2.37, and an aspartic acid on TM6, D6.30, stabilizes the inactive 
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conformation, and subsequent experimental GTPγS assays proved that R2.37 plays an important 
role in preventing activation (33; 34). 
 
Here, we use a similar procedure to predict the structure of the CB2 receptor as we did for the 
CB1 receptor.  Since T3.46 plays an important role in CB1’s structure, it is unique to the 
cannabinoid family, and its mutation affects CB1’s function, we also predicted the structures of 
CB2 T3.46A and T3.46I.  Since there is a large percentage of conserved sequence identity 
between the two cannabinoid receptors (54.56%, see below), we expected that there would be 
significant structural similarities and included CB1 along with the experimentally determined 
crystallized GPCRs to act as starting templates for our CB2 structure prediction.  Surprisingly, the 
predicted CB1 and CB2 WT receptor structures are very different from one another and share 
very few stabilizing salt bridges or contact patterns.  Even more unexpected, mutating the T3.46 
residue did significantly impact the structure, but not the function of the receptor as in CB1.  All 
three predicted structures of the CB2 WT and mutants appear to be constitutively active.  The 
R/K2.37 and D6.30 salt bridge that stabilized the fully inactive CB1 T3.46A mutant was not 
present in the consensus of our ensemble of low energy structures.  However, our CB2 predicted 
structures are supported by agonist binding assays that show the agonist has strong binding 
affinities for all three receptors.  Based on our structural predictions, we propose a double mutant 
for CB2, G2.48V/T3.46A, that we anticipate will be fully inactive. 
 
METHODS 
 
(For more details about structure prediction methodology, see Chapter II.) 
 
We followed a similar approach to predicting the structures of the human CB2 WT receptor and 
its two mutants as we did with the CB1 receptors (Figure 6.1) (28-32).  Briefly, we estimated the 
lengths of the TMs by using PredicTM to identify the seven hydrophobic regions of the amino 
acid sequence, and by using online servers’ secondary structure predictions (SSP) to develop a 
consensus of the alpha-helical extensions beyond the bilayer.  Then there were two different ways 
to generate the actual TMs—with the program OptHelix or using homology methods with the 
crystal and CB1 templates.  For the OptHelix route, canonical poly-alanine helices were 
individually constructed to match the lengths of the TMs predicted by PredicTM and SSP.  The 
glycine, proline, serine, and threonine residues were added in with the Side Chain Excitation 
Analysis Method (SCREAM) software program (38).  After a series of molecular dynamics (MD) 
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and minimization to obtain the optimized helical shape, the remaining residues replace the alanine 
residues using SCREAM.  Then, the seven individual helices are aligned to one of the crystal or 
predicted CB1 templates.  With the homology route, the crystallized or predicted receptor is 
separated into seven individual helices that are mutated with SCREAM to match the target 
sequence before being optimized and added back to the receptor bundle.  Then both types of 
helices are used to generate starting structures for the BiHelix program (28), where pairs of the 
seven helices are rotated in 30º increments.  The pairwise interactions between the helices are 
summed to create an estimate for the energy for the entire bundle.  The lowest energy bundles are 
constructed and minimized in the program ComBiHelix.  The lowest total energy structure is 
starting structure for the SuperBiHelix program (32), which calculates the energies of pairs of 
helices while sampling local rotation, tilt, and sweep angles (as defined in Chapter II).  The 
lowest energy structures estimated from SuperBiHelix are constructed in SuperComBiHelix, and 
four types of energies are calculated for the entire helical bundle—the total charged energy, the 
total neutralized energy, the charged interhelical energy, and the neutralized interhelical energy.  
The structures are ranked according to the average of the four energy ranks, and an ensemble of 
ten low energy structures are selected for further analysis and ligand docking. 
 
 
Figure 6.1 Diagram explaining the procedure for predicting the structure of the CB2 receptor and its two 
mutants.  Figure courtesy of Kyle Tejada.  
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Predicting the CB2 TM lengths 
We performed a BLAST (39) search for protein sequences related to CB2.  Using the default E-
value (0.1) value, we found 1097 sequences ranging in overall sequence identity from 81.11% to 
12.22%.  The number of sequences found for CB2 is significantly smaller than the number 
identified for CB1 (1387 sequences ranging in overall sequence identity from 100% to 8.47%).  
The default E-value was not sufficient for identifying enough related sequences to the target 
human CB2 sequence, so the BLAST search was repeated with a larger E-value of 1.0, which 
returned a larger number, 1337, and a more diverse set of sequences ranging in overall sequence 
identities from 81.11% to 12.22%, which is closer to the spread for the CB1 sequences.  These 
sequences are aligned, and the hydrophobic values for each amino acid are averaged over all 1337 
sequences to produce an average hydrophobic value for each residue (Figure 6.2).  The human 
CB2 sequence has seven hydrophobic regions corresponding to the seven alpha-helical TM 
regions. 
 
Figure 6.2 CB2 hydrophobicity plot.  The seven TMs, three intracellular loops (ICs), three extracellular 
loops (ECs), N-terminus, and C-terminus regions are indicated. 
 
Since the alpha-helical regions can extend beyond the hydrophobic lipid bilayer, the TMs 
provided by PredicTM are augmented with the SSP consensus estimate.  Using prior knowledge 
from our predicted CB1 structures, we extended TMs 2, 4, and 6 to include residues that engaged 
in salt bridges and played an important role in stabilizing the CB1 receptor. 
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Optimizing CB2’s TMs 
The program OptHelix produces two types of helices based on different selection methods.  The 
helices are selected from the MD simulations according to the minimum potential energy 
(mineng) structure and the structure closest in RMSD to the average structure of the simulation 
(minrmsd).  The resulting minrmsd OptHelix helices are shown below in Figure 6.3 with the 
corresponding CB1 helices.  Six of the seven helices are very similar to each other in that their 
backbone root mean-squared displacement (RMSD) is less than 0.70 Å.  Helix 6 has a substantial 
RMSD of 1.18 Å because CB1 has a glycine residue (rather than CB2’s phenylalanine) adjacent 
to the proline residue in CWXP motif resulting in a differently kinked helix.  Thus, small 
differences between the sequences of the receptors cause significant differences in the receptors’ 
structures. 
 
Figure 6.3 Comparison of the minrmsd helices generated by OptHelix for the CB1 and CB2 receptors. 
 
Constructing the CB2 helical bundle 
Since the CB1 and CB2 receptors are in the same family, we anticipate that they will be 
structurally similar, and we can use our predicted structure for the CB1 WT receptor, which has 
been supported by subsequent experiments (33; 34).  We added the CB1 WT receptor to the 
available crystalized GPCR templates.  The CB1 structure was the third lowest in energy, but it 
was chosen because it best represented the consensus of polar interactions present in the majority 
of the top ten lowest energy WT CB1 structures (for more information, see Chapter III).  Since 
the CB1 structure prediction was done, many more GPCRs have been crystallized including the 
human lipid sphingosine 1-phosphate receptor type 1 (hS1P1) (PDB ID: 3V2Y) (40) and human 
dopamine D3 receptor (hDD3R) (PDB ID: 3PBL) (41) that are more closely related to the 
cannabinoid receptors (Table 6.1A).  To date, the hS1P1 receptor has the highest TM sequence 
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identity with respect to CB2 of all the crystallized GPCRS at 35.92%.  The inactive turkey β1 
adrenergic receptor (inactTβ1AR) (chain B, PDB ID: 2VT4) (42) and the human β2 adrenergic 
receptor (inactHβ2AR) (PDB ID: 2RH1) (43) are also used because of their large TM sequence 
identities, 31.21% and 24.44% respectively, and because of the previous success we had using 
them for our CB1 structure predictions.  These four structures (WT CB1, hS1P1, inactTβ1AR, 
inactHβ2AR) are the templates that the CB2 WT OptHelix helices are aligned to and are the 
starting points for the homology models. 
 
Table 6.1 Constructing the WT, T3.46A, T3.46I receptors using first-based principles.  (A) Comparison to 
the human CB2 receptor sequence of the overall sequence identity and TM sequence identity of human 
CB1 and crystallized GPCR sequences including hS1P1, Tβ1AR, hDD3R, HA2AAR, and Hβ2AR.   
(B) Energy comparison for CB1 receptors with OptHelix helices and homologized helices.  Optimized eta 
(η, rotation) angles from the ComBiHelix analysis for the WT receptors with various helices: OptHelix 
helices aligned to the predicted CB1 model (33; 34), homologized CB1 helices, homologized inactTβ1AR 
(PDB ID: 2VT4) (42) helices, homologized hS1P1 (PDB ID: 3V2Y) (40) helices, homologized 
inactHβ2AR (PDB ID: 2RH1) (44) helices. 
A. 
GPCR Name Overall Sequence 
Identity (%) 
TM Sequence 
Identity (%) 
Human CB2 Receptor 100.00 100.00 
Human CB1 Receptor 41.11 54.56 
Human S1P1 Receptor 21.11 35.92 
Turkey Beta 1 Adrenergic Receptor 21.94 31.21 
Human D3 Dopamine Receptor 15.83 27.43 
Human A2A Adenosine Receptor 17.50 25.66 
Human Beta 2 Adrenergic Receptor 16.11 24.44 
 
B. 
 η  (°) TotalE 
Method H1 H2 H3 H4 H5 H6 H7 kcal/mol 
OptHelix helices with CB1 
template 
-120 180 -30 30 90 -120 -60 -41.4 
OptHelix helices with 
inactTβ1AR template 
0 90 30 120 30 60 -120 -5.3 
Homologized CB1 Helices -120 0 0 30 0 30 -60 52.3 
Homologized inactTβ1AR 
Helices 
0 0 0 0 0 60 150 258.4 
Homologized hS1P1 
Helices 
0 0 0 30 -90 90 -60 271.1 
Homologized inactHβ2AR 
Helices 
0 0 0 0 -150 90 150 293.0 
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For the OptHelix helical bundles, there are two ways to align the helices to the template—where 
the horizontal plane bisects the helical bundle at the raw midpoint of the respective helices’ 
hydrophobic region (the rawmid center) or at the residue splitting the area of the hydrophobic 
region (the area center).  Thus for each of the four templates, there are four starting bundles 
generated [two types of helices (minrmsd, mineng) and two types of alignments (rawmid, area)].  
Only one homologized helical bundle is created for each of the four templates since the helical 
shape and alignment is provided by the crystal structure. 
 
Energetic comparison of templates 
During the ComBiHelix stage, we identified the lowest total charged energy structure out of the 
1000 structures that were constructed based on the BiHelix calculations.  Table 6.1B shows the 
corresponding structures for all the homologized bundles plus the two lowest energy structures 
for the OptHelix helices.  Since all of the structures contain the same number of atoms, we can 
compare their total charged energies after minimization.  Much like the CB1 case, the CB2 
structures from homologized crystal helices are much worse in energy than those predicted from 
the OptHelix helices or the homologized CB1 helices.  Since the lowest energy bundles produced 
by the crystal homologized helices are ~200 kcal/mol and ~300 kcal/mol higher in energy than 
the CB1 homologized helices and the CB2 OptHelix helices, they were not used for the 
subsequent SuperBiHelix and SuperComBiHelix steps.  The three structures that were the starting 
points for the subsequent local sampling were: the CB1 homologized helices, the OptHelix 
minrmsd helices aligned to the CB1 template with rawmid hydrophobic centers, and the OptHelix 
minrmsd helices aligned to the inactTβ1AR template with area hydrophobic centers.  
SuperBiHelix testing entailed sampling ±10º in 10º increments in the theta (θ, tilt) angles, ±30º in 
15º increments in the phi (ϕ, sweep) and eta (η, rotation) angles with the exception of the rotation 
angle in TM3 of the OptHelix helices aligned to CB1, which was sampled from -45º to +30º in 
15º increments.  The 2000 lowest energy structures predicted by SuperBiHelix were constructed 
as complete bundles in SuperComBiHelix. 
 
Single point mutant structure prediction 
To predict the T3.46A and T.346I mutants, we closely followed the procedure described above 
for the CB2 WT receptor.  Starting with the OptHelix helices, the alanine or isoleucine residue 
replaced T.346 with the SCREAM program.  The T3.46I mutant’s OptHelix helices were aligned 
to all four templates with all helical and alignment combinations, while those belonging to the 
T3.46A mutant were aligned to the CB1 template with minrmsd helices at the rawmid center and 
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the inactTβ1AR template with minrmsd helices at the area center.  T3.46A and T3.46I were both 
constructed with the homologized helices from WT CB1 and hS1P1.  For the T3.46A and T3.46I 
mutant, SuperBiHelix and SuperComBiHelix were performed on the lowest total charged energy 
structures from the OptHelix helices aligned to the WT CB1 template and the homologized WT 
CB1 helices using the same sampling angles described above. 
 
RESULTS 
 
Predictions of the stable structural ensembles for CB2 WT and mutant T3.46A and T3.46I 
receptors 
As in the CB1 study, we used the GEnSeMBLE method to generate trillions of potential CB2 
structures and identify ten low energy conformations that best represent the WT poses.  For the 
CB2 WT conformation, seven of the top ten poses were generated from OptHelix helices aligned 
to the CB1 WT template (Table 6.2).  The other three are generated from the CB1 homology 
helices.  Similarly, for the T3.46I mutant, eight of the top ten poses resulted from CB2 OptHelix 
helices as opposed to two poses from the CB1 WT homologized helices.  All of the top ten poses 
for the T3.46A mutant used the CB2 OptHelix helices. 
 
The average energy ranges for the top ten poses for the three CB2 receptors are: 
• T3.46A: -261.2 kcal/mol to -249.1 kcal/mol, 
• WT: -304.6 kcal/mol to -277.4 kcal/mol, 
• T3.46I: -272.5 kcal/mol to -247.9 kcal/mol. 
And the backbone RMSD, with respect to the lowest energy structure, ranges are: 
• T3.46A: 0.3 Å to 2.6 Å, 
• WT: 0.4 Å to 2.9 Å, 
• T3.46A: 0.4 Å to 2.9 Å. 
The range for the RMSD values may seem large, but the top ten structures according to average 
energy rank were constructed from two types of helices—one type with the OptHelix program 
and another type constructed from homologized helices.  The range of RMSD values for the CB2 
WT OptHelix helices are 0.4 to 1.7 Å, all smaller than the best GPCR crystal resolution to date, 
which means that these structures are similar.  Also, the RMSD range for the T3.46I structures 
from OptHelix helices is very small—0.5 to 0.8 Å.  Thus, for these two receptors, even slightly 
different helical shapes impacted the overall structure of the TM bundles, whereas the structures 
generated with OptHelix helices are very similar. 
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Table 6.2 Comparison of the conformations of the low energy structures for the three CB2 receptors 
T3.46A, WT, and T3.46I.  Methodology, theta (θ, tilt), phi (ϕ, sweep), eta (η, rotation) angles, average 
energy, and the backbone RMSD (Å) with respect to the lowest energy conformation for each of the ten 
structures are shown below.  The poses were chosen according to their average energy rank, the average of 
the charged total energy rank, neutralized total energy rank, charged interhelical energy rank, and 
neutralized interhelical energy rank. 
Name Methodology Ave E RMSD
TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 (kcal/mol) Å
T3.46A-1 WT CB1-rawmid-minrmsd -10 -10 0 10 0 -10 0 0 30 30 0 0 0 -30 30 -30 30 -15 30 -15 -30 -255.5 0.0
T3.46A-2 WT CB1-rawmid-minrmsd -10 -10 0 10 -10 -10 0 0 30 30 0 0 15 -30 30 -30 30 -15 0 -30 -30 -261.2 1.1
T3.46A-3 WT CB1-rawmid-minrmsd 0 -10 10 0 10 0 0 0 0 15 -30 -30 0 -15 30 -15 0 0 30 0 -30 -254.5 2.6
T3.46A-4 WT CB1-rawmid-minrmsd -10 -10 0 10 0 -10 0 0 15 30 0 0 0 -30 30 -30 30 -15 30 -15 -30 -253.4 0.3
T3.46A-5 WT CB1-rawmid-minrmsd 0 -10 10 0 10 0 0 0 -15 15 -30 -30 0 -15 30 -15 0 0 30 0 -30 -254.5 2.6
T3.46A-6 WT CB1-rawmid-minrmsd 0 -10 10 0 10 0 0 0 15 15 -30 -30 0 -15 30 -15 0 0 30 0 -30 -254.5 2.6
T3.46A-7 WT CB1-rawmid-minrmsd 0 -10 10 0 10 0 0 0 -30 15 -30 -30 0 -15 30 -15 0 0 30 0 -30 -254.9 2.6
T3.46A-8 WT CB1-rawmid-minrmsd 0 -10 10 0 10 0 0 0 30 15 -30 -30 0 -15 30 -15 0 0 30 0 -30 -254.5 2.6
T3.46A-9 WT CB1-rawmid-minrmsd -10 -10 0 10 -10 -10 0 0 15 30 0 0 15 -30 30 -30 30 -15 0 -30 -30 -257.5 1.1
T3.46A-10 WT CB1-rawmid-minrmsd -10 -10 0 10 0 -10 0 0 30 30 0 0 15 -30 30 -30 30 -15 30 -15 -30 -249.1 0.3
WT-1 WT CB1-rawmid-minrmsd 0 0 0 0 0 0 0 0 0 -15 0 -15 30 0 0 0 0 0 0 -15 -15 -300.5 0.0
WT-2 WT CB1-rawmid-minrmsd 0 0 0 0 0 0 0 15 0 -15 0 -15 30 -15 0 0 0 0 0 -15 -15 -304.6 0.5
WT-3 CB1-Homology 10 0 0 0 0 -10 0 0 0 -15 15 0 15 15 0 0 0 0 -30 15 0 -291.5 3.0
WT-4 WT CB1-rawmid-minrmsd 0 0 0 0 0 0 0 15 0 -15 0 -15 30 -15 0 0 15 0 0 -15 -15 -286.3 0.6
WT-5 CB1-Homology 0 0 0 0 0 -10 0 -15 15 -15 15 0 15 15 0 0 0 0 -30 15 0 -282.9 2.9
WT-6 WT CB1-rawmid-minrmsd 0 0 0 0 0 0 0 15 0 -15 0 -15 30 -15 0 0 0 -15 0 -15 -15 -286.2 0.6
WT-7 WT CB1-rawmid-minrmsd 0 -10 -10 0 -10 0 0 -15 30 15 0 15 15 -15 15 -15 -15 0 -15 -15 -15 -279.0 1.7
WT-8 WT CB1-rawmid-minrmsd 0 -10 -10 0 -10 0 0 -15 15 15 0 15 15 -15 15 -15 -15 0 -15 -15 -15 -278.9 1.7
WT-9 WT CB1-rawmid-minrmsd 0 0 0 0 0 0 0 0 0 -15 0 -15 30 -15 0 0 15 0 0 -15 -15 -277.4 0.5
WT-10 CB1-Homology 0 0 0 0 0 -10 0 -15 0 -15 15 0 15 15 0 0 0 0 -30 15 0 -280.8 3.0
T3.46I-1 WT CB1-rawmid-minrmsd 0 0 0 0 0 -10 -10 15 -15 0 0 -15 0 0 0 0 15 0 -15 -15 -30 -272.5 0.0
T3.46I-2 WT CB1-rawmid-minrmsd 0 0 0 0 0 -10 -10 0 -15 0 0 -15 0 0 15 0 15 0 -15 -15 -30 -265.4 0.5
T3.46I-3 WT CB1-rawmid-minrmsd 0 0 0 0 0 -10 -10 0 -15 0 0 -15 0 0 0 0 15 0 -15 -15 -30 -265.6 0.5
T3.46I-4 WT CB1-rawmid-minrmsd 0 0 0 0 0 -10 -10 0 -15 0 0 0 -30 0 0 0 15 -15 0 -15 -30 -257.5 0.8
T3.46I-5 WT CB1-rawmid-minrmsd 0 0 0 0 0 -10 -10 15 -15 0 0 0 -30 0 0 0 15 0 0 -15 -30 -255.8 0.6
T3.46I-6 WT CB1-rawmid-minrmsd 0 0 0 0 0 -10 -10 0 -15 0 0 0 -30 0 0 0 15 0 0 -15 -30 -254.8 0.7
T3.46I-7 WT CB1-rawmid-minrmsd 0 0 0 0 0 -10 -10 0 -15 0 0 0 -30 0 15 0 15 0 0 -15 -30 -256.3 0.8
T3.46I-8 CB1-Homology -10 -10 10 0 10 -10 -10 -15 -15 15 -30 -15 -15 -30 -15 -15 15 -15 0 15 -30 -250.2 2.9
T3.46I-9 CB1-Homology -10 -10 10 0 10 -10 -10 -15 0 15 -30 -15 -15 -30 -15 -15 15 -15 0 15 -30 -249.8 2.9
T3.46I-10 WT CB1-rawmid-minrmsd 0 0 0 0 0 -10 -10 0 -15 15 0 0 -15 0 15 0 30 0 -15 -15 -30 -247.9 0.7
θ (°) φ (°) η (°) 
 
 
Intermolecular interactions in the constitutively active CB2 WT 
Our predicted structure of the CB2 WT receptor contains two salt bridges characteristic of other 
class A GPCRs, D3.49+R4.41 and R3.50+D6.30 (Figure 6.4A).  (Throughout this chapter, we 
will indicate a salt bridge with a ‘+’ sign and a hydrogen bond with a ‘-’.)  These two salt bridges 
are also observed in our predicted CB1 structures (Figure 6.4B).  The former salt bridge is 
similar to one observed in the crystal structure of hCXCR4 (D3.49+K4.37) (45) and the one that 
may form in hDD3R (the arginine side chain was not resolved in the crystal) (41).  As for the 
later salt bridge, it has been found in bRho (46-52), sRho (53; 54), hDD3R (41) and thermally 
stabilized inactHAA2AR (55) and inactTβ1AR (56)  and also has been supported by experimental 
studies (57; 58).  It is considered an ionic lock for class A GPCRs, in that it forms in the inactive 
state and needs to be broken for activation to occur.  The other important salt bridges observed in 
the majority of low energy structures are K3.22+D5.38 and E1.49+R7.56.  Surprisingly, the 1-2-7 
and 2-3-4 hydrogen bond networks that are largely conserved in the class A GPCRs are absent 
from our CB2 structures because of the rotation of TMs 2 and 7.  However, the 1-2-7 hydrogen 
bond network was absent in the CB1 WT receptor as well because of TM7’s significant rotation.  
Surprisingly, T3.46 and S2.45 do not form hydrogen bonds in the CB2 WT receptor, as we had 
predicted for the CB1 receptor, even though both residues are conserved.  TM2 is rotated so that 
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S2.45 faces TM1 not TM3.  CB2 does contain a hydrogen bond between TM3 and TM4 via an 
interaction between T3.37 and S4.57. 
 
Figure 6.4 Comparison of the intracellular ends of the (A) CB2 WT (cyan) and  (B) CB1 (red).  Salt 
bridges in the CB2 WT structure that are conserved in the CB1 WT receptor are represented by dotted red 
lines.  Residues that participate in polar contacts in CB1 WT but not in CB2 are labeled in blue.  A pose 
that most accurately represents the consensus of low-lying energy structures, in that it had the same polar 
contacts that the majority of the ten structures, was selected for each receptor and shown above.  CB2 WT 
is represented by the second lowest energy conformation, and the CB1 WT is represented by the third 
lowest energy conformation.  These respective structures will be used throughout the rest of this chapter. 
 
Intermolecular interactions in the CB2 T3.46A receptor 
Without any prior knowledge of agonist or G-protein binding to the mutant T3.46A receptor, we 
predicted the structures using both CB1 WT homologized helices as well as CB2 OptHelix 
helices constructed from canonical poly-alanine helices.  According to GTPγS assays and ligand 
binding assays, this threonine to alanine mutation caused the CB1 receptor to become fully 
inactive (33; 34; 36; 37).  According to Table 6.2, all of the lowest average energy T3.46A 
structures were constructed with the CB2 OptHelix helices.  By analyzing the results of the top 
ten structures, we see a lot of variability in the polar contact patterns.  There are 10 hydrogen 
bonds that appear in five of the ten top structures.  Another three hydrogen bonds appear in at 
least one of the ten structures.  Many conformations have the D3.49+R4.41 salt bridge, which 
was seen in the CB2 WT receptor, and the D5.38+K7.33 salt bridge (Figure 6.5).  Surprisingly, 
in the CB2 T3.46A receptor, there are no R3.50+D6.30 and R2.37+D6.30 salt bridges that were 
present in the CB1 T3.46A receptor.  Figure 6.5B shows that the important residues that 
participate in the TM3+TM6 ionic lock are not actively forming interhelical interactions.  Also, 
as in the CB2 WT receptor, the typical 1-2-7 and 2-3-4 hydrogen bond networks are not present 
despite having all the participating residues conserved in the receptor.  However, there are non-
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traditional 1-2-7 and 2-3-4 hydrogen bonds.  For example, instead of interactions between N1.50, 
D2.50, and N7.49, there are hydrogen bonds between K1.32-N2.63 and E1.49-Y7.47 (the Y of 
the NPXXY motif).  As for the 2-3-4 hydrogen bond network, instead of the polar contacts 
between S2.45, S3.42, and W4.50, there are hydrogen bonds between T3.37 and S4.57 as well as 
S2.60 and K3.28.  None of these interactions are observed in the CB1 T3.46A receptor. 
 
Figure 6.5 Salt bridges and hydrogen bonds on the (A) extracellular end and the (B) intracellular end of the 
predicted structure of the CB2 T3.46A receptor.  Residues that participate in polar contacts in CB1 T3.46A, 
but not in CB2 T3.46A, are labeled in blue.  The structure shown (sixth lowest in energy) best represents 
the consensus of the polar contacts in the top ten predictions for the CB2 T3.46A structure. This structure 
will be used when discussing T3.46A throughout the rest of this chapter. 
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Intermolecular interactions in CB2 T3.46I 
Using a methodological approach similar to the one described above for the T3.46A receptor, we 
predicted the structure of the CB2 T3.46I receptor.  The corresponding mutant for the CB1 
receptor had been proven experimentally to be highly constitutively active (33; 34; 36; 37).  We 
do not observe the D2.63+K3.28, R2.37+D3.49, and R5.71+D6.30 salt bridges in the CB2 
structures that are present in CB1 T3.46I (Figure 6.6).  In fact, other than D3.49, none of these 
residues consistently form interhelical polar contacts in the CB2 version of the receptor.  
However, CB2 T3.46I does contain K3.22+D5.38 and D3.49+R4.41 salt bridges, both of which 
are observed in the predicted structures of the CB2 WT receptor.  The D3.49+R4.41 salt bridge is 
present both in the CB2 WT and T3.46A receptors as well as the full inactive CB1 T3.46A and 
weakly constitutively active CB1 WT receptor, but not the highly constitutively active CB1 
T3.46I receptor.  In fact, the K3.22+D5.38 salt bridge is the only polar interaction in CB2 T3.46I 
that does not occur between adjacent helices.  For example, the CB2 T3.46I receptor has 
hydrogen bonds between D2.50 and S3.39, Y5.39 and H6.57, and W6.48 and S7.46.  It is notable 
that the only polar connection between non-adjacent helices is on the extracellular end of the 
helical bundle.  The CB2 T3.46I receptor, much like the CB1 T3.46I receptor, has fewer 
hydrogen bonds than its corresponding WT and T3.46A receptors.  Also, this isoleucine mutant, 
like the other cannabinoid receptors and their various mutants, does not have the classical 1-2-7 
or 2-3-4 hydrogen bond networks. 
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Figure 6.6 Salt bridges and hydrogen bonds on the (A) extracellular end, (B) the middle portion, and the 
(C) cytoplasmic end of the predicted structure of the CB2 T3.46I receptor.  The structure shown (fourth 
lowest in energy) best represents the consensus of the polar contacts in the top ten predictions for the CB2 
T3.46I structure.  Residues that participated in polar contacts in CB1 T3.46I are labeled in blue.  This 
structure will be used when discussing T3.46I throughout the rest of this chapter. 
 
Salt bridge patterns differ across the three CB2 receptors 
Table 6.3 shows a comparison of the consensus of polar interactions observed in the three CB2 
receptors. The CB2 WT receptor has the classic R3.50+D6.30 that is believed to be an ionic lock 
that stabilizes the inactive form in class A GPCRs.  CB2 site-directed mutagenesis data, however, 
indicates that the TM3+TM6 ionic lock may not be present or necessary for stabilizing the 
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inactive CB2 structure.  Two separate studies show that the R3.50A mutation in CB2 does not 
affect agonist binding (59; 60), which suggests that despite having a broken TM3+TM6 coupling, 
the mutant receptor remains inactive.  Hence, we predict that a TM2+TM6 ionic lock would be 
present to stabilize the inactive conformation much like the way it does in the fully inactive CB1 
T3.46A mutant. 
 
Table 6.3 Comparison of consensus salt bridge patterns for each of the three CB2 receptors (T3.46A, WT, 
and T3.46I). 
Receptor K2.37 
+ 
D6.30 
ionic 
lock 
R3.50 
+ 
D6.30 
ionic 
lock 
D3.49 
+ 
R4.41 
salt 
bridge 
K3.22 
+ 
D5.38 
salt 
bridge 
D5.38 
+ 
K7.33 
salt 
bridge 
E1.49 + 
Y7.52/ 
R7.56 
salt 
bridge 
T3.37 - 
S4.53/ 
S4.57 
hydrogen 
bond 
D2.50 - 
S3.39 
hydrogen 
bond 
T3.46A No No Yes No Yes Yes Yes No 
WT No Yes Yes Yes No Yes Yes No 
T3.46I No No Yes Yes No No No Yes 
 
All of the receptors are in agreement in that they all are expected to contain the D3.49+R4.41 salt 
bridge that was observed in fully inactive and weakly constitutively active CB1 mutant and WT 
receptors.  This is the only polar connection observed in both the CB1 and CB2 receptors.  The 
CB2 WT and T3.46I receptors contain a K3.22+D5.38 extracellular salt bridge, whereas in the 
CB2 T3.46A mutant, D5.38 interacts with K7.33 instead.  While the traditional 1-2-7 and 2-3-4 
hydrogen bonds are absent in these CB2 structures, there are unusual connections.  TM1 in the 
CB2 WT receptor is anchored via a salt bridge between E1.49 and R7.56.  This salt bridge is 
present in half of the CB2 T3.46A structures, but the other half of the structures contain a 
analogous E1.49-Y7.52 hydrogen bond.  Similarly, CB2 WT has a T3.37-S4.57 hydrogen bond as 
do half of the CB2 T3.46A structures.  The other half have a T3.37-S4.53 hydrogen bond instead.  
The CB2 T3.46I mutant has a unique D2.50-S3.39 hydrogen bond not observed in the other 
receptors.  Usually, D2.50 interacts with N1.50 and N7.49 in the crystallized class A GPCRs.  
The hS1P1 receptor, the closest related crystallized GPCR to CB2, has a hydrogen bond between 
D2.50 and S3.39 because their oxygen-oxygen heteroatom distance is 3.12 Å.  This structural 
feature indicates that TM2 is rotated so that D2.50 can interact with TM3.  However, D2.50 
simultaneously forms a hydrogen bond with N7.49 (40), which is impossible in our predicted 
CB2 WT structure because of TM2’s significant rotation away from the TM 1-2-7 pocket and 
because of TM7’s orientation.  
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Ligand binding to CB1/2 WT, T3.46A, and T3.46I  
Our collaborators, Professor Debra Kendall and her lab at the University of Connecticut, have 
analyzed the cannabinoid ligands’ binding affinity to the CB2 and CB1 WT receptors and two 
mutants, T3.46A and T3.46I (Table 6.4).  Previously, using GTPγS assays, Ahn and co-workers 
showed that for the CB1 receptor, T3.46A is fully inactive and T3.46I is highly constitutively 
active (33; 34).  The ligand binding affinities, values of Ki, agree with the activity trends shown 
in the GTPγS assays in that the Rimonabant antagonist/inverse agonist has a three-fold stronger 
affinity for the inactive T3.46A mutant, but has a 25-fold weaker affinity for the active T3.46I 
with respect to the CB1 WT receptor.  Conversely, the agonist WIN55212-2 has a three-fold 
improved binding affinity for the active T3.46I mutant, but a 25-fold weakened binding affinity 
for the inactive T3.46A mutant.  While there are no GTPγS assays done for the CB2 WT and 
mutant receptors, we do have data for the agonist binding affinities.  The Ki values of CP55940 
for the CB2 WT and T3.46A mutant are 1.39 nM and 1.42 nM respectively.  These data indicate 
that cannabinoid agonists have the same attraction for both the mutant CB2 T3.46A and the WT 
receptors. 
 
Table 6.4 Ligand binding properties of CB1 and CB2 T3.46A, WT, and T3.46I receptors.  The competitor 
ligand was [3H]CP55940 or [3H]Rimonabant (indicated by an *). 
Cannabinoid 
Receptor 
Ligand 
Type 
Ligand 
Name 
T3.46A 
Ki (nM)  
WT Ki 
(nM) 
T3.46I 
Ki (nM) 
Ki Ratio 
T3.46A:WT 
Ki Ratio 
WT:T3.46I 
CB1 (36; 37) Anta-
gonist 
Rimonabant 2.2* 7.2*/7.5 190 1:3 1:25 
CB1 (36; 37) Agonist WIN55212-2 1440* 68*/73 28.3 21:1 3:1 
CB2 Anta-
gonist 
TBD TBD TBD TBD TBD TBD 
CB2 Agonist CP55940 1.39 1.42 0.23 1:1 6:1 
 
As for the CB2 T3.46I mutant, there are observable differences in the agonists’ binding affinity 
for it versus the WT receptor.  CP55940 has a Ki value of 0.23 nM for the T3.46I receptor, which 
is a six-fold stronger binding affinity than for the WT receptor.  These data follow the patterns for 
the CB1 WT and T3.46I receptor in that the T3.46I receptor has slightly stronger affinities for 
agonists. 
 
DISCUSSION 
 
The WT CB2 structures differ from their CB1 counterparts 
We anticipated that the two members of the cannabinoid family would share many structural 
similarities because of their high percentage of conserved amino acid identity within the TMs, 
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54.56%, but instead there are substantial differences between their predicted structures.  After 
testing a variety of crystal templates, we produced substantially lower energy structures using the 
previously predicted CB1 template as we had anticipated.  Many of the residues that stabilized 
CB1 and its various mutants are conserved in CB2.  However, it seems that the residues that are 
not conserved play a major role in influencing the structural differences.  Of the top ten lowest 
energy structures, the vast majority of them used the CB2 OptHelix helices, developed from 
canonical poly-alanine helices modified with SCREAM, MD, and minimization, rather than the 
mutated homology helices from the CB1 WT predicted structure.  OptHelix helices are structural 
optimized for the specific target sequence, so the resulting TM bundles built using OptHelix 
helices or CB1 homologized helices have large structural differences.  The CB1 structure was 
also constructed from OptHelix helices rather than homologized helices.  Unlike CB2, the lowest 
energy CB1 structures were built with mineng helices, not minrmsd helices.  The RMSD for the 
two minrmsd helices 6 is 1.18 Å, but the RMSD between CB2 minrmsd helix 6 and CB1 mineng 
helix 6 is much less at 0.51 Å, so the lowest energy CB2 structures prefer a certain conformation 
of helix 6 that is captured by the CB2 minrmsd OptHelix helices or the homologized CB1 mineng 
OptHelix helices. 
 
The biggest difference between the CB1 and CB2 WT predicted structures is the orientation of 
TM2.  In CB1 WT, we observed two salt bridges between helices 2 and 3 that we proved with 
mutations to be important for stabilizing the inactive or active conformations (33; 34).  For 
example, R2.37 in CB1 participates in a TM2+TM6 coupling in the fully inactive mutant 
receptors such as CB1 T3.46A (Figure 6.7A).  This salt bridge breaks to form a new one between 
R2.37 and D3.49 in the constitutively active mutants.  It was expected that K2.37 in CB2 would 
play a similar role.  Likewise, D2.63 forms a salt bridge with K3.28 in weakly or highly 
constitutively active receptors like CB1 L3.43A (Figure 6.7C).  By mutating the aspartic acid to 
an alanine, the active mutant became fully inactive.  It was also expected that Q2.63 in CB2 
would interact with the conserved K3.28 residue.  Also, residues S2.45 and T3.46 are conserved 
in both receptors.  In the CB1 WT receptor, these two residues formed a hydrogen bond (Figure 
6.7E), which might explain why the T3.46 residue is so important for the CB1 receptor structure, 
and it was anticipated to have a similar role in the CB2 receptor. 
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Figure 6.7 Comparison of CB1 (red) and CB2 (cyan) TM2 residue placement for (A) R/K2.37 and D3.49, 
(B) D/Q2.63 and K3.28, and (C) S2.45 and T3.46. 
 
However, none of these contacts were present in the sister CB2 WT receptor (Figures 6.7 B, D, 
and F).  It does not have any polar interactions between TMs 2 and 3, and the CB1 salt bridges 
and hydrogen bond networks cannot possibly form.  TM2 is rotated almost 60° from where it is 
oriented in the CB1 WT receptor and is stabilized by two lysine residues, K2.37 and K1.32, 
which form hydrogen-bonds with backbone atoms on adjacent helices.  The CB2 WT receptor’s 
different orientation of TM2 suggests that there are significant structural differences, and thus 
functional differences, with respect to CB1. 
 
There are other differences in the salt bridge patterns between the two types of cannabinoid 
receptors.  A D6.58+K7.32 interaction forms in the majority of CB1 WT structures, but this salt 
bridge is not observed in CB2 WT because there is a serine instead of an aspartic acid at position 
6.58 in the CB2 receptor.  It does, however, have several salt bridges that are not shown in the 
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CB1 WT structures.  For example, the CB2 WT receptor has an extracellular polar contact 
between K3.22 and D5.38.  This salt bridge is not observed in CB1 because CB2’s aspartic acid 
corresponds to a serine at position 5.38 in CB1, and R3.22 was not included in CB1’s TM3 
because it was predicted to be in the loop region.  This TM3-TM5 interaction can form in CB1 
during dynamic simulations.  Furthermore, the CB2 WT receptor shows a strong preference for 
forming a salt bridge between TM1+TM7, E1.49+R7.56.  This polar contact stabilizes the TM1 
orientation, which was quite variable in the CB1 WT receptor.  The R7.56 residue was not 
included in TM7 in CB1 WT because it was not predicted to be in the helical region.  This salt 
bridge does form during dynamics provided that TM7 is in an orientation that makes the residue 
accessible.  We observe the formation of this salt bridge during CB1 WT MD simulations.  
Perhaps this interaction is why the predicted structures of the cannabinoid receptors do not 
contain the typical 1-2-7 hydrogen bond networks—because TM1 and TM7 need to be oriented a 
specific way in order to form that salt bridge, which is not conducive to the characteristic class A 
GPCR hydrogen bond network.  The only crystallized GPCR that contains the E1.49 residue is 
the hS1P1 receptor (40), but the side chain was not resolved (PDB ID: 3V2W), and the residue at 
7.56 is a tyrosine, so E1.49 does not form an interhelical salt bridge in hS1P.  Thus, hS1P1 does 
contain the expected 1-2-7 network.  In general, MD simulations may prove that the two 
cannabinoid receptors are more similar than the loopless and static predicted structures indicate. 
 
G2.48 may play an important role in the predicted WT CB2 structure 
We propose that the G2.48 residue in CB2 is what causes TM2 to have an unexpected orientation.  
The TM3s of the CB1 and CB2 WT receptors are very similar to each other.  TM2 has a greater 
variation in its sequence.  Figure 6.8A shows CB2 WT’s TM1 and TM2 with N1.50, D2.50, and 
G2.48 indicated.  CB2 has a glycine at position 2.48 whereas CB1 has a much bulkier valine.  We 
believe that this particular residue may play an important role in positioning TM2.  The predicted 
distance between the nitrogen atom in the side chain and glycine’s Cα atom is 3.25 Å.  This is not 
enough to accommodate a side chain without clashing with N1.50.  TM2 would have to rotate in 
order for the valine residue at position 2.48 to have enough space. 
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Figure 6.8 Orientation of residues that impact the TM2 orientation in (A) CB2 and (B) inactHA2AAR (PDB 
ID: 3EML) (61). 
 
Figure 6.8B shows the positions of the corresponding residues from Figure 6.8A in the inactive 
human adenosine A2A receptor (inactHA2AAR) crystal structure (PDB ID: 3EML) (61).  N1.50 is 
in relatively the same position, but D2.50 and A2.48 are roughly a quarter-turn from where they 
are in the CB2 WT receptor.  In CB2, G2.48 faces TM1, and D2.50 faces TM3.  In inactHA2AAR, 
A2.48 is facing into the lipid bilayer, and D2.50 faces into the middle of the bundle to form 
hydrogen bonds with water molecules and other residues.  And in inactHA2AAR, unlike in CB2, 
TM2 is tilted so that N1.50 is not directly pointing at a residue. CB2’s TM2 orientation would not 
be feasible with the inactHA2AAR amino acid sequence.  By replacing CB2’s G2.48 with an 
alanine, we expect that the TM2 rotation will change significantly.  The other option would be for 
TM1 to move to accommodate the larger alanine residue, but we do not anticipate this because in 
its current conformation, CB2 TM1 is stabilized by a salt bridge with TM7, (E1.49+R7.56). 
 
Glycine at the 2.48 spot is found in very few GPCRs.  Of the crystallized class A GPCRs, which 
all have a 1-2-7 network, hCXCR4, bRho, and hDD3R have a valine (like CB1), HAA2AR has an 
alanine, Tβ1AR and Hβ2AR have a cysteine, and sRho has a phenylalanine residue at this 
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position.  Of the 1559 related sequences found in BLAST, only the CB2 receptors and certain 
Mas-related GPCRs, gp162, olfactory receptors, ribosome maturation factors, and the Protease 
HtpX homologs have a glycine at this position.  None of these proteins have been crystallized, so 
it is unknown if the 1-2-7 hydrogen network forms.  In the latter two proteins listed above, the 
residues participating in the 1-2-7 network are not conserved, so the polar contacts must be 
different. 
 
To confirm our prediction, it would be necessary to predict the structures of the CB2 G2.48V and 
CB2 G2.48V/T3.46A.  We propose that this G2.48V mutation would force TM2 to change its 
orientation.  The former mutant should resemble the CB1 WT receptor in that it should have a 
polar TM2+TM3 coupling.  The latter mutant should compare with the fully inactive CB1 
T3.46A mutant in that it should have a TM2+TM6 ionic lock. If these structural predictions are 
correct, then our collaborators will perform GTPγS binding assays to determine the degree of G 
protein binding and the respective activity levels.  Thus, we expect that the G2.48V receptor has a 
higher level of GTPγS binding than the G2.48V/T3.46A double mutant, and thus has a higher 
level of constitutive activity than the G2.48V/T3.46A mutant, and that there will be a clear 
distinction between the two receptors’ function and behavior.  If the results do not change with 
the mutation of G2.48 to valine, then the residue at that position is unimportant in orienting TM2 
and probably does not interact with N1.50.  If our predictions are correct, then that would indicate 
the G2.48 residue plays a significant role in differentiating the structures and signaling.   
 
The CB2 T3.46A mutant is constitutively active 
We conducted structure prediction experiments that were performed independently and before we 
had experimental data to attest the functional state of the CB2 T3.46A and T3.46I mutants.  In our 
predicted structures, the CB2 T3.46A receptor lacked a TM2+TM6 coupling much like the 
predicted structures of the CB1 WT and T3.46I receptors that have been experimentally proven to 
be constitutively active.  The R3.50+D6.30 ionic lock is also absent in this CB2 T3.46A mutant 
as in the constitutively active CB1 T.346I receptor.  Thus we conclude, based on our structural 
predictions, that CB2 T3.46A is activated, which is different from what was observed in the CB1 
receptor. 
 
Even though our predicted structure of CB2 T3.46A is lacking a TM3+TM6 ionic lock, it does 
not mean that the structure is in the highly constitutively active conformation as opposed to the 
weakly constitutively active one.  In our designed CB1 mutants, T3.46A/R2.37A and 
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L3.43A/D2.63A/R2.37A, the predicted structures lacked this same salt bridge and are stabilized 
by the D3.49+K4.41 salt bridge, which is not present in the highly constitutively active mutants 
like T3.46I or L3.43A.  Experimental GTPγS binding assays proved that these mutants are 
constitutively active, and not highly constitutively active, as we had predicted (33; 34).  
 
Subsequent agonist binding assays (Table 6.4) support our predicted CB2 T3.46A structure.  The 
agonist CP55940 has similar binding affinity for both the CB2 WT and T.346A receptors, which 
suggests that they are equally activated.  While this preliminary data looks very promising, there 
are other experiments that would be necessary to inconclusively prove that both these receptors 
are constitutively active.  First, the experiments with agonists need to be repeated, so there will be 
a margin of error for the agonists’ binding affinities.  Second, the experimental binding affinities 
of antagonists needs to be measured to all of these receptors.  If they are constitutively active, we 
would expect the antagonists to have equal binding affinities to the mutant receptors with respect 
to the CB2 WT in the same way the agonists did.  If the CB2 WT, T3.46A, and T3.46I receptors 
do not have equal activation levels, then the antagonists would bind strongest the receptor that is 
least active.  For example, we anticipate that the antagonists will have larger binding affinities for 
the CB2 WT and T3.46A receptors than the T3.46I mutant because, based on the agonist binding 
data, we expect CB2 T3.46I to be more highly activated. 
 
It is reasonable to assume that the agonists would prefer to bind to the more activated 
conformation.  However, we cannot come to any definitive conclusions about activation levels 
until we have the results from the GTPγS assays.  These assays will determine the level of GTPγS 
binding, an indicator of G protein binding, in absence of the ligand, which is a more accurate 
indicator of constitutive activity than ligand-induced activation.  Based on the agonist binding 
affinities, the T3.46I mutant is expected to have a larger GTPγS binding affinity and thus, be 
more constitutively active, and the WT and T3.46A receptors will have weaker binding affinities 
than T3.46I and be equal to one another. 
 
The CB2 T3.46I mutant is also constitutively active 
We also predicted the structure of the CB2 T3.46I mutant and found that it too lacked the 
TM2+TM6 and TM3+TM6 couplings that are known to stabilize the inactive conformations of 
the CB1 receptor.  However, it also lacks the R2.37+D3.49, D2.63+K3.28, and R5.71+D6.30 salt 
bridges that are present in the highly constitutively active CB1 T3.46I receptor.  One of these, 
D2.63+K3.28, is believed to stabilize the constitutively active conformations (33).  The 
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R5.71+D6.30 salt bridge is only observed in the constitutively active CB1 T.346I receptor, but 
similar ones are observed in the putatively active bOps receptor (62; 63), the constitutively active 
bRhod mutant (64), the meta II receptor (65), and perhaps a water-mediated one in the nanobody-
bound actHβ2AR (66).  However, our predicted structure for the highly constitutively active 
L3.43A mutant lacks this salt bridge as well (33), but it did contain both TM2+TM3 couplings.  
Surprisingly, this CB2 T3.46I mutant contains the D3.49+R4.41 salt bridge, which is present in 
the fully inactive CB1 T3.46A mutant and other weakly constitutively active CB1 mutant and 
WT receptors (33).  Similar salt bridges have been observed in antagonist-bound receptors (41; 
45).  Possibly, this contact stabilizes the inactive and weakly constitutively active receptors.  The 
CB2 T3.46I receptor does have a K3.22+D5.38 salt bridge, which is the only contact in the 
majority of structures that is not between adjacent helices.  It occurs at the extracellular end, so 
the intracellular end is spacious enough for potential proteins to bind.  Despite the lack of 
agreement with the CB1 T3.46I structure, the CB2 T3.46I prediction appears constitutively active 
due to its lack of the two major ionic locks.  Though surprisingly, of the top ten lowest energy 
structures, three of them had the R3.50+D6.30 ionic lock and two of them had the R2.37+D6.30 
ionic lock, but these locks were never present in the same structure or the majority of 
conformations. 
 
Our predicted structures agree with experimental results, in that agonist CP55940 has a six-fold 
improvement in binding affinity for the CB2 T3.46I mutant compared to the CB2 WT or T3.46A 
receptors, which is a strong indicator that T3.46I is constitutively active.  However, there will not 
be any definite conclusions without more ligand binding assays and the GTPγS assays.  Based on 
our structural predictions, which contain the D3.49+R4.41 salt bridge, but none of the TM2+TM3 
or TM5+TM6 salt bridges, CB2 T3.46I is not expected to be highly constitutively active like its 
CB1 counterpart. 
 
CB2 WT, T3.46A, and T3.46I structures are very different from one another, and the receptors 
may have different functional properties 
Even though there is some agonist binding evidence to suggest that the CB2 WT, T3.46A, and 
T3.46I receptors are all constitutively active, they are structurally very different.  The CB2 WT 
conformation has a conserved R3.50+D6.30 salt bridge absent in the T3.46A one, and they have a 
significant RMSD of 2.77 Å, which is larger than the value for active versus inactive crystallized 
GPCRs (43; 50; 61; 62; 65; 67-69).  The backbone RMSD between the CB2 WT and T3.46I 
receptor is slightly smaller, at 2.28 Å.  The two mutants have a significantly different RMSD, of 
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3.22 Å.  The structural diversity could indicate functional differences for the three constitutively 
active receptors. 
 
GPCRs have multiple active states as explained by the ensemble state theory (70-73) and 
crystallized Hβ2AR conformations (43; 66; 69).  As discussed earlier, the CB1 receptor is a prime 
example because of its ability to bind to multiple types of G proteins including Gi (74) and Gs 
(37; 75; 76) as well as the β arrestin proteins (64; 77-79).  Our computational studies in Chapter 
III agree with this concept because we predict different conformations for the CB1 WT and 
L3.43A receptors and they have been experimentally proven to bind to different G proteins (33; 
37; 74). Furthermore, previous experiments show that agonists affect G protein binding to the 
CB1 receptor and subsequent activation.  For example, when CB1 binds to the Gi protein, agonist 
CP55940 had approximately the same level of activity as WIN55212-2.  However, when binding 
to a Gs protein, the CP55940 had only 45% of the activity that WIN55212-2 produced.  Possibly, 
the agonists stabilize different active conformations of CB1 that lead to different intracellular 
reactions with the G proteins and thus different activity levels (80).  Perhaps CB2 experiences 
similar phenomena. 
 
Based on the differences between the predicted structures, we anticipate that the CB2 WT and 
T3.46A receptors have different functions despite having the same binding affinity for the 
agonists.  Much less is known about the CB2 signaling pathway than the CB1 one, but it is 
reasonable to believe that the receptor might have different conformations to interact with 
different types of proteins.  For example, the CB2 WT receptor has been shown experimentally to 
bind to the Gi protein, but the CB2 T3.46A mutant may bind to the Gs or Gq proteins or perhaps 
one of the β arrestin proteins.  However, these conjectures about the CB2 structures need to be 
validated with molecular biology experiments.  Cyclic adenosine monophosphate (cAMP) assays 
will indicate which type of G protein the two mutant receptors bind to.  These assays will show 
how well our structural predictions can indicate differences in function and GPCR behavior. 
 
CONCLUSIONS 
 
We predicted the structures of the CB2 WT plus two mutant receptors, T3.46A and T3.46I.  
Previous experiments showed that mutating this threonine residue as position 3.46 significantly 
changes the function of the CB1 receptor, and we were curious to see if this was true for its sister 
cannabinoid CB2 receptor.  Surprisingly, despite the large sequence conservation between the 
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two receptors, the resulting WT structures are very different.  TM2 is rotated so that none of the 
TM2-TM3 polar interactions observed in the CB1 receptor are present in the CB2 one.  
Furthermore, the CB2 T3.46A mutant, which was fully inactive in CB1, lacks the R2.37+D6.30 
and R3.50+D6.30 ionic locks that prevent activation.  We predict that this mutation does not have 
the same impact in CB2 as it does on CB1, and therefore, the T3.46A receptor is constitutively 
active.  Similarly, the T3.46I mutant also lacks these important ionic locks, so it too resembles a 
constitutively active receptor.  Our structure predictions are supported by agonist binding assays 
done by the Kendall lab.  They show that agonists have equal binding affinities for the CB2 WT 
and T3.46A receptors and a slightly stronger affinity for the T3.46I mutant.  However, antagonist 
binding and GTPγS assays need to be performed to conclusively prove these findings.  In the 
meantime, we have designed a double mutant, CB2 G2.48V/T3.46A, that is predicted to contain 
the R2.37+D6.30 ionic lock and thus be fully inactive.  After verifying our receptor structure 
predictions, we can subsequently design anti-obesity drugs and pain medication to interact with 
this CB2 receptor without resulting in psychological side effects. 
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Chapter VII 
 
STRUCTURE PREDICTION OF THE HUMAN MU-OPIOID RECEPTOR AND 
CONSTITUTIVELY ACTIVE MUTANTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The majority of the human mu-opioid structure prediction computational experiments 
were performed by Nicholas Parker as part of the Caltech Freshman Summer Research 
Institute (FSRI). 
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ABSTRACT 
 
The human mu-opioid receptor (hMOR) plays an important role in mediating pain and is the 
target for many drugs such as morphine and codeine.  Designing drugs that interact with this 
receptor has proven difficult because its structure was not crystalized until 2012.  Even then, the 
crystal structure captures a single pose of a dynamic molecule.  Before the mouse mu-opioid 
receptor (mMOR) was crystallized, we used the Monte Carlo GEnSeMBLE method to predict the 
structure of the highly conserved hMOR using the crystallized human chemokine CXCR4 
receptor as the template.  Our lowest energy prediction closely resembled the crystallized mMOR 
since it had a backbone RMSD of 1.94 Å, well within the crystal resolution of 2.80 Å. The 
predicted hMOR also contained many of the same hydrogen bond networks observed in the 
crystallized GPCR.  However, this mMOR was crystallized with a covalently bound antagonist, 
which may impact the structure of the receptor.  Since our GEnSeMBLE method accurately 
produced the hMOR structure, we used it to perform a local sampling on the mMOR crystal 
structure and found five structures that are more energetically favorable than the crystal structure.  
Not surprisingly, the transmembrane region (TM) with the largest variations in rotation and 
sweep angles is TM5, which contains the residue covalently linked to the antagonist.  These 
findings suggest that although the crystal structure is accurate, it may not be the best 
representation of the receptor without the antagonist present.  Finally, we used the homologized 
mMOR as a template to build the hMOR wild-type (WT) receptor as well as five other mutants 
that have been experimentally determined to be functionally significant in the rat mu-opioid 
(rMOR) sequence.  The predicted structures of the six receptors have different patterns of salt 
bridges and hydrogen bonds that can explain the functional differences observed in the 
experiments.  For example, the highly constitutively active mutant T6.34K is the only receptor 
that has a hydrogen bond between a threonine on the intracellular end of TM2 and the aspartic 
acid of the highly conserved DRY motif.  This polar connection may be important for stabilizing 
the active conformation.  Thus, not only have we predicted the structure of hMOR but of its 
mutants that represent the constitutively active form of the receptor.  By understanding the 
different structures at various functional levels, in the future, we can design drugs that induce or 
stabilize these different conformations. 
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INTRODUCTION 
 
Morphine is one of the most effective pain medications available, but it is highly addictive and 
induces tolerance and dependency as well as having serious side effects such as respiratory 
depression (1).  This drug primarily targets the mu-opioid receptor (MOR) as evidenced by MOR 
knock-out mice who do not experience the analgesic effects or physical dependence associated 
with morphine (2).  Obviously, a pain medication with less serious side effects is desirable, but 
none has yet been developed or widely used.  The MOR is a G protein-coupled receptor (GPCR) 
that has seven alpha-helical transmembrane regions (TMs) that span the cellular bilayer.  This 
receptor primarily binds to the intracellular Gi protein, which inhibits the production of cyclic 
adenosine monophosphate (cAMP), but only one Gi protein subunit subtype, 
Gi2α, is responsible for the antinociception effects caused by morphine (3).  Perhaps it is possible 
to design a drug that evokes the signaling pathway for pain mediation, but not the ones associated 
with other undesirable side effects.  To do this, the drug would have to stabilize a particular MOR 
conformation that binds to a specific intracellular signaling receptor.  However such drug design 
has proven difficult because MOR was not crystallized until 2012, and until then, its structure 
was unknown. 
 
That year, the four members of the opioid family were crystallized including the mouse MOR 
(mMOR) (4), the mouse delta-opioid receptor (5), the human kappa-opioid receptor (6), and the 
human nociception/orphanin FQ receptor (7).  Despite the wealth of structural information, the 
crystal structures are just a single conformation of a very flexible and dynamic macromolecule 
that binds to a variety of intracellular proteins and different types of agonists (3; 8; 9).  Thus, our 
lab has developed computational methodology to predict an ensemble, rather than a single 
conformation, of energetically accessible GPCR structures.  The strength in this process is that 
these programs quickly and efficiently calculate the energies of a trillion possible structures by 
rotating and tilting the seven alpha-helices.  Unlike homology methods, this procedure is sensitive 
enough to detect the structural impact of a single residue as proven by our previous applications 
to the human cannabinoid type 1 (CB1) receptor and its respective constitutively active mutants 
(CAMs) (10-12).  We applied similar procedures to explain the CAMs of the rat MOR (rMOR) 
shown in Table 7.1 (13).  A single or double point mutation showed significant changes in the 
binding affinity for the DAMGO opioid agonist.  In two cases, the L6.30E/T6.34K and T6.34K 
had a substantial increase in GTPγS assays compared to the wild-type (WT) rMOR receptor, 
which indicates an increase in basal level constitutive activity.  These rMOR single point or 
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double point CAMs have not been crystallized, so it is unknown how these mutations affect the 
structures. 
 
Table 7.1 Constitutively active mutants (CAMs) for the rMOR sequence (13). 
rMOR 
Receptor 
Ki Ratio 
Mutant:WT  
Agonist DAMGO 
Ki (nM) 
Basal GTPγS 
binding (% of WT) 
Relative 
activity level 
L6.30E/T6.34D 447:1 3189 100 Very inactive 
T6.34D 96:1 684 100 Less active 
L6.30E 93:1 667 100 Less active 
WT 1:1 7.14 100 ---------- 
L6.30E/T6.34K 1:1 6.98 124 Same as WT 
T6.34K 1:21 0.34 210 More active 
 
Here, we use the GEnSeMBLE (GPCR Ensemble of Structures in Membrane BiLayer 
Environment) programs (11; 14-17) to predict the structure of the human MOR (hMOR).  The 
resulting conformations are similar to the crystallized structure of mMOR in that the lowest 
energy hMOR structure has a backbone RMSD of 1.94 Å.  However, the mMOR was crystallized 
with the covalently bound β-funaltrexamine (β-FNA), which may affect the overall structure, so 
we used our methods to preform a local sampling of the crystal structure and found five 
conformations that are energetically more favorable than the crystallized one.  Then using the 
mMOR helices as templates, the structures of the hMOR and the five mutants listed in Table 7.1 
are predicted.  After a thorough sampling, the resulting receptors are very different, and these 
structural differences can explain the experimental differences in function.  By understanding the 
different structures, in the future, drugs can be designed to interact with specific receptor 
conformations for a desired function. 
 
METHODS 
 
(For more details about structure prediction methodology, see Chapter II.) 
 
hMOR structure prediction 
The methods described herein are similar to the ones used for the CB1 (10; 12) and CB2 
receptors discussed in Chapters III and VI respectively (Figure 7.1).  We used the Monte Carlo 
GEnSeMBLE method (11; 14-17) developed within our lab to perform a thorough sampling of 
helical rotation (eta, η), tilt (theta, θ), and sweep (phi, ϕ) angles by quickly and efficiently 
calculating the energies of a trillion structures.  The shape of the helices were constructed in two 
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ways—with OptHelix helices, or helices originally constructed from poly-alanine canonical 
helices and modified with molecular dynamics (MD) simulations and minimization; or with 
homologized helices, or helices from a crystallized GPCR mutated to match the target sequence. 
 
Figure 7.1 Schematic illustration explaining the computational GEnSeMBLE methodology used for 
predicting the hMOR structure.  Figure courtesy of Nicholas Parker. 
 
hMOR structure prediction with OptHelix helices 
For the OptHelix helices, we had to first determine the respective lengths of the seven individual 
helices.  A BLAST search (18) with an E-value of 0.1 found 1834 sequences related to hMOR 
ranging in TM sequence identity from 100% to 7.75%.  After using MAFFT software (19) to 
align these sequences, a hydrophobicity value based on the Wimley-White scale (20) was 
assigned to each residue, and these values were averaged over all 1834 sequences to get an 
average hydrophobic value for every residue in the hMOR sequence.  The program PredicTM 
identified seven hydrophobic regions that would correspond to the seven TM regions spanning 
the greasy bilayer.  However, crystallized GPCRs have shown that the helical portions of the TMs 
extend beyond the lipid bilayer into the solvent.  Secondary structure prediction (SSP) servers 
PORTER (21; 22), APSSP2 (23; 24), and PSIPRED (25; 26) were used to predict the helical 
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regions and extend the hydrophobic portions identified with PredicTM.  Once the TM lengths 
have been determined, the helices were built using OptHelix.  OptHelix constructed the TMs 
initially with canonical helices made entirely of alanine residues.  The alanines were replaced 
with the rotamers of the correct residues over the course of the program using the Side chain 
Rotamer Excitation Analysis Method (SCREAM) (27).  The individual helices were stabilized 
with MD, and two structures were collected based on the lowest energy structure of the 
simulation (MinEng) and the structure with whose root-mean-square deviation (RMSD) is closest 
to the average structure of the simulation (MinRMSD).  Once the seven helices were built, they 
were aligned to one of the crystallized GPCRs listed in Table 7.2 or the predicted structure of the 
human chemokine CCR5 receptor (hCCR5).  There were two ways to align the TMs to the 
templates.  The first way was to align the residue representing the midpoint of the raw 
hydrophobic region of the TM to the midplane bisecting the TM bundle (rawmid).  The second 
way was to align the residue bisecting the area of the hydrophobic region of the TM to the bundle 
midplane (area). 
 
Table 7.2 Comparison of the TM sequence identity of hMOR with crystallized GPCR sequences including 
hCXCR4 (28), bRho (29), Hβ2AR (30), HA2AAR (31), and hCCR5 (32-34). 
Crystallized Receptor Percent TM sequence identity with 
respect to hMOR 
Human Mu-Opioid Receptor 100% 
Human Chemokine CXCR4 Receptor 46.96% 
Bovine Rhodopsin Receptor 45.56% 
Human β2 Adrenergic Receptor 37.79% 
Human Adenosine A2A Receptor 34.68% 
Human Chemokine CCR5 Receptor 26.89% 
 
hMOR structure prediction with homologized helices 
Rather than constructing individual helices from scratch, we also mutated crystallized helices so 
that they matched the target sequence and then optimized the helices.  Unlike homologized 
helices, OptHelix helices were constructed individually, so their respective shapes were not 
affected by interactions with the other TMs or the loop regions.  Since the receptor sequence 
affects the helical shape, the homologized helices produce favorable energies for target receptors 
that they are closely related to.  Fortunately, when this project began, there were already multiple 
crystallized GPCRs with a high percentage of conserved sequence identity in the TM regions 
(Table 7.2).  A high sequence identity is anything greater than 30%, and there are two structures 
with TM sequence identities at 45% or greater.  Thus, there are four crystallized GPCRs that were 
appropriate homology templates including the human chemokine CXCR4 receptor (hCXCR4) 
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(28), the bovine rhodopsin receptor (bRho) (29), the human β2 adrenergic receptor (Hβ2AR) (35), 
and the human A2A adenosine receptor (HA2AAR) (31).  The GEnSeMBLE predicted structure of 
hCCR5 was also included despite its low sequence identity and the fact it had not been 
crystallized at the time.  It was included because it is closely related to hCXCR4, which had the 
highest sequence identity with the target sequence.  Also, even though hCCR5 had not been 
crystallized, it agreed with a sufficient amount of experimental evidence (32-34).  In 2013, 
hCCR5 was crystallized (36), and it was in good agreement with the predicted structure. 
 
Sampling the helical orientations 
After constructing the helical bundles, we performed a complete sampling using the BiHelix and 
ComBiHelix programs (14).  In BiHelix, pairs of interacting helices were rotated 360° in 30° 
increments.  The pairwise energies were calculated and summed up to obtain an estimate of the 
energies of the entire bundle.  Then, the 2000 lowest energy estimates were constructed as 
complete 7TM bundles in ComBiHelix, and the charged interhelical and the charged total 
energies were calculated.  The interhelical energy is equal to the difference in energy of the entire 
bundle and the sum of the energies of the seven individual helices.  Table 7.3 shows the lowest 
energy conformations for each template.  There are significant changes in helical orientations for 
all the templates except Hβ2AR with homologized helices and hCXCR4 with homologized 
helices, and slight changes in HA2AAR with homologized helices and hCCR5 with homologized 
helices.  The hMOR structure with hCXCR4 homologized helices had the most favorable average 
of the charged and neutralized interhelical energies by over 100 kcal/mol.  Thus, we used the top 
three structures from the hCXCR4 homologized helices ComBiHelix results according to average 
energy rank for further local sampling in the SuperBiHelix and SuperComBiHelix programs (11).  
The theta (θ, tilt) angles were sampled in from -10° to 10° in 10° increments and the phi (ϕ, 
sweep) and the eta (η, rotation) angles were sampled from -30° to +30° in 15° increments.  If the 
last two residues of the helix were charged, they were replaced with alanine residues using the 
SCREAM program (27).  The 2000 lowest energy estimates for each starting hCXCR4 structure 
were constructed with the correct sequence in SuperComBiHelix, and the charged total energy, 
the neutralized total energy, the charged interhelical energy, and the neutralized interhelical 
energy were calculated.  The resulting structures were ranked according to these four criteria, and 
they were averaged to give a final ranking.  The structures of the three starting points were 
combined and re-ranked.  The ten lowest average energy rank structures were the result of 
sampling the lowest energy ComBiHelix structure. 
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Table 7.3 Interhelical energy comparison for hMOR with OptHelix helices and homologized helices.  
Optimized eta (η, rotation) angles from the ComBiHelix analysis for the WT hMOR receptors with various 
helices: OptHelix helices aligned to the crystallized Hβ2AR (PDB ID: 2RH1) (30), the crystallized bRho 
(PDB ID: 1U19) (29), the crystalized hCXCR4 (PDB ID: 3OE6) (28), the crystallized HA2AAR (PDB ID: 
3EML) (31), and the predicted hCCR5 structure (32-34), as well as homologized helices with the same 
templates. 
 
 
Local sampling of mMOR crystal structure 
To test the flexibility of the mMOR (PDB ID: 4DKL) (4) without the antagonist present, we 
preformed a local sampling on the crystallized structure using the angles specified in Table 7.4. 
 The phi (ϕ, sweep) and eta (η, rotation) angle sampling range was wider than usual because the 
range was extended until none of the low energy structures had angles that reached the end of the 
span, meaning we had exhausted sampling the possible helical orientations.  During the 
SuperBiHelix stage, if the last two residues of the helix were charged, they were replaced with 
alanine residues.  The 2000 structures with the lowest energy estimates in SuperBiHelix were 
constructed with the correct sequence in SuperComBiHelix and ranked according to average 
energy rank. 
 
Helix 
Method Template Helix Type
Hydrophobic 
Center TM1 Eta TM2 Eta TM3 Eta TM4 Eta TM5 Eta TM6 Eta TM7 Eta
Charge 
Interhelical 
Energy
Neutral 
Interhelical 
Energy
Average 
Interhelical 
Energy
Homology Hβ2AR Homology Homology 0 0 0 0 0 0 0 -345.6 -391.9 -368.8
OptHelix Hβ2AR MinEng Area 0 -60 150 30 -120 -120 90 -306.6 -296.3 -301.5
OptHelix Hβ2AR MinEng Rawmid 0 -60 150 30 -150 60 120 -268.1 -288.0 -278.1
OptHelix Hβ2AR MinRMSD Area 0 -90 -120 0 -120 -120 60 -304.7 -309.6 -307.2
OptHelix Hβ2AR MinRMSD Rawmid 30 -90 150 0 -150 120 180 -287.5 -295.4 -291.5
Homology bRhod Homology Homology 0 0 0 30 180 -30 0 -350.8 -316.2 -333.5
OptHelix bRhod MinEng Area -60 -150 90 120 -150 120 -120 -209.1 -253.1 -231.1
OptHelix bRhod MinEng Rawmid -30 180 120 30 -150 -120 -60 -263.0 -244.0 -253.5
OptHelix bRhod MinRMSD Area 30 -150 150 0 180 120 -120 -257.3 -265.0 -261.2
OptHelix bRhod MinRMSD Rawmid 0 -90 150 30 120 120 -120 -276.6 -273.4 -275.0
Homology hCXCR4 Homology Homology 0 0 0 0 0 0 0 -523.1 -430.3 -476.7
OptHelix hCXCR4 MinEng Area 0 150 -60 60 180 90 -150 -288.5 -266.0 -277.3
OptHelix hCXCR4 MinEng Rawmid -150 150 60 60 30 150 -90 -80.4 -429.1 -254.8
OptHelix hCXCR4 MinRMSD Area 0 180 -150 30 -30 -90 -60 -243.3 -277.6 -260.5
OptHelix hCXCR4 MinRMSD Rawmid -30 180 -60 -30 60 -120 -60 -288.7 -291.5 -290.1
Homology hAA2A Homology Homology 0 0 0 0 -90 0 0 -359.3 -366.2 -362.7
OptHelix hAA2A MinEng Area 30 60 -60 60 -60 120 90 -239.7 -206.2 -223.0
OptHelix hAA2A MinEng Rawmid -60 -120 30 0 -30 30 90 -254.7 -226.6 -240.7
OptHelix hAA2A MinRMSD Area 30 30 180 -30 -30 120 60 -234.1 -207.9 -221.0
OptHelix hAA2A MinRMSD Rawmid -60 -120 -30 60 -60 120 90 -270.5 -234.1 -252.3
Homology CCR5 Homology Homology -30 30 0 60 0 0 0 -323.1 -376.7 -349.9
OptHelix CCR5 MinEng Area 60 -60 0 30 -90 -90 0 -285.6 -309.9 -297.8
OptHelix CCR5 MinEng Rawmid -60 120 90 0 -120 -150 -90 -301.8 -288.7 -295.3
OptHelix CCR5 MinRMSD Area -30 -120 90 -30 -150 120 120 -293.7 -303.1 -298.4
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Table 7.4 Theta (θ, tilt), phi (ϕ, sweep), and eta (η, rotation) angles sampled during local sampling of 
mMOR crystal structure with SuperBiHelix and SuperComBiHelix programs. 
 
 
hMOR CAMs structure prediction 
Using the mMOR crystal structure, homologized helices were constructed for the WT hMOR as 
well as the five mutants listed in Table 7.1.  The mutant residue rotamer, either a glutamic acid at 
position 6.30, an aspartic acid at 6.34, a lysine at 6.34, or a combination [using Ballesteros-
Weinstein numbering (37)], was added with the SCREAM program.  First, we performed a 360° 
helical sampling using the BiHelix and ComBiHelix programs.  The 2000 bundles with the lowest 
energy estimates in BiHelix were constructed in their entirety in ComBiHelix and ranked 
according to their average energy ranks.  The last two charged residues in each helix of the lowest 
average energy rank structure were replaced with alanine residues for the SuperBiHelix step.  
Again, the 2000 lowest energy estimates from SuperBiHelix were constructed in their entirety 
including the terminal charged residues for SuperComBiHelix.  Generally, theta (θ, tilt) angles 
were sampled in from -10° to 10° in 10° increments and the phi (ϕ, sweep) and the eta (η, 
rotation) angles were sampled from -30° to +30° in 15° increments.  If a structure sampled one of 
the angles at the end of the range, then another round of sampling was performed with an 
extended range.  All of the SuperComBiHelix structures were combined and ranked according to 
their average energy rank to determine the lowest energy structures. 
 
RESULTS AND DISCUSSION 
 
hMOR structure prediction and comparison to crystallized mMOR 
Shortly after predicting the structure of hMOR, the crystal structure of the mouse mMOR was 
published (PDB ID: 4DKL) (4).  The mMOR has a 99.21% conserved TM sequence identity with 
respect to hMOR, so it is highly likely that the mMOR has an extremely similar structure.  Our 
predicted lowest energy structure for the hMOR has a 1.94 Å backbone RMSD with respect to 
mMOR (Table 7.5 and Figure 7.2).  Of the lowest energy predicted structures, the conformation 
TM Theta angle sampling Phi angle sampling Eta angle sampling
1 -10, 0, 10 -30, -15, 0,  15, 30 -30, -15, 0,  15, 30
2 -10, 0, 10 -30, -15, 0,  15, 30 -30, -15, 0,  15, 30
3 -10, 0, 10 -30, -15, 0,  15, 30 -30, -15, 0,  15, 30
4 -10, 0, 10 -30, -15, 0,  15, 30 -30, -15, 0,  15, 30
5 -10, 0, 10 -45, -30, -15, 0,  15, 30 -30, -15,  0,  15, 30, 45, 60
6 -10, 0, 10 -30 ,-15, 0,  15, 30 -30, -15, 0,  15, 30
7 -10, 0, 10 -30, -15, 0,  15, 30 -30, -15, 0,  15, 30
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ranked eighth according to lowest average energy rank (WT8) has the lowest backbone RMSD 
with 1.78 Å.  The range in backbone RMSD in our top ten predicted structures according to 
average energy rank is 1.78 - 2.04 Å, which is a close range and smaller than 2.80 Å, the crystal 
resolution of the mMOR.  Because of the high percentage of conserved sequence identity and the 
small backbone RMSD value with respect to the crystallized mMOR, we trust our predicted 
structures of hMOR.  The structure with ‘0’ for all the angles, the hCXCR4 homology model, was 
close to having the lowest RMSD at 1.80 Å, but it was ranked tenth in energy.  Since the helical 
sampling produced a structure with a slightly smaller RMSD and more favorable energies, the 
GEnSeMBLE method improved upon the homology model and shows the importance of helical 
sampling. 
 
Table 7.5 Changes in theta (θ, tilt) angles, phi (ϕ, sweep) angles, eta (η, rotation) angles, and backbone 
RMSD of low energy predicted hMOR structures with respect to the crystallized mMOR (PDB ID: 4DKL) 
(4). 
 
Theta TM1 TM2 TM3 TM4 TM5 TM6 TM7 Phi TM1 TM2 TM3 TM4 TM5 TM6 TM7 Eta TM1 TM2 TM3 TM4 TM5 TM6 TM7 7TM RMSD (Å)
Theta 0 0 0 0 0 0 0 Phi 0 0 0 15 -15 0 -15 Eta 0 0 0 15 15 0 0 1.94
Theta 0 0 0 0 0 0 0 Phi 0 0 0 0 -15 0 -15 Eta 0 0 0 0 15 0 0 1.98
Theta 0 0 0 0 0 0 0 Phi 0 0 0 0 -15 15 -15 Eta 0 0 0 0 15 0 0 2.02
Theta 0 0 0 0 0 0 0 Phi 0 0 0 15 -15 0 -15 Eta 0 0 -15 0 15 0 0 1.98
Theta 0 0 0 0 0 0 0 Phi 0 0 0 15 -15 0 -15 Eta 0 0 0 0 15 0 0 1.96
Theta 0 0 0 0 0 0 0 Phi 0 0 0 0 -15 0 0 Eta 0 0 0 0 15 0 0 1.90
Theta 0 0 0 0 0 0 0 Phi 0 0 0 30 -15 0 15 Eta 0 0 0 15 15 0 0 1.81
Theta 0 0 0 0 0 0 0 Phi 0 0 0 15 0 0 0 Eta 0 0 0 0 -15 0 0 1.78
Theta 0 0 0 0 0 0 0 Phi 0 0 0 -15 -15 0 -15 Eta 0 0 -15 0 15 0 0 2.04
Theta 0 0 0 0 0 0 0 Phi 0 0 0 0 0 0 0 Eta 0 0 0 0 0 0 0 1.80
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Figure 7.2 Comparison of the crystallized mMOR receptor (blue) (PDB ID: 4DKL) and the lowest energy 
predicted hMOR structure (red).  Backbone RMSD of the TMs is 1.94 Å. 
 
All ten predicted structures in Table 7.5 have a TM1-TM2-TM3-TM7 hydrogen bond network 
similar to the ones shown for hMOR and the crystallized mMOR in Figure 7.3.  Our hMOR 
structures predict that N1.50 forms a hydrogen bond with the S7.46 backbone amide oxygen, 
which is also observed in mMOR.  In this crystal structure, there is a water-mediated hydrogen 
bond between D2.50 and N3.35.  The predicted hMOR structure lacks water molecules, so 
instead there is a direct hydrogen bond between D2.50 and N3.35 in eight of the top ten 
predictions including the lowest energy and lowest RMSD poses.  The crystal structure also 
shows that D2.50 has water-mediated interactions with N7.49 and Y7.53.  In the absence of water, 
our lowest energy pose has a hydrogen bond between D2.50 and S7.46.  The D2.50 residue is 
5.94 Å away from N7.49—close enough for a water-mediated hydrogen bond.  In most class A 
GPCRs, the N7.49 residue usually interacts with D2.50, but that is not the case in the mMOR 
crystal or the hMOR predicted structures.   In the mMOR crystal, N7.39 is interacting with W6.48 
via a water molecule, whereas in hMOR, there is a direct hydrogen bond.  There is also a D3.32-
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Y7.43 hydrogen bond in the predicted hMOR structures and the mMOR crystal structure as well 
as other crystallized GPCRs such as the Hβ2AR (PDB ID: 2RH1) (30), the turkey β1 adrenergic 
receptor (Tβ1AR) (PDB ID: 2VT4) (38), the human dopamine D3 receptor (hDD3R) (PDB ID: 
3PBL) (39), the human muscarinic M2 receptor (PDB ID: 3UON) (40), and the human 
muscarinic M3 receptor (PDB ID: 4DAJ) (41).  (For the remainder of the chapter, hydrogen 
bonds will be indicated by a ‘-’, and salt bridges will be indicated by a ‘+.’) 
 
 
Figure 7.3 Comparison of the 1-2-3-7 hydrogen bond networks for the crystallized mMOR 
receptor (blue, left) and the lowest energy predicted structure of hMOR (red, right).  Hydrogen 
bonds are indicated with black dotted lines, and their distances and interacting residues are 
labeled.  The green dotted line on the right represents a possible water-mediated hydrogen bond.  
Water molecules are shown in the crystal structure on the left. 
 
As for the TM2-TM3-TM4 hydrogen network, the mMOR crystal structure shows a very standard 
one of N2.45-W4.50 and N2.45-T3.42 connections.  In the lowest energy hMOR predicted 
structure, there is a similar hydrogen bond between N2.45 and N4.46, which is one turn below the 
conserved tryptophan W4.50.  The mMOR crystal structure has also a T3.42-N4.49 hydrogen 
bond, which is in the lowest RMSD predicted hMOR structure.  In the lowest energy predicted 
hMOR structure, T3.42 is 3.34 Å away from N4.49, which is close enough for a possible 
hydrogen bond.  In this structure, W4.50 has a different rotamer than in the mMOR crystal 
structure.  The one in the lowest energy hMOR structure is perpendicular to the membrane rather 
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than parallel to it as in the crystal mMOR and lowest RMSD hMOR structures.  However, in the 
mMOR crystal structure this W4.50 rotamer is forced into position by the 1-monooleoyl-rac-
gylcerol molecule, which is absent from the predicted hMOR structures. 
 
While the predicted hMOR structure and crystallized mMOR structure do have a lot of similar 
polar contacts and structural motifs, there are some differences between the two poses.  Both of 
the lowest energy and lowest RMSD predicted hMOR structures show two salt bridge networks 
absent from the mMOR crystal (Figure 7.4).  The first set involves the DRY motif on the 
intracellular end of TM3 (Figure 7.4A).  In our structures we predict that D3.49 forms a salt 
bridge with R4.40 and a hydrogen bond with Y2.42.  The salt bridge between D3.49 and R4.40 is 
similar to the one observed between D3.49 and R4.37 in hCXCR4 (28), D3.49 and R4.41 in the 
hDD3R (although the side chain of R4.41 was not resolved, PDB ID: 3PBL, chain B) (39), D3.49 
and K4.41 in the predicted structure of CB1 (10; 12), and D3.49 and R4.41 in the predicted 
structure of CB2 (see Chapter VI).  However, the presence of IC2 in the crystallized mMOR 
causes the intracellular portion of TM4 to wind up tighter than anticipated.  This D3.49+R4.40 
salt bridge does not form in the crystal, but instead D3.49 interacts with R179 of the second 
intracellular loop (IC2).  The second set of salt bridges present in hMOR, but not mMOR is 
between K5.39+E5.35+K6.58 on the extracellular end (Figure 7.4B).  In the mMOR crystal, 
K5.39 forms a covalent bond with the β-FNA ligand, so the K5.39 residue cannot form any salt 
bridge.  Meanwhile, the K6.58 residue is forming a hydrogen bond with Q7.31, but the β-FNA 
ligand may be blocking the K6.58 residue’s potential interaction with E5.35. 
 
 
Figure 7.4 Hydrogen bond and salt bridge networks for (A) TMs 2, 3, and 4 and (B) TMs 5 and 6 for the 
lowest energy predicted structure of hMOR.  Hydrogen bonds are indicated with black dotted lines, and 
their distances and interacting residues are labeled. 
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The crystallized mMOR contains a hydrogen bond not predicted in the hMOR structure.  The 
mMOR structure has a hydrogen bond between R3.50 and T6.34.  Since both the hMOR and 
mMOR lack the D6.30 conserved residue, this salt bridge between TM3 and TM6 may 
compensate for the lost ionic lock, which is believed to be important for preventing activation and 
is present in many crystallized GPCRs including bRho (29; 42-47), squid rhodopsin (48; 49), 
hDD3R (39), and thermally stabilized HA2AAR (50) and inactive Tβ1AR (51) and has been 
supported by experimental studies (52; 53).  Perhaps this R3.50-T6.34 hydrogen bond is a polar 
contact important for stabilizing the inactive conformation, and is unique to the MORs.   
 
The differences between the two structures described above, however, are very few, and the 
overall conformation of the receptors is very similar.  Furthermore, the hMOR structure was 
predicted without loops, water molecules, or the β-FNA antagonist, which impact the residues’ 
interactions and the TMs’ backbone conformations.  Even though there is a very high conserved 
sequence identity percentage between mMOR and hMOR, that does not guarantee that the two 
species’ receptor structures are identical.  As discussed below, a single mutation can have 
significant impact on the receptor’s function and thereby structure (13).  Yet, it is reasonable to 
expect a strong similarity between the two receptors’ structures, which is what is observed and 
thereby gives credence to the hMOR predictions. 
 
Local sampling of mMOR crystal structure: Identifying lower energy structures 
As stated above, mMOR was crystallized in the presence of an antagonist, β-FNA, which is 
covalently bound to K5.39.  It is assumed that the crystallization process captures the 
physiologically relevant receptor structure.  According to Boltzmann’s distribution, the lowest 
energy state is the most populated (54; 55).  However, there are multiple issues to consider when 
analyzing crystal structures.  First, GPCRs can have multiple inactive and active conformations 
(56), and crystal structures are just snapshots of a very dynamic and flexible macromolecule.  
Second, crystal packing can have an effect on the receptor structure, especially if receptors from 
different unit cells interact with one another.  Third, multiple GPCRs, including mMOR, have 
been crystallized with a T4 lysozyme to replace IC3 and stabilize the receptor conformation.  Yet, 
the fusion of the lysozyme protein to the GPCR may impact the structure, especially the attached 
TM5 and TM6.  Fourth, ligands can impact the receptor structure so that it will not resemble the 
apo-form lacking a ligand.  This last issue is rarely a problem, but it is particularly important for 
the β-FNA antagonist in mMOR.  The covalent bond between the ligand and the receptor might 
impact the receptor structure, especially TM5.  Here, we used SuperBiHelix to sample local theta 
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(θ, tilt), phi (ϕ, sweep) and eta (η, rotation) angles to obtain a more energetically favorable 
structure than the crystal conformation. 
 
Table 7.6 shows the top ten average energy rank mMOR structures using homologized mMOR 
helices and extensive local sampling.  The range of backbone RMSD is between 0.00 and 2.06 Å.  
None of the helices preferred a different tilt (θ) angle (data not shown in the table), but changes in 
the sweep (ϕ) angles ranged from -45º to 0º, and changes in the rotation (η) angles ranged from  
-15º to 45º.  The vast majority of the helix sweeps and rotations occurred in TM5 as expected 
because β-FNA is not present to anchor or restrain TM5.  TM5 rotates and/or sweeps as much as 
45º, whereas TMs 4 and 6 sweep 15º, and TM3 rotates 15º.  TMs 1 and 2 do not experience any 
tilt, sweep, or rotation.  The crystal structure, represented by all ‘0º’ for angles, is ranked sixth, 
which means five structures with more favorable energies were identified with local sampling.  
The backbone RMSD values of these five conformations is rather small with the top four having 
values less than 1.0 Å.  The ten structures shown below have backbone RMSDs well below the 
crystal resolution of mMOR with 2.8 Å (4).  However, even though the differences in the 
structures are slight, they are other more energetically favorable TM bundles identified via 
thorough sampling.  Hence, the crystallized structure may not be the most accurate representation 
of mMOR. 
 
Table 7.6 Predicted structures of mMOR after local sampling the crystallized mMOR (PDB ID: 4DKL) (4) 
structure with SuperBiHelix (11).  Changes in phi, (ϕ, sweep) angles, eta (η, rotation) angles, and backbone 
RMSD of predicted mMOR 7TM bundles with respect to the crystallized mMOR (PDB ID: 4DKL) (4) are 
shown. 
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Structural differences in hMOR CAMs can explain functional differences 
Previous studies with CB1 have shown that our GEnSeMBLE structural prediction methods are 
sensitive enough to detect the conformational impact, which explains the functional impact, 
caused by a single point mutation (10; 12).  Here, we apply these techniques to single and double 
point mutations to observe conformational changes that could possibly explain changes in agonist 
binding affinity (Table 7.1).  Furthermore, the experimental data that we are using for 
comparison was done with the rMOR sequence (13), but these residues are conserved in the 
hMOR sequence.  Even though rMOR and hMOR share a 99.21% sequence identity in the TMs, 
a single point mutation can have a serious affect on function as the experiment discussed here 
proves, so the goal of the analysis below is to predict if the trends in the rat sequence experiments 
would be applicable to the human one.   
 
Since the crystallized mMOR receptor was available, we used it to create homologized helices for 
the WT hMOR and its five single and double point mutants.  At the ComBiHelix stage, which 
consists of sampling 360º of rotation angles for the entire 7TM bundle, the majority of the most 
energetically favorable receptors’ helices match the crystal structure (Table 7.7).  The only two 
receptors that deviated from the crystal structure were the double mutants, L6.30E/T6.34D and 
L6.30E/T6.34K.  Not surprisingly, the only TM that changed was TM5, and the receptor that had 
the largest RMSD with respect to the crystal structure was L6.30E/T6.34K, which was 
experimentally shown to have a significant binding affinity for the peptide agonist DAMGO and 
for GTPγS, and thus be constitutively active.  What is surprising is that this double mutant has the 
same affinity for the agonist DAMGO that the WT does, but it has a backbone RMSD of 1.84 Å 
with respect to the WT.  It was expected that the agonist would have the same binding affinity for 
similar structures, but it could be that the agonist does not interact with TM5, which is the only 
difference between the two receptors.  The L6.30E/T6.34D sees only a slight change of 30º in 
TM5, but experimentally, it experiences a significant decrease of agonist binding affinity of 447-
fold with respect to the WT receptor.  However, further structural refinement was completed with 
the SuperBiHelix and SuperComBiHelix programs. 
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Table 7.7 Predicted structures of hMOR and respective mutants with the best average energy rank at the 
ComBiHelix level using homologized helices from the crystallized mMOR (PDB ID: 4DKL) (4) template.  
Eta, η (rotation) angles, backbone RMSD of predicted mMOR 7TM bundles with respect to the WT hMOR 
are shown. 
hMOR 
receptor 
Relative activity 
level (13) 
η  (º) 7TM 
RMSD 
  TM1 TM2 TM3 TM4 TM5 TM6 TM7 (Å) 
L6.30E/ 
T6.34D 
Very inactive 0 0 0 0 -30 0 0 0.54 
T6.34D Less active 0 0 0 0 0 0 0 0.00 
L6.30E Less active 0 0 0 0 0 0 0 0.00 
WT --------- 0 0 0 0 0 0 0 0.00 
L6.30E/ 
T6.34K 
Same as WT 0 0 0 0 -150 0 0 1.84 
T6.34K More active 0 0 0 0 0 0 0 0.00 
 
After sampling the tilt, sweep, and rotation angles, we developed a consensus of the hydrogen 
bonds and salt bridge patterns for the top 20 structures according to average energy rank for each 
of the six receptors.  Those polar contacts involving the DRY motif at the intracellular end of 
TM3 are shown below in Table 7.8.  These residues interact with those on TM6 to stabilize the 
inactive form and prevent activation and G protein binding.  There are different intracellular polar 
contacts depending upon the mutation, which affects the structure and thus activity level of the 
receptor.  We can explain the different activity levels based on the different interhelical contacts.  
The number of salt bridges and hydrogen bonds involving the DRY motif increases with 
decreasing activation levels.  We predict that the L6.30E/T6.34D mutant has two salt bridges, 
R3.50+T6.34D and R3.50+L6.30E, and a hydrogen bond Y2.43-D3.49.  The TM3+TM6 salt 
bridges include the ionic lock observed in other class A GPCRs and are effective at preventing 
activation.  Four out of the six receptors have an intracellular TM3+TM6 salt bridge with the 
exception being the highly constitutively active T6.34K mutant and the constitutively active WT 
receptor, which does have an R3.50-T6.34 hydrogen bond in the crystallized mMOR.  The 
Y2.43-D3.49 salt bridge is observed in all the receptors except the most active one, T6.34K.  This 
receptor has a T2.39-R3.50 hydrogen bond, which is not observed in any of the other receptors.  
Perhaps this hydrogen bond is necessary for stabilizing the highly constitutively active form of 
hMOR.  Even though these functional experiments were done with the rMOR, our structural 
predictions suggest that the hMOR would show similar trends in activity levels. 
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Table 7.8 Hydrogen bond and salt bridge patterns of the predicted structures of hMOR and respective 
mutants at the using homologized helices from the crystallized mMOR (PDB ID: 4DKL) (4) template. 
hMOR 
receptor 
Relative 
activity 
level 
(13) 
Hydrogen Bond/Salt bridge 
Patterns involving DRY motif 
# Salt 
bridges 
# H-
bonds 
L6.30E/ 
T6.34D 
Very 
inactive 
R3.50+L6.30E, R3.50+T6.34D, 
Y2.42-D3.49 
2 1 
T6.34D Less 
active 
R3.50+T6.34D, Y2.42-D3.49 1 1 
L6.30E Less 
active 
R3.50+L6.30E (ionic lock), 
R3.50-T6.43, Y2.42-D3.49  
1 2 
WT ---------- [R3.50-T6.43 (seen in crystal 
4DKL, not predicted 
structures)], Y2.42-D3.49 
0 1 
L6.30E/ 
T6.34K 
Same 
activity 
as WT 
R3.50+L6.30E (ionic lock), 
Y2.42-D3.49 
1 1 
T6.34K More 
active 
T2.39-R3.50 (no 3+6 
interaction) 
0 1 
 
Surprisingly, the WT and L6.30E/T6.34K receptors have the same level of GTPγS basal and 
agonist DAMGO binding affinity, but the predicted structures are very different.  Figure 7.5A 
shows a comparison of the TM bundles with the WT receptor in red and the double mutant in 
green.  TM5 tilts and rotates significantly, while TM6 experiences some tilting resulting in a 
backbone RMSD of 2.20 Å between the two structures.  It is expected that two receptors with 
such similar functional behaviors would have similar structures as well, but straight homology 
modeling of the L6.30E/T6.34K sequence in the WT structure (Figure 7.5A) shows that the 
resulting conformation is not energetically favorable.  In the straight homology model, T6.34 is 
replaced with the longer side chain of lysine, which would block the formation of the ionic lock 
between R3.50 and L6.30E.  Also, the T6.34K side chain would clash with M5.61.  To alleviate 
high energies resulting from residue clashes, TM5 tilts and rotates to provide space for the long 
lysine side chain. 
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Figure 7.5 Comparison of the predicted structures for the WT (red) and L6.40E/T6.34K (green) mutant 
(A), L6.40E/T6.34K (green) and L6.30E (purple) mutants (B), and L6.40E (purple) and T6.34D (cyan) 
mutants (C).  Straight homology models of L6.30E/T6.34K in the WT template [WT structure with 
L6.30E/T6.34K sequence (A)] and L6.30E/T6.34K in the L6.30E template [L6.30E/T6.34K structure with 
L6.30E sequence (B)] are shown.  An overlap comparison of mutants T6.34D and L6.30E (C) are also 
shown. 
 
In addition, straight homology models of the L6.30E mutant and the L6.30E/T6.34K double 
mutant are energetically unfavorable (Figure 7.5B).  By replacing the threonine residue with the 
lysine one, TM5 tilts and rotates, and the backbone RMSD becomes 1.99 Å.  Similarly to the WT 
and L6.30E/T6.34K double mutant, the straight homology model of the L6.30E/T6.34K sequence 
in the L6.30E template will not produce energetically favorable structures.  By replacing 
threonine with the long lysine side chain, the R3.50+L6.30E ionic lock cannot form due to the 
newly introduced interference.  T6.34K would clash with M5.61, so TM5 moves to accommodate 
the new side chain.  The WT and L6.30E predicted structures are more similar with a backbone 
RMSD of 0.80 Å. 
 
The T6.34D and L6.30E receptors are also functionally similar, but structurally different.  They 
have similar binding affinities in the agonist and the GTPγS binding assays, and their backbone 
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RMSD is rather small at 1.07 Å, but there is significant tilting in TM5 (Figure 7.5C).  By 
overlapping the two receptors’ structures, we see that if the threonine side chain is increased to 
the size and shape of the aspartic acid, then it would clash with M5.61.  Thus, the single point 
mutation causes TM5 to swing out to make room for the new side chain.  Even though these six 
receptor structures show significant differences in the positions of TM5, it has no obvious effect 
on the intracellular hydrogen bond networks involving the DRY motif, the portion of the receptor 
where the G protein binds.  However, TM5 needs to move to provide space for the mutations on 
TM6.  These connections between TM3 and TM6 play important structural, and thereby 
functional, roles. 
 
CONCLUSIONS 
 
We used the homologized helices from the previously crystallized hCXCR4 GPCR and 
GEnSeMBLE methodology to predict the structure of hMOR, which was later verified by the 
crystallized structure of the closely related mMOR.  The backbone RMSD of the two receptors is 
1.94 Å, well within the crystal resolution of 2.80 Å.  The mMOR, crystal structure, however, 
contains an antagonist β-FNA covalently bound to K5.39, which might affect and constrain the 
shape of the receptor.  We performed sampling on the mMOR crystal structure without the ligand 
and found five conformations that we predict to be more favorable in energy with backbone 
RMSDs ranging from 0.52 Å to 1.48 Å with respect to the crystallized mMOR.  Not surprisingly, 
there was great variability in the position and orientation of TM5.  These results show that while 
the crystallized version of mMOR is accurate, it may not be the conformation of the apo-form of 
the receptor.  Finally, using the homologized mMOR helices, we predicted the structures of the 
hMOR WT receptor and five mutants that have different agonist affinities in the rMOR sequence.  
The predicted structures contain intracellular interhelical interactions involving the DRY motif 
that can explain the different levels of activation for the respective receptors.  Salt bridges 
between R3.50 and L6.30E or T6.34D are important for preventing activation.  The highly active 
structure lacks any connections spanning the helical bundle and has a T2.39-R3.50 hydrogen 
bond, which might stabilize the active conformation.  Straight homology models would not be 
sufficient for predicting structures.  Hence, GPCRs like hMOR are flexible and dynamic 
macromolecules that are sensitive to the structural impact of a single residue.  The GEnSeMBLE 
method is particularly useful for predicting GPCR structures because it performs a thorough 
sampling of the helical rotation, tilt, and sweep angles and can detect the energetic impact that a 
single or double point mutation can have on the overall conformation.  Since we have accurate 
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predicted hMOR structures, in the future we will be able to design new ligands that will modulate 
pain and perhaps be the starting scaffold for new medication. 
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ABSTRACT 
 
The bacterium Escherichia coli penetrates the blood brain barrier via sugar moiety chitobiose-
mediated interactions with the human glycoprotein Ecgp96 leading to the onset of the potentially 
lethal neonatal meningitis.  By blocking Ecgp96’s glycosylation site with small molecules, 
chitobiose binding to bacteria and subsequent bacterial invasion can be prevented.  Experimental 
studies show that three ligands, Doxazosin, MSR15, and Telmisartan, are effective at inhibiting 
bacterial invasion.  We use hierarchical docking methods, DarwinDock and GenDock, to dock 
these ligands to Ecgp96 and based on the predicted binding sites, we suggest modifications of the 
three ligands that we predict will be stronger binders and would be more effective at preventing 
bacterial invasion.  Furthermore, we dock the small molecules Geldanamycin and Z154, one of 
the identified strong binders, to the glycosylated form of Ecgp96 and identify two other potential 
regions that ligands would bind to.  We ran virtual ligand screening on the Geldanamycin binding 
site to find novel ligands that could bind to unexplored regions of Ecgp96.  Three of the 500 
ligands selected by DOCK Blaster 3 form three hydrogen bonds with the protein.  The new 
ligands from this study are shared with our experimental collaborators, so that they can synthesize 
them (if needed) and determine their binding affinities and effectiveness at preventing meningitis. 
 
INTRODUCTION 
 
Neonatal meningitis is a serious disease affecting the central nervous system, resulting in hearing 
loss, blindness, convulsions, abnormal speech, mental retardation, and often death.  Lack of 
knowledge about the mechanism of disease onset has inhibited the development of vaccines and 
treatment [for reviews, see (1-4)].  Previous studies from the Nemani and Goddard labs have 
elucidated the process of bacterial invasion causing this disease (5-8).  Escherichia coli K1 is 
transported across the blood-brain barrier (BBB) via sugar moiety-mediated interactions between 
E. coli’s outer membrane protein A (OmpA) and the human glycoprotein Ecgp96 (5).  Ecgp96, a 
receptor with a large sequence identity with the previously crystallized heat shock protein 90 
(Hsp90), is located on the surface of the human brain microvascular cells (HBMCs) (6).  The 
sugar moiety N-acetyl-D-glucosaminyl-β(1-4)-N-acetyl-D-glucosamine (chitobiose) binds to one 
of three glycosylation sites on the protein (including N142 and N252 in the model discussed 
below), facilitating interactions between Ecgp96 and OmpA.  Recently published work from the 
Goddard and Nemani labs indicate that the chitobiose epitopes bind to the loops of OmpA (7).  
Ecgp96 has been experimentally proven to associate with the angiotensin II type 1 receptor 
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(AT1R), and it is hypothesized that this molecular complex governs protein kinase C-α (PKC-α) 
phosphorylation during E. coli invasion (9).   
 
Currently, we are interested in finding where chitobiose interacts with Ecgp96.  Previously, Dr. 
Tod Pascal and co-workers of the Goddard lab computationally docked 52 ligands that had been 
crystallized with Hsp90 and used the 15 lowest energy binders with the software program Phase 
to produce a pharmacophore of the Hsp90 binding site.  Virtual ligand screening (VLS) identified 
2000 small molecules out of a database of 2 million ligands that at least partially matched this 
proposed pharmacophore.  Fifty ligands, 45 of which exactly matched the pharmacophore, were 
selected to dock to Ecgp96.  Prof. Nemani’s lab tested the Goddard lab’s ligand recommendations 
as well as others synthesized by a collaborator with the pharmacophore in mind.   
 
Table 8.1 shows three of the seven ligands that were effective in preventing bacterial invasion: 
MSR15, Doxazosin, and Telmisartan with the latter two in the list of 50 ligands obtained above.   
The inhibition percentage in Table 8.1 ranges from 90.8% with Doxazosin to 74.5% with 
Telmisartan.  Doxazosin, an alpha-blocker that treats high blood pressure, and Telmisartan, an 
AT1R blocker that treats hypertension, are both commercially available.  Telmisartan is 
especially interesting because of when it binds to the AT1R, which interacts with Ecgp96, the 
drug prevents PKC-α phosphorylation and subsequent bacterial invasion and onset of meningitis 
in mouse models (9).  Also, the AT1R blocker Candesartan has been shown to bind directly to the 
Ecgp96 homologue Hsp90 (10), which suggests Telmisartan might bind to Ecgp96 as well as the 
AT1R in the protein complex (9).  MSR15 was specially synthesized for this study.  Here, we 
dock these three ligands discussed above to identify their respective binding sites, and then we 
offer suggestions for new derivatives with enhanced affinity for interacting with Ecgp96.  We 
expect that these ligands will be more effective in inhibiting bacterial invasion. 
 
Table 8.1 Percentage of E. coli inhibition caused by ligands matching a pharmacophore generated based on 
computational docking studies of known ligands to similar protein Hsp90. 
Ligand Average Bacterial Inhibition 
Doxazosin 90.8% 
MSR15 78.7% 
Telmisartan 74.5% 
 
As noted above, Hsp90 and Ecgp96 contain glycosylation sites.  However, Hsp90 has not been 
crystallized with a ligand in its glycosylated form [for example, see (11)], so it is unknown where 
co-crystallized molecules like Geldanamycin would bind in the presence of the glycans.  We 
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consider this possibility by docking Geldanamycin to five different regions of the glycosylated 
Ecgp96 protein and find that the ligand has more favorable binding energies with other regions of 
the protein if the glycosylated unit is present in the traditional ATP binding site.  Since we have 
identified possible novel binding sites that have not been explored before, we conduct virtual 
ligand screening (VLS) to identify small molecules that could preferentially bind to this portion 
of the protein that is accessible in the biologically relevant glycosylated form. 
 
METHODS 
 
(For more details about docking methodology, see Chapter II.) 
 
Preparing the protein Ecgp96 model 
Previous work from the Goddard lab suggests that Ecgp96 has one transmembrane region and a 
solvent-exposed globular portion, which contains two of the three glycosylation sites where 
chitobiose can interact (N142 and N252).  One of the sites, residue numbers 142-145 with a 
sequence of NASD, is located in the ATP binding site.  In previous work, a model of human 
Ecgp96 protein residue numbers 102 to 618 was constructed using a homology model based on 
the Hsp90 crystal structure due to the two proteins’ high sequence identity.  Pascal et al. used 
Swiss Model software to generate the structure of the globular portion of Ecgp96 consisting of 
191 residues based on the Hsp90 crystal structure.  Spheres were generated for this SGB (12) 
solvated version of this predicted protein structure.  The actual protein used for docking has 
CHARMM (13) charges and neutralized terminal ends and was not minimized in a solvated 
environment, but since its heteroatom RMSD is 0.195 Å with respect to the solvated protein, the 
sphere sets for the two proteins should not differ significantly.  Doxazosin, Telmisartan, and 
MSR15 were docked to the model of protein before minimization with SGB solvation.  
Geldanamycin was docked to the same model after SGB solvated minimization.  Spheres were 
regenerated for the protein after minimization. 
 
To create the glycosylated version of the Ecgp96 protein, we abstracted glycosylated sugars from 
the crystal structure of human glucosylceramidase (PDB ID: 2V3F) (14) and linked them to either 
N142 and N252, both Ecgp96 glycosylation sites, of the Ecgp model after minimization with 
SGB solvation.  The N-linked glycan consists of two N-acetyl-D-glucosamine monosaccharides 
and a terminal alpha-D-mannose sugar. 
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In order to locate binding sites for various ligands, we generated five sphere regions each for the 
non-minimized and minimized forms of the protein.  Two sphere sets for the minimized protein 
are indicated in Figure 8.1.  Region 1, in yellow, is particularly important because it contains one 
of the glycosylation sites at residue N142.  This is the conserved residue that Geldanamycin (11) 
and ATP (15) bind to in the crystallized Hsp90 proteins.  Ligands docked to Region 2, in purple, 
form favorable or low energy complexes with the glycosylated protein that will be discussed 
below. 
 
 
Figure 8.1 Two of the five regions of the solvated minimized human Ecgp96 protein to which small 
molecule ligands were docked to.  Region 1 (yellow) contains the glycosylation site involving residues 
N142 and D145.  Region 2 (purple) does not cover any glycosylation site, but ligands have strong binding 
energies in this space on the glycosylated protein. 
 
Constructing small molecule ligands 
Ligands were constructed with Maestro software (16) and used Jaguar software (17) to determine 
Mulliken charges.  A MacroModel (18; 19) conformational search was performed as described in 
Chapter II. Two hundred and forty-four poses of Doxazosin, 825 poses of MSR15, and 3309 
poses of Telmisartan were minimized with SGB solvation (12) for 100 steps.  Four hundred and 
sixty-two poses of Z154 were minimized with SGB solvation for 200 steps or to the RMS 
threshold of 0.1 kcal/mol/Å.  The poses of Doxazosin and Telmisartan were clustered twice with 
a diversity of 2.0 Å, whereas the poses of MSR15 were clustered by 2.0 Å, then 2.5 Å, and the 
poses of Z154 were clustered for two rounds, each with a diversity of 1.0 Å.  Ten conformations 
of Doxazosin, 10 conformations of MSR15, 11 conformations of Telmisartan, and 17 
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conformations of Z154 were used for docking. After clustering, the ligand poses are minimized 
100 steps with MPSim software (20) and SGB solvation.  
 
Geldanamycin, one of the ligands used for docking, was extracted from the crystallized Hsp90 
(PDB ID: 1YET) (11).  Geldanamycin was minimized 361 steps to an RMS threshold of 0.2 
kcal/mol/Å using MPSim (20) software with SGB solvation and the Dreiding III (21) force field 
with the Lennard-Jones van der Waals (vdw) potential. 
 
Docking small molecules to Ecgp96 
To determine how these three ligands interact with the Ecgp96, we used DarwinDock and 
GenDock hierarchical docking programs (22-26).  The DarwinDock program generated 5000 
poses with DOCK 6 (27) of the ligand in the alanized protein, clustered similar poses within a 
specified diversity of 2.0 Å into families, and generated 5000 new conformations.  This cycle was 
repeated until no more new conformations could be generated, or no more than 2% of the current 
number of families could be created.  Overall approximately 50,000 poses were generated and 
clustered into ~1500 families.  A family head, average representative of each family, was chosen 
and the respective energies were calculated.  The 10% of family heads with lowest energies were 
selected, and the energies were evaluated for all the members of these families.  From these 
poses, fifty poses were chosen with the lowest polar energy, fifty were chosen with the lowest 
phobic energy, and fifty were chosen with the lowest total energy. 
 
The next step was to refine the selected docked poses.  The bulky hydrophobic groups replaced 
the smaller alanine residues, and simultaneously polar residues in the binding sites were 
optimized using the program Side chain Rotamer Excitation Method analysis (SCREAM) (28).  
The complex was minimized 10 steps.  Then the charged residues (D, E, H, K, R) were 
neutralized because electrostatic interactions can have a large impact on energy calculations, and, 
again, the complex was minimized by 10 steps.  Finally, the entire complex was minimized 100 
steps and ranked according to various energy categories including the local cavity energy, binding 
energy, full Delphi energy, partial Delphi energy, total energy, and unified cavity energy.  Local 
cavity energy is the interaction between the ligand and the residues in the binding sites.  The 
binding energy is the equivalent of the protein and ligand energies subtracted from the complex 
energy.  The full Delphi energy is the energy of the solvated complex, and the partial Delphi 
energy is the energy with only the ligand solvated.  The unified cavity energy equals the energy 
of the ligand and the residues of the binding site of any ligand pose generated. 
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Neutral versions of Doxazosin, MSR15, and Telmisartan were docked to the non-glycosylated 
form of Ecgp96.  Geldanamycin was docked to both the non-glycosylated and the glycosylated 
versions of Ecgp96.  Z154 was docked to only the glycosylated form of this protein. 
 
Matching novel ligands into the binding site of docked ligands 
The ultimate goal of this study was to identify new ligands that have strong binding affinities for 
Ecgp96 and prevent chitobiose binding.  The online database PubChem (29) was used to search 
for known small molecules.  The online server ALOGPS 2.1 (30) calculated the solubility values 
of the ligands.  To verify the effectiveness of binding, we matched the derivatives to the original 
ligand pose of the docked complex.  The generated charged ligand pose was extracted from the 
complex generated during the initial step DarwinDock.  In Maestro, it was altered to resemble the 
derivative.  The resulting ligand was minimized in MacroModel with the solvent specified and 
dielectric constant specified for water.  The OPLS-2005 force field (31) was used for 
minimization.  Mulliken charges were calculated with Jaguar software.  The new ligand was 
inserted into the respective alanized version of Ecgp96 matching the protein the original ligands 
were docked to.  Subsequently, all the original residues replaced the alanines, and residues in the 
binding site were optimized using the SCREAM program.  These residues were specified in the 
second step of the original docking procedure of DarwinDock.  Then, selected individual residues 
in the binding site were optimized with SCREAM in order to maximize their interactions with the 
ligand.  Forty rotamers were produced.  All 41 complexes were minimized by 10 steps in vacuum 
with the MPSim program (20) and the universal force field Dreiding III (21).  These complexes 
were neutralized and completely minimized using the last two modules in GenDock. 
 
VLS with DOCK Blaster 3 to identify novel ligands to bind to the glycosylated Ecgp96 
After docking Geldanamycin to our model of the glycosylated human glycoprotein Ecgp96, we 
identified the lowest energy binding site for the ligand (Figure 8.1), which is different from the 
non-glycosylated Geldanamycin binding site.  We performed VLS to identify possible ligands 
that would bind to this new site when the protein is glycosylated. 
 
We took the glycosylated Ecgp96-Geldanamycin complex with the lowest binding and cavity 
energies with strain and ligand solvation, removed the ligand, and selected the residues that were 
within 6 Å of the docked Geldanamycin.  The glycosylated Ecgp96 protein was our target, and 
the selected residues were the binding site provided to DOCK Blaster 3 (32).  DOCK Blaster 
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docked small molecules from a database to the provided structure and ranked them according to 
energy.  The structures of 500 lowest energy ligands, or hits, were provided.  We chose 19 low 
energy hits with significant structural differences. 
 
We enriched and evaluated the complexes using a force field and program, GenDock, created in 
our lab.  First, we calculated the Mulliken charges for the ligands using Maestro (16) and Jaguar 
(17) software by performing a single energy point calculation with density functional theory 
(DFT), the B3LYP functional, and the 6-31G** basis set.  The ligands were merged with an 
alanized form of the glycosylated Ecgp96 protein.  By ‘alanized,’ we mean that the large, bulky 
hydrophobic residues (M, F, I, L, Y, V, W) were replaced with alanine residues.  Then, we used 
the SCREAM program (28) to replace the alanines with the correct sequence and to sample 
different rotamers of all the residues within 4 Å of the ligand before minimizing the entire 
complex for 10 steps.  The next step was to neutralize the protein by removing protons from the 
basic residues (R, K, and H) and adding protons to the acidic residues (D and E).  Lastly, we 
minimized the complex by 110 steps and determined the binding energy.  We used the Dreiding 
III force field (21) with the exponential-6 term replaced with the Lennard-Jones term (DIIIFF-LJ) 
to evaluate energies. 
 
RESULTS AND DISCUSSION 
 
Doxazosin derivatives can attach fluorophores to track Ecgp96 at the BBB 
Previous studies indicate that Doxazosin is the most effective in preventing bacterial invasion, as 
seen in Table 8.1.  Figure 8.2 shows our docking results, where complexes were selected based 
on their lowest energy ranking in the most number of categories including binding energy, 
binding energy with ligand strain, binding energy with Delphi solvation and ligand strain, full 
Delphi, partial Delphi, and total energy.  Doxazosin forms five hydrogen bonds, two with 
residues N142 and D145, which are located in one of the glycosylation sites.  Thus, our results 
agree with experimental data because Doxazosin can prevent chitobiose from interacting with the 
glycosylation site.  Another two hydrogen bonds are formed with backbone amide protons of 
G233 and F234, so mutations would not affect the binding of Doxazosin or its effectiveness in 
preventing bacterial invasion.  The fifth hydrogen bond is formed with T280.  The ligand also has 
hydrophobic interactions with V232 and M189. 
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Figure 8.2 Doxazosin docked to human Ecgp96 using GenDock.  This Doxazosin-Ecgp96 pose has the 
lowest binding energy, binding energy with strain, binding energy with delphi solvation and strain, full 
delphi, partial delphi, and total energy.  The prediction shows that Doxazosin forms five hydrogen bonds 
with T280, D145, N142, and with the backbone amide protons of G233 and F234.  D145 and N142 are 
residues in one of the glycosylation sites, so our results indicate that Doxazosin would be effective in 
blocking that region from interactions with chitobiose, which agrees with experimental data.  Hydrogen 
bonds are indicated by black dotted lines in the pictures and are in bold red in the tables.  The cavity 
analysis breaks down the non-bonding energy into van der Waals (vdW), coulombic (Coulomb), and 
hydrogen bond (H-Bond) interactions.  Only residues whose energetic interactions are greater than 1 
kcal/mol are shown in the table. 
 
In future studies, our experimental collaborators will attach a fluorophore to a ligand to monitor 
Ecgp96’s behavior after binding to the small molecule.  Our proposed Doxazosin derivatives, 
which are shown in Figures 8.3B-D, are functionalized with a ketone, for example Pubchem 
compound ID (CID) 15591670 (S4.2) and CID15591672 (S4.3), or a sulfonamide, such as 
CID15591676 (S4.4), so that they can react and attach to the fluorophore.  Matching results, or 
altering the docked ligand conformation within the protein to resemble the derivative, show that 
these functional groups are exposed to the solvent and in turn suggest that the attached 
fluorophore would not disrupt the ligands’ binding to Ecgp96.  
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Figure 8.3 Schematic drawings of (A) Doxazosin and the proposed derivatives including (B) Pubchem 
compound ID (CID) 15591670 (S4.2), (C) CID15591672 (S4.3), and (D) CID15591676 (S4.4).  Red 
portions of the ligand are parts altered from the Doxazosin scaffold.  
 
Furthermore, the energy results of matching the derivatives to Doxazosin show that the calculated 
interactions energies will decrease, or become more favorable, as seen in Table 8.2.  For 
example, CID15591670 (S4.2) is significantly lower in local cavity energy, binding energy, full 
Delphi energy, and unified cavity energy.  Lower binding and cavity energies suggest that these 
derivatives have a stronger interaction with Ecgp96 and could possibly be more effective than 
Doxazosin in preventing chitobiose-mediated interactions with E. coli at the BBB.  
 
Table 8.2 Energy results of matching the Doxazosin derivative ligands shown in Figure 8.2B-D to the 
Doxazosin-Ecgp-96 complex shown in Figure 8.1.  All the derivatives are lower than or comparable to 
Doxazosin in various energy types and are significantly lower in terms of unified cavity energy.  In these 
complex poses, the red portions of the ligands are exposed and can be functionalized by fluorescent tags. 
Ligand 
 
Local Cavity 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Full 
Delphi 
(kcal/mol) 
Partial 
Delphi 
(kcal/mol) 
Total 
Energy 
(kcal/mol) 
Unified Cavity 
Energy 
(kcal/mol) 
Doxazosin -45.56 -69.88 -29.17 -47.75 -869.80 -41.17 
15591670 (S4.2) -47.75 -71.78 -34.48 -48.38 -831.86 -47.75 
15591672 (S4.3) -48.85 -73.48 -37.27 -50.25 -839.02 -48.85 
15591676 (S4.4) -49.95 -74.08 -35.35 -48.05 -765.87 -49.95 
 
MSR15 blocks the glycosylation site and chitobiose interactions 
MSR15 is the only ligand discussed here that is not commercially available since it was 
synthesized by Prof. Nemani’s collaborators.  It is the second-most effective ligand in blocking 
bacterial invasion because it was successful in doing so for 78.7% of all cases.  Figure 8.4 shows 
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our proposed binding site generated from docking MSR15 to Ecgp96.  MSR15 forms four 
hydrogen bonds with two residues, N142 and T280.  N142 is one of the residues in the 
glycosylation site, so our results support experimental data because we prove that MSR15 is 
effective in blocking the site from chitobiose. 
 
 
Figure 8.4 MSR15 docked to human Ecgp96 using GenDock.  This MSR15-Ecgp96 pose has the lowest 
binding energy, partial delphi, and unified cavity energy.  The prediction shows that MSR15 forms four 
hydrogen bonds with T280 and N142.  N142 is in one of the glycosylation sites, so our prediction indicates 
that MSR15 can block chitobiose from interacting with the protein, which agrees with experimental data.  
Hydrogen bonds are indicated by black dotted lines in the pictures and are in bold red in the tables.  The 
cavity analysis breaks down the non-bonding energy into van der Waals (vdW), coulombic (Coulomb), and 
hydrogen bond (H-Bond) interactions.  Only residues whose energetic interactions are greater than 1 
kcal/mol are shown in the table. 
 
Based on the binding site in Figure 8.4, we identified several derivatives of MSR15 as shown in 
Figures 8.5B-G.  Ligands in Figures 8.5B-E were found in a search of the database PubChem 
(29).  The other two ligands in Figures 8.5F and 8.5G were designed based on the binding site.  
Ligands in Figures 8.5B-D are commercially available and can be purchased from from the 
vendor Ambinter, while the other ligands need to be synthesized.   
 
 
 189 
 
Figure 8.5 Schematic drawings of (A) MSR15 and the proposed derivatives including  (B) Ambinter ID 
(AID) 81805868 (S5.1), (C) AID82150035 (S5.4), (D) AID83257400 (S5.8), (E) CID7379308 (S5.9), and 
our own designs (F) S5.14 and (G) S5.16.  Red portions of the ligand are parts altered from the MSR15 
scaffold.  Ligands B-D are commercially available from Ambinter.  Ligands E-G need to be synthesized. 
 
Our results from matching the ligand derivatives to MSR15 in the Ecgp96 complex are shown in 
Table 8.3.  All of the ligands included are lower (more favorable) or comparable in energy to 
MSR15.  Ligand S5.14 shows the most improvement because its complex’s unified cavity energy 
is 10 kcal/mol lower and its full Delphi energy is 30 kcal/mol lower than that of the MSR15 
complex.  Complexes with derivatives AID82150035 (S5.4) and AID83257400 (S5.8) do not 
show a significant improvement, but they are included here since the ligands are commercially 
available and are easier to purchase than MSR15. 
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Table 8.3 Energy results of matching the MSR15 derivative ligands shown in Figure 8.5B-F to the 
MSR15-Ecgp96 complex shown in Figure 8.3.  All the derivatives are lower than or comparable to MSR15 
in various energy types. 
Ligand Local 
Cavity 
Energy 
(kcal/mol) 
Binding  
Energy 
(kcal/mol) 
Full Delphi 
Energy 
(kcal/mol) 
Partial 
Delphi 
Energy 
(kcal/mol) 
Total 
Energy 
(kcal/mol) 
Unified 
Cavity 
Energy 
(kcal/mol)  
MSR15 -28.64 -53.75 -33.24 -45.17 -766.97 -30.48 
81805868 (S5.1) -34.53 -56.42 -34.28 -44.88 -760.83 -36.38 
82150035 (S5.4) -30.01 -53.64 -19.98 -35.25 -776.77 -31.03 
83257400 (S5.8) -28.73 -54.72 -31.28 -42.77 -812.04 -31.60 
7379308 (S5.9) -34.76 -64.32 -41.61 -51.13 -822.92 -34.76 
S5.14 -38.68 -77.74 -63.53 -48.84 -871.81 -40.64 
S5.16 -32.92 -69.76 -46.20 -55.86 -818.96 -34.49 
 
Telmisartan has strong binding energies for the Ecgp96 protein 
Unlike Doxazosin and MSR15, we have some knowledge about how Telmisartan binding impacts 
the bacterial invasion mechanism.  While it has been shown that Telmisartan interacts with AT1R 
that is in complex with Ecgp96 (9), we show here that Telmisartan has strong binding energies 
with the Ecgp96 protein itself and suggest that it may bind to either protein.  Previously, another 
AT1R blocker has been proven to bind directly to the similar Hsp90 protein (10), so it is likely 
that Telmisartan can bind to Ecgp96.  Telmisartan is effective in preventing bacterial invasion 
with a 74.5% success rate, but its usefulness is hampered by its low solubility value.  The 
ALOGPS 2.1 predicted solubility of Telmisartan is 3.50 mg/l.  This concentration is relatively 
low compared with Doxazosin whose solubility is predicted to be 790 mg/l.  Our goal is to 
develop a ligand that has an equally strong binding affinity for Ecgp96 as Telmisartan, but is 
more soluble. 
 
Figure 8.6 shows the lowest local cavity and unified cavity energy product from docking 
Telmisartan to Ecgp96.  Telmisartan forms two hydrogen bonds with D145 and K149.  Our 
docking results support experimental data because D145 is part of one of the glycosylation sites.  
Telmisartan also has significant non-bonding interactions with N142, another residue in the 
glycosylation site.   Therefore, Telmisartan blocks chitobiose from interacting with Ecgp96.  
Based on this proposed binding pose, derivatives of Telmisartan were designed to maximize 
favorable interactions with surrounding residues as well as improve the solubility.  
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Figure 8.6 Telmisartan docked to human Ecgp96 using GenDock.  This Telmisartan-Ecgp96 pose has the 
lowest local cavity energy and unified cavity energy.  The prediction shows that telmisartan forms two 
hydrogen bonds with D145 and K149.  D145 is a residue in one of the glycosylation sites, so our results 
indicate that Telmisartan would be effective in blocking that region from chitobiose interactions, which 
agrees with experimental data.  Hydrogen bonds are indicated by black dotted lines in the pictures and are 
in bold red in the tables.  The cavity analysis breaks down the non-bonding energy into van der Waals 
(vdW), coulombic (Coulomb), and hydrogen bond (H-Bond) interactions.  Only residues whose energetic 
interactions are greater than 1 kcal/mol are shown in the table. 
 
Figure 8.7B shows TelmisartanB, a ligand synthesized in Prof. Brian Stoltz’s lab and tested for 
effectiveness by Prof. Nemani’s group (9). We predict that its solubility value is 4.70 mg/l, which 
is a slight improvement over Telmisartan (see Table 8.4).  Furthermore, it is experimentally 
proven to be equally effective at preventing the onset of meningitis in mouse models (9).  Table 
8.5 shows a comparison of our calculated energies for matched poses with the original docked 
Telmisartan-Ecgp96 complex.  TelmisartanB is at least 7 kcal/mol lower in energy in every 
energy category except total energy.  Our docking results support experimental observations 
because we have shown that TelmisartanB has a strong affinity for interacting with Ecgp96. 
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Figure 8.7 Schematic drawings of (A) Telmisartan and the proposed derivatives including (B) 
TelmisartanB, (C) S6.10, (D) S6.11, (E) S6.12, and (F) S6.13.  Red portions of the ligand are parts altered 
from the Telmisartan scaffold.  Ligand B was designed and synthesized by Prof. Brian Stoltz and co-
workers, and has been experimentally shown to be as effective as Telmisartan in inhibiting bacterial 
invasion.  Ligands C-G were designed by the Goddard group members and need to be synthesized by 
collaborators.  All the derivatives have higher solubility than Telmisartan. 
 
Table 8.4  Calculated ALOGPS 2.1 solubility values of Telmisartan shown in Figure 8.7A and the 
Telmisartan derivative ligands shown in Figure 8.7B-F.  All the derivatives are two to ten times lower than 
Telmisartan in solubility. 
 
 
 
 
 
 
 
 
 
 
Ligand Solubility (mg/l) 
Telmisartan 3.50 
TelmisartanB 4.71 
S6.10 30.15 
S6.11 14.23 
S6.12 29.43 
S6.13 7.67 
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Table 8.5 Energy results of matching the telmisartan derivative ligands shown in Figure 8.7B-F to the 
Telmisartan-Ecgp96 complex shown in Figure 8.6.  All the derivatives are lower than or comparable to 
Telmisartan in various energy types.  TelmisartanB is significantly lower in local cavity energy, binding 
energy, full Delphi energy, partial delphi energy, and unified cavity energy.  Experimental evidence 
supports our matching results because experiments indicate that TelmisartanB is equally effective as 
Telmisartan in preventing bacterial invasion. 
 
Figures 8.7C-F are Telmisartan derivatives that we designed based on our predicted binding site.  
A solubility comparison is shown in Table 8.4.  Our proposed ligands have improved solubility 
values that are two to ten times larger than that of Telmisartan.  Table 8.4 shows that not only do 
the ligands have better solubility, but more affinity for the protein.  All the ligands are lower in 
local cavity, total, and unified cavity energies.  Ligand S6.12’s pose shows the largest 
improvement in energies over Telmisartan.  For example, its unified cavity energy is 16.5 
kcal/mol lower in energy, and its binding energy is 14 kcal/mol lower in energy than the docked 
Telmisartan pose.  The next step is to dock these poses to see if there are any lower energy 
binding sites for the ligands. 
 
Geldanamycin would preferentially bind to a different site depending upon glycosylation 
To test the impact of glycosylation on known ligand binding, we docked Geldanamycin to  
unglycosylated forms of Hsp90 and Ecgp96 to compare with the crystallized version of the 
Hsp90-Geldanamycin complex.  Upon confirming that we can accurately reproduce the correct 
ligand pose in the binding site for both proteins, we docked Geldanamycin to the glycosylated 
form of the protein to identify which region of the protein produces a binding site with the most 
favorable binding energies.  We docked Geldanamycin to all five regions of the non-glycosylated 
and solvated minimized human Ecgp96 protein and ranked the complexes according to binding 
energy.  The ligands docked to Region 1 (seen in Figure 8.1) have the best energy, indicating that 
this region is the most probable ligand-binding domain.  The best binding energy of the complex 
in this region is -64.67 kcal/mol, and the best unified cavity energy is -53.87 kcal/mol.  In 
comparison, the best binding complex in Region 2 is over 20 kcal/mol worse (binding energy at  
Ligand Local Cavity 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Full 
Delphi 
(kcal/mol) 
Partial 
Delphi 
(kcal/mol) 
Total 
Energy 
(kcal/mol) 
Unified Cavity 
Energy 
(kcal/mol) 
Telmisartan -44.42 -63.09 -27.06 -50.81 -746.42 -45.44 
TelmisartanB -57.07 -78.37 -34.76 -59.40 -734.02 -57.72 
S6.10 -56.36 -86.77 -51.65 -57.54 -885.10 -56.60 
S6.11 -46.32 -62.69 -22.32 -43.43 -754.93 -46.87 
S6.12 -61.67 -87.26 -52.31 -57.75 -870.38 -61.93 
S6.13 -45.72 -62.96 -26.11 -44.54 -754.92 -46.24 
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-43.88 kcal/mol and unified cavity energy of -37.87 kcal/mol).  The other regions did not produce 
a complex with better binding energies than that of Region 2.   
 
Figure 8.8A shows the non-glycosylated complex with the best binding energy.  Geldanamycin 
forms hydrogen bonds with five residues in the binding site including N142.  Our predicted 
binding site agrees with our computationally docked and experimentally crystallized Hsp90-
Geldanamycin complexes.  Geldanamycin and ATP interact with this conserved asparagine 
residue in all crystallized Hsp90 systems. 
 
 
Figure 8.8 (A) Non-glycosylated Ecgp96-Geldanamycin complex with lowest binding energy.  
Geldanamycin (licrorice, grey) preferentially binds to N142 when the sugars are absent.  Ecgp96’s residue 
side chains are in CPK (ball-and-stick) form and are colored pink.  (B) Glycosylated Ecgp96-
Geldanamycin complex with lowest binding energy.  Geldanamycin (licorice, grey) preferentially binds to 
Region 2 when N142 is glycosylated. Ecgp96’s residue side chains are in CPK (ball-and-stick) form and 
are colored green.  Hydrogen bonds are indicated by black dotted lines in the pictures.  
 
Since Hsp90 has never been crystallized with its glycosylated segment (the biologically relevant 
form), we do not know the binding site of ATP or Geldanamycin in the presence of sugars.  In 
order to predict an accurate binding site for Geldanamycin in Ecgp96, we docked the ligand to all 
five specified regions after adding sugars to N142 and N252.  We found that the binding energy 
of Geldanamycin docked to Region 1 was worse after glycosylation because the binding energy 
increases from -64.67 kcal/mol to -53.60 kcal/mol, and the unified cavity increased from -53.87 
kcal/mol to -48.44 kcal/mol, with the number of hydrogen bonds decreasing from five to two.  
The lowest energy pose (shown in Figure 8.8B) has a binding energy that 5 kcal/mol better than 
the best energy pose from Region 1 (binding energy of -58.90 kcal/mol; the unified cavity energy 
is 3.5 kcal/mol better at -52.07 kcal/mol).  This site forms five hydrogen bonds with three 
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residues—R137, R151, and N311.  Thus, our docking results suggest that Geldamycin 
preferentially would bind to a different site under glycosylated conditions. 
 
DOCK Blaster 3 identifies small molecules that bind to unique region of the glycosylated 
protein 
After identifying a novel region that can potentially bind known ligands after protein 
glycosylation, we decided to select new molecules via VLS that would preferentially bind to this 
part of the protein.  Using the online server DOCK Blaster 3, we identified the portion of the 
glycosylated protein that we are interested in docking small molecules to.  Table 8.6 shows the 
binding energies calculated for the 500 selected ligands from DOCK Blaster 3.  The binding 
energy of the 19 ligands covers a wide range, -21.47 to 21.07 kcal/mol.  The number of hydrogen 
bonds varies from zero to three, and they seem to correlate with the binding energy.  We do not 
observe a correlation between the VLS rank generated by DOCK Blaster 3 and our calculated 
binding energies, thus indicating the importance of enriching and evaluating the complexes with a 
different force field.  For example, C03448152 (S7.3) has the lowest binding energy, but using 
the VLS standards it was ranked 18th out of the 19 ligands examined here. 
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Table 8.6 List of hits from DOCK Blaster 3 that we evaluated with the GenDock enrichment procedure and 
Dreiding-III FF and the comparison of our binding energy rank versus VLS rank. 
Ligand  
name 
Ligand 
name 
abbreviation 
Binding 
Energy 
(kcal/mol) 
Number of 
hydrogen 
bonds 
Binding 
Energy Rank 
VLS 
rank 
C00176096 S7.1 -5.58 0 12 19 
C03158777 S7.2 -16.82 3 4 4 
C03448152 S7.3 -21.47 2 1 18 
C09889887 S7.4 -12.00 0 7 11 
C11697764 S7.5 10.51 1 18 7 
C11820488 S7.6 -18.80 3 3 2 
C12543557 S7.7 -13.44 2 6 8 
C12577074 S7.8 -9.15 1 9 3 
C12646952 S7.9 -15.65 0 5 9 
C14950042 S7.10 -19.96 3 2 1 
C17298946 S7.11 1.09 0 15 14 
C22981496 S7.12 21.07 1 19 13 
C24907001 S7.13 5.22 0 17 10 
C30524473 S7.14 -6.67 0 10 12 
C32777201 S7.15 -6.56 0 11 15 
C45605944 S7.16 2.27 0 16 5 
C47535390 S7.17 -10.80 0 8 16 
C49028759 S7.18 -4.32 0 13 6 
C58175257 S7.19 -3.23 1 14 17 
 
The two ligands that we will investigate more closely are C034488152 (S7.3) and C11820488 
(S7.6) (Figure 8.9).  C034488152 (S7.3) had the lowest binding energy, as mentioned above, and 
C11820488 (S7.6) had the third lowest binding energy and is structurally very different.  Figure 
8.10 shows how the respective ligands interact in the binding site.  C034488152 (S7.3), in Figure 
8.10A, has two hydrogen bonds with D148 and N311 and strong van der Waals interactions with 
I310 and F309.  C11820488 (S7.6) in Figure 8.10B has three hydrogen bonds with D148, S141, 
and S144.  The non-bonding interaction with D148 is extremely strong with -10.174 kcal/mol.  
This ligand also has significant hydrophobic interactions with I310, F309, and F312.   
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Figure 8.9.  Chemical structures of two hit molecules from DOCK Blaster 3: (A) C03448152 (S7.3) and 
(B) C11820488 (S7.6). 
 
While it is a positive sign that these low binding energy ligands form multiple strong hydrogen 
bonds with the protein, they have many polar atoms that are not being used effectively.  Perhaps 
we could optimize the ligands further to maximize the interactions in that binding pocket.  Also, 
we could dock various conformations of the ligands using our DarwinDock program to generate 
thousands of possible ligand positions for the given binding site rather than rely on the one 
provided by DOCK Blaster 3.  We also need to test more ligands of the 500 provided.  We have 
already performed a VLS for the non-glycosylated Ecgp96 protein, and we need to conduct the 
same analysis as described above. 
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Figure 8.10.  Hit molecules (A) C03448152 (S7.3) and (B) C11820488 (S7.6) in the glycosylated Ecgp96 
model with cavity analysis.  Hydrogen bonds are indicated by black dotted lines in the pictures and are in 
bold red in the tables.  The cavity analysis breaks down the non-bonding energy into van der Waals (vdW), 
coulombic (Coulomb), and hydrogen bond (H-Bond) interactions.  All residues with predicted energetic 
interactions with Ecgp96 are shown. 
 
Z154 preferentially binds to a third region of Ecgp96 
Z154 is a unique ligand in that it does not bind to Regions 1 or 2 as shown in Figure 8.1.  Instead, 
it has the most favorable or lowest binding energies with the loop portion of the protein above 
Region 1.  According to Figure 8.11, it only forms one hydrogen bond with N164, but since it is 
positively charged, it has strong electrostatic interactions with polar residues in the area.  It has a 
very favorable binding energy of -63.46 kcal/mol, which is a significant 6 kcal/mol lower in 
energy than the known binding ligand Geldanamycin (Table 8.7).  The predicted binding site of 
Z154 suggests another unexplored region for potential small molecule binding.  We plan to 
conduct VLS for this region of the protein to identify possible hits that can be tested by 
experimental collaborators. 
 
 
Figure 8.11. Hydrogen bonds are indicated by black dotted lines in the pictures and are in bold red in the 
tables.  The cavity analysis breaks down the non-bonding energy into van der Waals (vdW), coulombic 
(Coulomb), and hydrogen bond (H-Bond) interactions.  Only residues whose energetic interactions are 
greater than 1 kcal/mol are shown in the table. 
 
Table 8.7. Comparison of binding energies of Z154 and Geldenamycin to the glycosylated form of Ecgp96. 
Protein (Ecgp96) Ligand Binding Energy (kcal/mol) 
Glycosylated Geldanamycin -57.47 
Glycosylated Z154 -63.46 
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CONCLUSIONS 
 
We docked three known ligands that are effective at preventing bacterial invasion to our predicted 
structure of Ecgp96 and, based on the predicted binding site, we recommend novel ligands that 
we anticipate to have stronger binding affinities for this protein than the ligands that are already 
known.  Even more excitingly, we offer strong computational evidence that Telmisartan can bind 
to Ecgp96, not just AT1R.  We also docked Geldanamycin to Ecgp96 in both its non-glycosylated 
and glycosylated forms only to find that the ligand has more favorable energies with a different 
part of the protein upon glycosylation.  This computational finding needs to be explored further 
through additional experiments, which will be done at a future time.  We performed VLS using 
DOCK Blaster 3 to identify potential small molecules that would bind to this novel and 
unexplored region.  We identify several candidates, which will be tested using binding assays.  If 
these ligands bind strongly, then perhaps we have located a new binding site on the protein that 
has never been considered or used until now and that would be effective in preventing interaction 
with the OmpA protein of E. coli and subsequent onset of meningitis. 
 
REFERENCES 
1. Unhanand M, Mustafa MM, McCracken GH, Nelson JD (1993) Gram-negative bacillary 
meningitis: A 21-year experience. J Pediatr 122:15-21. 
2. Gladstone IM, Ehrenkranz RA, Edberg SC, Baltimore RS (1990) A 10-year review of neonatal 
sepsis and comparison with the previous 50-year experience. Pediatr Infect Dis J 9:819-
825. 
3. Koedel U, Pfister HW (1999) Models of experimental bacterial meningitis: Roles and 
limitations. Infect Dis Clin North Am 13:549-577. 
4. Leib SL, Tauber MG (1999) Pathogenesis of bacterial meningitis. Infect Dis Clin North Am 
13:428-527. 
5. Prasadarao NV (2002) Identification of Escherichia coli outer membrane protein A receptor of 
human brain microvascular endothelial cells. Infect Immun 70:4556-4563. 
6. Prasadarao NV, Srivastava PK, Rudrabhatla RS, Kim KS, Huang S, Sukumaran SK (2003) 
Cloning and expression of the Escherichia coli K1 outer membrane protein A receptor, a 
gp96 homologue. Infect Immun 71:1680-1688. 
7. Pascal TA, Abrol R, Mittal R, Wang Y, Prasadarao NV, Goddard WA, III (2010) Experimental 
validation of predicted binding site of Escherichia coli K1 outer membrane protein A to 
human brain microvascular endothelial cells. J Biol Chem 285:37753-37761. 
8. Datta D, Vaidehi N, Floriano WB, Kim KS, Prasadarao NV, Goddard WA, III (2003) 
Interactions of E. coli outer-membrane protein A with sugars on the receptors of the brain 
microvascular endothelial cells. Proteins 50:213-221. 
9. Krishnan S, Shanmuganathan MV, Behenna D, Stoltz BM, Prasadarao NV (2014) Angiotensin 
II receptor type 1-A novel target for preventing neonatal meningitis in mice by 
Escherichia coli K1. J Infect Dis 209:409-419. 
 201 
10. Sugawara T, Kokubun K, Ishida R, Fujiwara K, Yamamoto S, Kinouchi H, Itoh H, Mizoi K. 
Angiotensin receptor blocker directly binds to HSP and stimulates its production in the 
brain. In: Munteanu V, Raducanu R, Dutica G, Croitoru A, Balas VE, Eds. (2010) Recent 
Advances in Mathematics and Computers in Business, Economics, Biology & Chemistry. 
WEAS Press, Iasi, Romania, pp. 350-357. 
11. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal 
structure of an Hsp90‚ geldanamycin complex: Targeting of a protein chaperone by an 
antitumor agent. Cell 89:239-250. 
12. Ghosh A, Rapp CS, Friesner RA (1998) Generalized born model based on a surface integral 
formulation. J Phys Chem B 102:10983-10990. 
13. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M (1983) 
CHARMM: A program for macromolecular energy, minimization, and dynamics 
calculations. J Comput Chem 4:187-217. 
14. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-
Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D (2007) Production of 
glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of 
Gaucher's disease using a plant cell system. Plant Biotechnol J 5:579-590. 
15. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1997) Identification and 
structural characterization of the ATP/ADP-binding site in the Hsp90 molecular 
chaperone. Cell 90:65-75. 
16. Maestro, version 7.5. (2006). Schrodinger, LLC, New York, NY. 
17. Jaguar, version 6.5. (2006). Schrodinger, LLC, New York, NY. 
18. MacroModel, 9.5. (2007). Schrodinger, LLC, New York, NY. 
19. Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield C, Chang G, 
Hendrickson T, Still WC (1990) Macromodel -- An integrated software system for 
modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 
11:440-467. 
20. Lim KT, Brunett S, Iotov M, McClurg RB, Vaidehi N, Dasgupta S, Taylor S, Goddard WA, 
III (1997) Molecular dynamics for very large systems on massively parallel computers: 
The MPSim program. J Comput Chem 18:501-521. 
21. Mayo SL, Olafson BD, Goddard WA, III (1990) DREIDING: A generic force field for 
molecular simulations. J Phys Chem 94:8897 - 8909. 
22. Floriano WB, Vaidehi N, Zamanakos G, Goddard WA, III (2004) HierVLS hierarchical 
docking protocol for virtual ligand screening of large-molecule databases. J Med Chem 
47:56-71. 
23. Goddard WA, III, Kim S-K, Li Y, Trzaskowski B, Griffith AR, Abrol R (2010) Predicted 3D 
structures for adenosine receptors bound to ligands: Comparison to the crystal structure. J 
Struct Biol 170:10-20. 
24. Kim S-K, Li Y, Abrol R, Heo J, Goddard WA, III (2011) Predicted structures and dynamics 
for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors. J Chem 
Inf Model 51:420-433. 
25. Kim S-K, Riley L, Abrol R, Jacobson KA, Goddard WA, III (2011) Predicted structures of 
agonist and antagonist bound complexes of adenosine A(3) receptor. Proteins: Struct 
Funct Bioinform 79:1878-1897. 
26. Nair N, Kudo W, Smith MA, Abrol R, Goddard WA, III, Reddy VP (2011) Novel purine-
based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: Synthesis, neuronal cell 
culture investigations, and CDK5 docking studies (vol 11, pg 3165, 2001). Bioorg Med 
Chem Lett 21:5649-5649. 
27. Lang PT, Brozell SR, Mukherjee S, Pettersen ET, Meng EC, Thomas V, Rizzo RC, Case DA, 
James TL, Kuntz ID (2009) DOCK 6: Combining techniques to model RNA-small 
molecule complexes. RNA 15:1219-1230. 
 202 
28. Kam VWT, Goddard WA, III (2008) Flat-bottom strategy for improved accuracy in protein 
side-chain placements. J Chem Theory Comput 4:2160-2169. 
29. Bolton E, Wang Y, Thiessen P, Bryant S. PubChem: Integrated platform of small molecules 
and biological activities. (2008) Annual Reports in Computational Chemistry. Elsevier 
Ltd., Oxford, UK., pp. 217-240. 
30. Tetko IV, Tanchuk VY (2002) Application of associative neural networks for prediction of 
lipophilicity in ALOGPS 2.1 program. J Chem Inf Comput Sci 42:1136-1145. 
31. Jorgensen WL, Maxwell DS, TiradoRives J (1996) Development and testing of the OPLS all-
atom force field on conformational energetics and properties of organic liquids. J Am 
Chem Soc 118:11225-11236. 
32. Irwin JJ, Shoichet BK, Mysinger MM, Huang N, Colizzi F, Wassam P, Cao Y (2009) 
Automated docking screens: a feasibility study. J Med Chem 52:5712-5720. 
 
 203 
Chapter IX 
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ABSTRACT 
 
With the decrease in the availability in fossil fuels and the increase in the amount of carbon 
dioxide released into the atmosphere, it has become necessary to maximize the use of alternative 
fuels.  Natural gas, made mostly of methane, is an attractive option due to its abundance in the US 
and the decreased amount of carbon dioxide emissions it produces.  However, methane is 
expensive to retrieve and transport in its gaseous state and difficult to modify without extreme 
conditions due to its very high bond dissociation energy of 105 kcal/mol.  Thus, we have 
proposed and virtually explored the reactivity of high valent metal-oxo catalysts (trans-
dioxovanadium(V) porphyrin and corrin complexes) that are reactive enough to break alkane 
bonds.  Using quantum mechanical computations, we surveyed the free energy surface of states 
involved in hydrocarbon bond activation.  We learn that the proposed catalyst, due to its high 
nucleophilicity, has an O-H bond dissociation energy comparable to that of methane and 
furthermore that this catalyst can produce alkyl radicals that escape to form chemical species 
other than the typical alcohol products of radical rebound.   Hence, we provide sufficient 
evidence that suggests trans-dioxovanadium(V) is reactive enough to be an attractive catalyst that 
can be useful in functionalizing alkanes and warrants characterization and testing in the future. 
 
INTRODUCTION 
 
One of the greatest scientific challenges is finding a clean and sustainable fuel that can power 
modern technology and act as an alternative to fuels such as petroleum and coal.  Methane, the 
major component of natural gas, is an inexpensive and plentiful fuel that does not release as much 
carbon dioxide into the atmosphere.  Upon consumption, methane produces 47% and 27% less 
carbon dioxide gas than coal and petroleum, respectively (1).  There are enormous methane 
reserves in the United States, but unfortunately, they are in remote locations, making methane 
transportation very expensive using infrastructure designed for liquid fuels.  One solution to the 
transportation issue is to convert methane into liquid methanol, but this process is very difficult 
because methane is kinetically stable.  Its C-H bond dissociation enthalpy (BDE) is 105 kcal/mol 
(2).  Our goal is to design a catalyst that can convert methane into methanol at a reasonable rate. 
 
The reaction examined here involves an alkane reacting with an oxo-metal compound to produce 
a hydroxo-metal complex and an alkyl radical that is free to interact with other species and form 
new products.  This type of reaction has been studied previously (3; 4).  For example, alkanes 
react with trans-oxofluoromanganese(V) complexes to produce an alkyl radical, which can 
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further react with the Mn(IV)(TMP)F2 to produce a compound with C-F bonds (3).  Secondly, 
alkanes react with trans-dioxomanganese to produce an alkyl radical and an L-Mn(IV)-OH 
complex.  Subsequently, an L-Mn(IV)-OCl complex may react with the alkyl radical to form a 
product with C-Cl bonds (4).  Here, the first half of the reaction between trans-dioxovanadium 
compounds and alkanes, which produces alkyl radicals, is examined.  These radicals are expected 
to interact further to form new products in a manner similar to the reactions in the studies 
mentioned above. 
 
The mechanism discussed in Figure 9.1 is the high valent metal-oxo hydrocarbon bond activation 
catalytic cycle.  During this process, the metal (M) undergoes oxidation to create a metal-oxo to 
activate the alkane’s (R-H) C-H bond.  The hydrogen is removed from the hydrocarbon and 
attaches to the oxygen of the metal-oxo complex.  If the metal is electrophilic, like manganese, 
then the OH group will detach from the metal and rejoin with the alkyl radical to produce the 
rebound product (5).  However, if the metal is nucleophilic, like vanadium, then the hydrogen 
could remain on the catalyst and the alkyl radical groups could react with one another or with a 
different chemical species leading to the radical escape products rather than alcohol products.  
Another process is necessary to regenerate the initial starting materials to complete the catalytic 
cycle.  Our collaborators have previously isolated and characterized stable high valent metal-oxos 
including a manganese porphyrin compound Mn(TMP)Cl that catalyzes oxidative aliphatic 
fluorination (3).  However, as noted above, manganese is an electrophilic metal, so the number 
and variety of potential products catalyzed by such a complex is limited.  In this report, we use 
quantum mechanical simulations to explore the potential of the nucleophilic vanadium porphyrin 
complexes to be catalysts that are strong enough to activate alkane bonds as well as produce 
radical escape compounds.  Furthermore, we propose a regeneration mechanism, compare these 
results with those of manganese complexes, and analyze the effect that the ligand plays on the 
thermochemistry.  We provide sufficient evidence that trans-dioxovanadium(V) compounds 
could be effective catalysts that can react with methane and produce an array of new chemical 
products. 
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Figure 9.1 Diagram of the high valent metal-oxo hydrocarbon bond activation catalytic cycle.  M stands for 
the metal, R-H represents the alkane, q is the oxidation state of the metal.  Oxygen and hydrogen are 
represented by their respective chemical symbols.  Modified version of Figure 1 from Ref. (5). 
 
 
METHODS 
 
We performed geometry optimizations using Jaguar 7.9 (6) with the B3LYP-D3 density 
functional (7-10) and the 6-31G** basis set (11-14) except for with the metal atoms that use the 
LACV3P++ basis set (15).  Using the optimized molecules, we calculated the frequencies at 
298.15 K and performed a single energy point calculation including aqueous solvation with the 
M06 functional (16) and the 6-311G**++ basis set (11-14) except for with the metal atoms, 
vanadium and manganese, which use the LACV3P**++ basis set (15).  We calculated the 
solvation energies with the Poisson-Boltzmann solvation model (17; 18) with a dielectric constant 
of 80.37 and probe radius of 1.40 Å.  To determine the stability of all the components of the 
reaction, including the intermediates and transition states, we determined the Gibbs free energy 
(G) and enthalpy (H) using Equations 9.1 and 9.2 respectively: 
 
G = E +PV −TS  
    = Eelec +Gsolv + 6kT +Hvib + ZPE −TStot , (9.1) 
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H = Eelec +Gsolv + 6kT +Hvib + ZPE . (9.2) 
 
To obtain the Gibbs energy (9.1), the electronic energy, (Eelec) and solvation free energy (Gsolv) 
from the single point energy calculation are added to the vibrational enthalpy (Hvib), the zero-
point energy (ZPE), and total entropy (Stot) from the frequency calculation, and 6kT, which 
accounts for ½ kT of potential and kinetic energy of the six external degrees of freedom.  We also 
use these quantities in (9.1) to compute bond dissociation free energies (BDFE) and bond 
dissociation enthalpies (BDE) (9.2). 
 
The G determined from (9.1) is used to find the protonation driving force, or pKa in Equation 
9.3: 
 
€ 
pKa =
ΔG
2.303RT( ) ,
 (9.3) 
 
with R equal to the ideal gas constant of 1.987*10-3 kcal/Kmol and T equal to 298.15 K. 
 
Oxidation driving potentials, E, are given relative to SHE and depend on G from (9.1) as seen in 
Equation 9.4:  
 
E = ΔGnF −ESHE ,
 (9.4) 
 
with F equal to Faraday’s constant, or 23.06 kcal/(V*mol), n equal to the number of electrons, 
and ESHE equal to the standard hydrogen reference potential, an empirical value of 4.28 V (19). 
 
RESULTS AND DISCUSSION 
 
Thermochemistry of trans-dioxovanadium(V) compounds 
Figure 9.2 shows the pH-dependent redox thermochemistry of the trans-dioxovanadium(V) 
tetrahydroporphyrin (THP) molecule and the oxohydroxovanadium(IV) porphyrin.  Equivalent to 
hydrogen atom transfer from an alkane, trans-dioxovanadium(V) can undergo reduction followed 
by protonation.  A reduction potential of 0.0 V is required to generate the trans-
dioxovanadium(IV) molecule.  (The free energy of this linear O-VV-O isomer is more favorable 
than that of its isomer, trans-dioxovanadium(V) coordinated to a radical anionic porphyrin ring, 
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by 25 kcal/mol.)  Trans-dioxovanadium(IV) has a large driving force for protonation, with a pKa 
of 35.0, to create the trans-oxohydroxovanadium(IV).  Alternatively, trans-dioxovanadium(V) 
can undergo protonation then reduction.  This route has a slightly smaller driving force for 
protonation with a pKa of 21.0 followed by a higher reduction potential of 0.9 V.  Protonation is 
accompanied by an electronic rearrangement in which an electron from the porphyrin π-system 
moves to the vanadium dxy orbital, generating a V(IV) center.  Overall, trans-dioxovanadium(V) 
has a O-H bond BDE of 103 kcal/mol, a BDFE of 97 kcal/mol, and a high pKa of 21.0.  These 
energies make trans-dioxovanadium(V) an appealing catalyst because its BDE is approximately 
equal to that of the bond energy of methane, 105 kcal/mol.  They also highlight the challenges to 
developing working catalytic cycles by limiting the media in which the intermediates would 
persist and the means of oxidatively regenerating the reactive trans-dioxovanadium(V).   
 
A. 
 
B. 
 
Figure 9.2 (A) Structure of the porphyrin macrocycle.  (B) Thermochemistry of trans-dioxovanadium(V) 
THP compounds.  The oxidation potentials (E, V vs. SHE), free energy (G, kcal/mol), pKa, total spins (S), 
bond dissociation enthalpy (BDE), and bond dissociation free energy (BDFE) required to generate 
oxohydroxovanadium(IV) from trans-dioxovanadium(V) are shown above. 
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Hinting at the electron richness that drives the vanadium(V) reactivity, oxidation of the trans-
dioxovanadium(V) anion to generate the neutral doublet requires a moderate potential of 1.2 V 
versus SHE.  The trans-dioxovanadium(V) anion singlet is more favorable in energy than the 
triplet by 3 kcal/mol.  The singlet has four σ, four πx, and four πy electrons, but no δ electrons.  
The result of one-electron oxidation is the neutral trans-dioxovanadium(V) doublet, which is 6 
kcal/mol lower in energy than the quartet.  In the doublet, the V-O single bond (1.84 Å) is longer 
than the double bond (1.61 Å), and the singly bonded oxygen hosts 0.95 e- of spin density (by 
Mulliken analysis) while the vanadium atom has a somewhat down spin.  The product of the 
trans-dioxovanadium(V) anion protonation is the triplet of the neutral oxohydroxovanadium(IV), 
which is 4 kcal/mol more stable than the singlet.  In the triplet, the V-O-H bond is significantly 
longer than the V-O double bond, 2.03 Å and 1.62 Å respectively.  The dxy orbital of the 
vanadium metal is singly occupied, and there is a hole on the porphyrin ligand. 
 
Figure 9.3 illustrates the importance of the trans-dioxo configuration.  Cis isomers of the V(V) 
dioxos are more stable than their trans counterparts since all five d-orbitals can be involved in 
covalent bonding to the oxygen atoms.  For the dioxovanadium(V) complex, the cis isomer is 
energetically favorable by 15.8 kcal/mol.  For the oxohydroxovanadium(IV) complex, on the 
other hand, the trans isomer is lower in energy by 21.7 kcal/mol.  Only in the trans configuration 
can the lone electron of V(IV) be stored in a d-orbital orthogonal to all the σ and π bonds to the 
oxygen atoms.  As a result, the O-H BDE to the cis isomer is 67 kcal/mol, not comparable to the 
bond energy of methane.  The trans geometry is necessary to generate oxovanadium(IV) with a 
high energy O-H bond. 
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Figure 9.3 Thermochemical comparison of the trans and cis geometries of dioxovanadium(V) and 
oxohydroxovanadium(IV) compounds.  The BDE between the dioxovanadium(V) and 
oxohydroxovanadium(IV) compounds and the change in free energy (ΔG) between the cis and trans 
geometries are indicated. 
 
Thermochemistry to regenerate trans-dioxovanadium(V) compounds 
Our simulations suggest that trans-dioxovanadium(V) would be an attractive catalyst in 
converting methane to methanol due to its high BDE.  We have examined the thermodynamics 
for three possible pathways, shown in Figure 9.4, for regenerating the high oxidation state.  In 
Figure 9.4A, trans-oxohydroxovanadium(IV) undergoes deprotonation followed by oxidation.  
The deprotonation step requires a large pH of 35.  The oxidation step should occur easily since 
the vanadium(IV) dianion is oxidized at a mild potential of 0.0 V.  In the second pathway, Figure 
9.4B, trans-oxohydroxovanadium(IV) undergoes one electron oxidation followed by 
deprotonation.  Here, the oxidation step will not occur as readily because the potential is more 
moderate at 0.9 V, but chemical and photochemical oxidants cover this potential range.  The pH 
required for the deprotonation step is 21, a significant step from 35 toward a manageable pH.  
Since O-atom transfer reagents have been used to turn over oxo-based catalysts, the third 
pathway, Figure 9.4C, consists of an oxygen atom transfer (a two-electron oxidation) followed 
by a one electron reduction.  The oxidation potential of the first step is very high at 1.4 V at 
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pH=14 and 1.8 V at pH=0, thus, a strong oxidant is required.  The resulting intermediate is 
reactive because it has a reduction potential of 1.5 V.  Of these three pathways, the second one 
seems most promising.  The first pathway requires a very large pH of 35, which would make 
deprotonation difficult.  The circuitous third pathway requires a chemical oxidant and 
electrochemical reduction making the second pathway the most feasible target. 
 
A. 
 
 
B. 
 
  
 212 
C. 
 
 
Figure 9.4 Three pathways for regenerating trans-dioxovanadium(V) from trans-
oxohydroxovanadium(IV).  (A) One electron oxidation followed by deprotonation.  (B) Deprotonation 
followed by one electron oxidation.  (C) Oxygen atom transfer followed by one electron reduction.  
Reduction and oxidation potentials (E) and pH for deprotonation are indicated. 
 
Comparison with trans-oxoaquamanganese(V) complex’s thermochemistry 
Oxomanganese porphyrin complexes competent for activating strong C-H bonds have previously 
been characterized (3; 20), so here we contrast the thermochemistry of trans-
oxoaquamanganese(V) and that of the trans-dioxovanadium(V).  Figure 9.5 shows the stepwise 
addition of a hydrogen atom to form trans-hydroxoaquamanganese(V).  The driving force for 
hydrogen atom transfer is dramatically shifted to reduction of the oxo in the manganese case (1.2 
V vs. SHE for Mn(V) vs. 0.0 V for V(V)) from protonation  of the reduced oxo in the vanadium 
case (pKa of 35 for V(IV) oxo vs. pKa of only 7.3 for Mn(IV) oxo).  The O-H bond dissociation 
energy of 93 kcal/mol for the manganese oxo is derived from its electrophilicity.  The 103 
kcal/mol BDE predicted for the putative vanadium oxo is derived from its nucleophilicity, with 
more driving force for protonating the vanadyl oxo. 
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Figure 9.5 Thermochemistry of trans-oxoaquamanganese(V) compounds.  The reduction potentials (E), 
protonation driving force (pKa), bond dissociation enthalpy (BDE), and bond dissociation free energy 
(BDFE) required to generate trans-hydoxoaquamanganese(IV) from trans-oxoaquamanganese(V) are 
shown above. 
 
The two complexes’ different driving forces for hydrocarbon bond activation can also be 
illustrated with molecular orbital diagrams shown in Figure 9.6.  The diagram in Figure 9.6A 
shows the energies for the σ, πx, πy, and δ orbitals of trans-dioxovanadium(V).  The dxy orbital at 
-2.9 eV is empty and can therefore accept electron density from the oxygen px lone pairs in the πx 
non-bonding orbital after the oxos ‘lean over’ the xz plane.  Thus, the trans-dioxovanadium(V) 
has a bent geometry (O-V-O = 146.2º) as shown in Figures 9.2, 9.4, and 9.6A.  The inset shows 
the overlap between the lone pairs of the oxos orbitals and vanadium’s empty dxy orbital.  For the 
trans-oxoaquamanganese(V) compound, on the other hand, the δ orbital at -8.9 eV is occupied by 
additional electrons as shown in Figure 9.6B.  Although this compound contains one πy and one 
πx Mn-O π-bond, we found each of these formed bonding and anti-bonding combinations with the 
overlapping nitrogen-based orbitals.  Figure 9.6C shows the comparison of the energy levels of 
trans-dioxovanadium(V) in blue versus trans-oxoaquamanganese(V) in red.  Orbitals of the 
electrophilic manganese complex are lower than those of the corresponding vanadium complex 
by roughly 5 eV.  Since the dxy orbital is occupied in trans-oxoaquamanganese(V), the πy* orbital 
is occupied upon H-atom transfer, whereas in trans-dioxovanadium(V), the dxy orbital is empty, 
so hydrogen’s electron would go into the δ orbital, which is 2 eV higher in energy than the Mn 
πy*.   
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A. 
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B. 
 
 
C. 
 
Figure 9.6 Molecular orbital (MO) diagrams of the manganese and vanadium compounds.  (A) MO 
diagram of trans-dioxovanadium(V).  The bent oxos lay on the x-axis.  (B) MO diagram of trans-
oxoaquamanganese(V).  Mn-N lie on the x-axis.  (C) MO diagram comparing the energies of the orbitals 
shown above in Figure 9.6A and 9.6B. 
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Changes in thermochemistry resulting from the replacement of the porphyrin ligand 
Since the proposed trans-dioxovanadium is predicted to be excessively reactive and is yet 
unsynthesized, less reactive variations were sought that may be more likely to be isolated.  
Ideally, the vanadium’s dxy orbital would lie higher in energy in order to stabilize the higher 
oxidation state.  We hypothesized that replacing the porphyrin macrocycle with a corrin ligand 
whose nitrogen atoms are closer to the metal would destabilize the dxy orbital.  As anticipated, the 
corrin macrocycle (Figure 9.7A) lowers the VIV/V oxidation potential by 0.5 V (Figure 9.7B), and 
destabilizes the vanadium dxy orbital by increasing its energy from -2.9 eV to -2.7 eV.  (The 
trans-dioxovanadium(IV) isomer is 13 kcal/mol more stable than the trans-dioxovanadium(V) 
bound by a radical anion.)  The O-H BDE of 94 kcal/mol (and the BDFE of 88 kcal/mol) is lower 
than that of the porphyrin complex, but it is still a tantalizing and perhaps a more accessible goal.  
Regenerating the trans-dioxovanadium(V) state via one-electron oxidation followed by a 
deprotonation would require a potential of 0.8 V and a pKa of 16.3.  Furthermore, the cis isomer 
of trans-dioxovanadium(V) with corrin is lower in energy by 30 kcal/mol, which suggests that 
generating the initial dioxovanadium(V) catalyst will require a route that kinetically favors the 
trans isomer. 
 
A. 
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B. 
 
Figure 9.7 Thermochemistry of trans-dioxovanadium(V) corrin compounds.  (A) Structure of the corrin 
macrocycle.  (B) The reduction potential (E), free energy (G), pKa, bond dissociation enthalpy (BDE), and 
bond dissociation free energy (BDFE) relating oxohydroxovanadium(IV) from trans-dioxovanadium(V) 
are shown above. 
 
Another possible candidate to replace THP is the macrocycle is tetra-(N,N-dimethyl)imidazolium 
porphyrin (TDMImP) shown in Figure 9.8, which we have used previously in manganese 
complexes (20).  We hoped that the electron-withdrawing groups of this ligand would decrease 
the hydroxo pKa’s during the protonation step and make regeneration of trans-dioxovanadium(V) 
more facile.  We find that in the case of TDMImP, the BDE of trans-dioxovanadium(V) increases 
to 104 kcal/mol, which is comparable to that of methane, but too large for the compound to be 
stable.  In Table 9.1, we compare the BDE and BDFE for the trans-dioxovanadium(V) 
compounds with three different ligands.  All of the complexes have BDE’s that are capable of 
activating strong CH bonds, which make these vanadium catalysts appealing candidates.   
 
 
Figure 9.8 Structure of TDMImP macrocycle. 
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Table 9.1 BDE and BDFE of trans-dioxovanadium(V) with different macrocyclic ligands. 
Ligand BDE (kcal/mol) BDFE (kcal/mol) 
THP 103 97 
Corrin 94 88 
TDMImP 104 97 
 
Fate of alkyl radical after hydrogen atom transfer (HAT) 
Figure 9.9 shows the relative free energies (G) of the transition states, intermediates, and 
products resulting from trans-dioxovanadium(V) porphyrin complex abstracting a hydrogen from 
methane.  Due to the high O-H BDE, the calculated activation free energy is a mere 20.3 
kcal/mol.  Following C-H activation, this reaction can proceed along two routes: rebound of the 
alkyl radical onto the hydroxo or the radical escape.  In the present vanadium case, the barrier to 
methyl rebound is much higher than the energies of the radical escape products (18.8 kcal/mol vs. 
-2.6 kcal/mol).  All the energies shown in Figure 9.9 are for molecules in the singlet state (S=0) 
for consistency.  We determined that the triplet state is lower in energy for the rebound transition 
state, but only by 0.6 kcal/mol.  These energetics indicate that we would observe the formation of 
alkyl radicals and oxohydroxovanadium(IV) rather than methanol and oxovanadium(III).  The 
alkyl radicals could further react with each other or different species to get a variety of products.  
The nucleophilic trans-dioxovanadium(V) compounds are therefore an interesting target based 
both on their predicted ability to activate alkanes and the possibility of accessing carbon-carbon 
bonds or other novel functionalization products of radical escape.  
 
 
Figure 9.9 Enthalpy (H) and free energy (G) of the intermediates, transition states, and products resulting 
from methane activation by trans-dioxovanadium(V) porphyrin.  H and G (kcal/mol) are shown with 
respect to trans-dioxovanadium(V) and methane as the reference (H=0.0, G=0.0). 
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CONCLUSIONS 
 
Here, we have presented convincing evidence that the trans-dioxovanadium(V) compounds 
would be effective in activating hydrocarbon bonds.  In complex with three different ligands, 
THP, corrin, and TDMImP, this compound’s OH bond dissociation enthalpy is 94-104 kcal/mol 
and comparable to that of methane.  We have also proposed a possible pathway to synthesize this 
compound from oxohydroxovanadium(IV).  These vanadium complexes are more appealing than 
the previously characterized manganese ones because the vanadium complexes are more reactive, 
and they are more likely to produce alkyl radicals that can perform interesting chemistry rather 
than alcohols.  Hence, we anticipate that these vanadium catalysts will play an important role in 
the future of the hydrocarbon bond activation field. 
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